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 IV 
Abstract 
 
A capsule composed of mainly α-glucan forms the most outermost layer of cell envelope 
of Mycobacterium tuberculosis, the causing agent of tuberculosis. Capsule acts as an inert 
barrier to prevent the diffusion of macromolecules towards inner parts of the envelope. 
Also, there is growing evidence that capsular glucans mediate the adhesion and 
penetration of bacilli into the host cells. In GlgE pathway, one of the three pathways 
involved in α-glucan synthesis, trehalose in converted to glucan through the activity of 
four enzymes, trehalose synthase, maltokinase Pep2, maltosyltransferase GlgE and 
branching enzyme GlgB. The first two enzymes catalyze the conversion of trehalose to 
maltose, and phosphorylating maltose, respectively. It has shown that M. tuberculosis 
TreS and Pep2 form an octameric complex together. During this study we solved the 
structure of the complex at 3.6 Å in M. smegmatis. The structure reveals two pairs of 
Pep2 monomers bind to the opposite sides of the diamond shaped TreS tetramer in a 4 + 
4 complex. However, studying the stoichiometry of the complex using other techniques 
such as: isothermal titration calorimetry (ITC), analytical ultracntrifugation (AUC) and 
X-ray scattering indicates a 4 + 2 complex formation in the solution. Moreover, our data 
using size exclusion chromatography would suggest that this complex formation is pH 
dependent and favors complex formation at more acidic pHs. This study is a step forward 
towards better understanding of the capsule synthesis in M. tuberculosis and highlights 
the role of complex formation between enzymes as an effective strategy to control the 
metabolic pathways in mycobacteria.  
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1 Introduction	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1.1 History	  of	  tuberculosis	  	  
 
 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, has been the main cause of 
death from microbial infections in the history of human life (Daniel , 2006). Modern 
techniques in molecular biology and genome sequencing indicate that current members of 
mycobacterial family are originated from a common ancestor in East Africa around 3 
million years ago (Daniel , 2006). However, the first evidences of tuberculosis go back to 
the discovery of a bone from Neolithic period (~ 5000 BC) in Heidelberg and spinal 
caries on the Egyptian mummies belong to 2400 BC (Herzog, 1998).  
 
The oldest available text mentioning a chronic lung disease, most likely TB, is the Code 
of Hammurabi, a cuneiform script engraved on a stone pillar at 1948-1905 BC. Then, it 
appeared in Greek literature by Hippocrates (460-370 BC) as phthisis or consumption. He 
described the disease as a condition that usually leads to death and discouraged his 
students of visiting the patients in advanced stages of the disease, since the patient is 
doomed to death it could damage the credibility of the physician. Although, he was able 
to observe TB-induced nodular lesions for the first time in the tissues of pigs, cattle and 
sheep but he didn’t find any analogous lesions in humans because human autopsy was not 
performed in that time (Basel, 1998). Aristotle (384-322 BC) described “scrofula” on the 
skin of phthisic pigs and believed that the disease is contagious not hereditary, which was 
the general opinion in that time (Basel, 1998). However, it was Roman physician Caelius 
Aurelianus in the 5th century AD, who described the symptoms of the disease for the first 
time as latent fever, strong cough with thin purulent sputum, breathing difficulties, 
flushed cheeks and ashen skin on the rest of the body. In spite of repellent appearance, 
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the patient usually shows stunning physical and mental activities. Clarissimus Galen, the 
physician of Roman Emperor Marcus Aurelius in 174, also re-emphasized on the 
contagious nature of consumption and therefore banned personal contact with phthisis 
patients (Basel, 1998).  
 
TB became prevalent throughout Europe during 18th and 19th centuries displacing leprosy 
as a dominant infectious disease. The rate of death in metropolitan cities in Europe was 
1,000 to 100,000 death per year (Daniel , 2006). In spite of high number of patients 
suffering from tuberculosis, there wasn’t an agreement on the nature of tuberculosis 
between practitioners and scientists. While in Northern Europe it was considered as 
hereditary, in Southern Europe they would treat the disease as an infections condition. In 
1790, Benjamin Marten considered the disease as infectious and assigned it to “some 
certain species of animalcula”, the term which used to be used for amazing very small 
living creatures. This term was used for the first time by Anton van Leeuwenhoek in 
1676 when he observed bacteria and spermatozoa under his microscope. However, Jean-
Antoine Villemin a century later was able to demonstrate the contagious nature of 
tuberculosis for the first time by studying the rabbits inoculated with a “small amount of 
purulent liquid from an tuberculosis cavity” isolated from an active TB patient. The 
major progress towards the bacteriology of tuberculosis was achieved by Robert Koch 
(1834-1910) when he demonstrated a specific microbe is the main cause of tuberculosis 
(Basel, 1998). He visualized the bacilli for the first time using special staining techniques 
within the infected tissue and eventually called them tubercle bacilli, or Mycobacterium 
tuberculosis. Using Tyndall’s method of sterilizing, he was, also, able to culture the 
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bacteria as a thin and delicate layer on the media and by inoculating the cultured cells 
into laboratory animals, demonstrated the transmission of tuberculosis. Finally he was 
awarded Nobel Prize due to his efforts on the bacteriology of Mycobacterium 
tuberculosis in 1905.  
 
1.2 Tuberculosis	  in	  modern	  era	  	  
 
It is estimated that one third of world population (about 2 billion people) are infected 
with tuberculosis (Koul et al., 2011). However, in most cases the infection remains 
dormant and only in 5% of patients will develop clinical disease (Figure 1-1). In case of 
normal TB, 95% of patients recover upon treatment with a cocktail of four different 
antibiotics, isoniazid, rifampicin, ethambutol and pyrazinamide for a duration of 6 month. 
But if it remains untreated it can be fatal in 50% of patients, currently leading to the death 
of around 1.5 million people per year (Koul et al., 2011). In 2012, 8630 cases of TB were 
reported in United Kingdom, out of those 432 patients died (Public Health England, 
2014).  
 4 
 
Figure 1-1. M. tuberculosis life cycle. For more details see section 1.2. Adopted from 
(Koul et al., 2011), with permission.  
 
1.3 The	  genus	  of	  Mycobacterium	  	  
 
 
The genus of mycobacterium is composed of more than 50 species, which most of them 
are non-pathogenic bacteria related closely to soil bacteria Streptomyces and Actinomyces 
(Cosma, Sherman and Ramakrishnan, 2003). The main pathogenic species of this genus 
are M. tuberculosis, M. leprae and M. ulcerans causing tuberculosis, leprosy and Buruli 
ulcers, respectively. The key factor in the success of these pathogens is their ability to 
survive inside the host macrophages, despite the antimicrobial nature of these cells 
(Cosma, Sherman and Ramakrishnan, 2003). The host arrests the growth of 
mycobacterium inside complex structures called granuloma but fails to eradicate the 
bacterial cells. Mycobacterial cells can survive inside the granuloma for several years in 
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latent or dormant form and activate as soon as the immune system of the patient weakens 
(Cosma, Sherman and Ramakrishnan, 2003 and Russell, 2007).  
 
M. tuberculosis complex 
M. tuberculosis complex is composed of M. tuberculosis, M. africanum, M. bovis, M. 
canetti and M. microti, that share more than 99% nucleotide identity at some genes but 
are different in biochemistry, morphology, host range and produce different disease 
patterns in the infected animals (Cosma, Sherman and Ramakrishnan, 2003). Although, 
M. tuberculosis is considered as main cause of tuberculosis, with 1.5 million deaths 
annually, M. africanum infects more people in some parts of Africa than M. tuberculosis. 
M. bovis can infect both humans and cattle and was the main cause of tuberculosis before 
pasteurization of milk. M. canetti infections are rare and M. microti only infects voles. M. 
tuberculosis, M. africanum and M. bovis produce similar diseases in humans. Attenuated 
forms of M. bovis BCG has been used as vaccines (Cosma, Sherman and Ramakrishnan, 
2003).  M. tuberculosis is an acid-fast, rod shaped bacillus with an unique cell envelope 
(Kaufmann, 2001). This fact that stained bacteria can not be de-stained by an acid, acid 
fast, is used as a laboratory test to determine if the sample of tissue or blood is infected 
with M. tuberculosis. Bacilli are slow growing with a replication time of about 20 hours. 
This slow rate of growth represents a key reason for chronic nature of infection, 
complication in microbial diagnosis and long-term drug treatment (Kaufmann, 2001).  
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1.4 Pathology	  and	  immunology	  of	  M.	  tuberculosis	  infection	  	  
 
 
TB is an air-borne disease, which transmits by inhalation of a few droplets containing 1-3 
bacilli secreted from respiratory tract of an infected person with active TB (Figure 1-2). 
Expelled droplets can remain for several hours and only a single bacterium is sufficient 
for pathogenesis (Russell, 2007). The lung is the main entry port and site of infection but 
TB can be found in any tissue, known as extrapulmonary TB. The chance of developing 
TB outside the lungs is less than 10% (Kaufmann, 2001).  
 
1.4.1 Phagocytosis	  of	  M.	  tuberculosis	  by	  macrophages	  	  
 
 
Contrary to obligate extracellular pathogens, such as Neisseria species, which developed 
multiple mechanisms to avoid entry into phagocytes, M. tuberculosis is quite eager to 
gain entry to macrophages (Ernst, 1998). However, internalization by different cell 
surface receptors can change the fate of bacilli inside the macrophage. There are different 
receptors on the surface of macrophages, such as dendritic cell-specific intercellular 
adhesion molecule (ICAM)-3-grabbing non-integrin (DC-SIGN), mannose receptor (MR) 
and Fc receptors that are involved in the uptake of M. tuberculosis (Pieters, 2008). 
Internalizing the bacterium via Fc receptors, for instance, stimulates the inflammatory 
response inside the macrophage, while ingestion of mycobacterial cells through 
complement receptor type 3 (CR3) is dependent on the presence of cholesterol (Pieters, 
2008 & Gatfield and Pieters, 2000). Cholesterol is essential for both recruiting and 
retaining TACO and mycobacterial uptake by host cells. TACO, also known as coronin 1, 
is a peripherally associated protein with membrane but without any transmembrane 
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domains. Moreover, mycobacterium can consume cholesterol to survive inside the host 
cells (see 1.4.3). Therefore, internalization by some surface receptors is more beneficial 
to M. tuberculosis in long-term survival inside the host cells (Sambou et al., 2008; 
Pieters, 2008).  
 
1.4.2 Development	  of	  TB	  granuloma	  	  
 
Following internalization by macrophages, bacilli exploit different strategies to ensure 
long-term survival inside host cells. In vitro studies of interactions between macrophages 
and M. tuberculosis bacilli have shown that the macrophages produce signaling factors, 
called cytokines, when ligands to the Toll-like receptor (TLR) molecules on the surface 
of bacteria interact with host TLRs. TLRs are transmembrane proteins composed of 
repeated leucine-rich motifs in the exracellular domain and a cytoplasmic domain, which 
activates the signaling pathways including NF-kB. A very well studied example of TLR 
agonists is 19 kDa lipoprotein from M. tuberculosis, which induces the production of 
interleukin-12 (IL-12) by human macrophages, upon interaction with host TLRs 
(Brightbill et al., 1999). IL-12 is essential for mediating immune responses and 
generating T-helper type 1-lymphocyte responses.  
 
Tumor necrosis factor (TNF)-α is the main cytokine secreted by activated macrophages 
and involved in stimulating inflammatory response and therefore, recruiting other 
mononuclear cells to the site of infection (Russell, 2007). Recruited cells including foamy 
macrophages, mononuclear phagocytes and lymphocytes, as well as extracellular matrix 
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will surround the infected macrophages and form a very complex structure known as 
tubercle or granuloma (Figure 1-2). This structure is obvious in X-ray images of the lungs  
 
Figure 1-2. The life cycle of M. tuberculosis. In lungs alveolar macrophages engulf the 
bacilli and by producing cytokines activate T-lymphocytes and recruit other mononuclear 
cells from neighboring blood vessels. Recruited cells will surround the infected 
macrophages and form a very complex structure known as tubercle or granuloma. In 
patients with attenuated immune system mycobacterium activates, breaks granuloma and 
enters the airways, a process know as caseation. Adopted from Russell, 2007, with 
permission.   
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of infected person. Depending on the stage of disease, granuloma may contain both 
actively dividing and dormant bacilli. In fact granuloma represents a balance between M. 
tuberculosis and immune system until the immune system becomes weak, mainly due to 
old age, poor nutrition or co-infection with HIV, and infection turns into a life-threating 
condition. In this case the cell walls of granuloma break down and thousands of viable, 
infectious bacilli are released into the air, a process know as caseation (Figure 1-2) 
(Russell, 2007 and Kaufmann, 2001).  
 
1.4.3 Survival	  inside	  macrophages	  
 
M. tuberculosis survives inside the macrophage by halting phagosome maturation and 
therefore, preventing phagosome fusion with pre-formed lysosomes (Russell, 2007) 
(Figure 1-3).  The first mechanism to prevent phagosome maturation is through recruiting 
tryptophan aspartate-containing coat protein (TACO) to the phagosome. Gatfield and 
Pieters (2000) showed that TACO binds to the phagosomal membrane only in the 
presence of cholesterol. On the other hand, cholesterol is essential for mycobacterial 
uptake by macrophages. Cholesterol depleted macrophages show substantial reduction in 
the mycobacterial uptake by about 85 to 90% (Gatfield and Pieters, 2000). Just prior to 
phagocytosis, the concentration of cholesterol at the site of bacterial entry increases thus; 
bacilli will be packed in cholesterol rich phagosomes. Cholesterol acts as a binding site 
for mycobacterial cells and promotes the interaction between bacilli and receptors on the 
surface of host cells (Gatfield and Pieters, 2000). M. tuberculosis responds to 
internalization by activating calcium flux pumps (Pieters, 2008). These pumps are 
dependent on TACO and following activation stimulate the production of phosphatase 
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calcineurin that is essential for preventing phagosome-lysosome fusion. The exact role of 
calcineurin in blocking lysosomal delivery of mycobacteria is not well understood but 
activated calcineurin is known to be involved in several downstream signalling pathways 
including the transfer of transcription factors to the nucleus and dephosphorylation of 
proteins involved in endocytosis (Pieters, 2008).   
 
The second approach developed by M. tuberculosis to prevent phagosome-lysosome 
fusion is by preventing phosphatidylinositol 3-phosphate (PI3P) accumulation on 
phagosomal membranes (Pieters, 2008). Phosphatidylinositol 3-kinase (PI3 kinase) 
phosphorylates PI on position 3 (of inositol) to generate PI3P on the early endosomal and 
phagosomal membranes. PI3P acts as a docking site for several proteins involved in the 
fusion of phagosomes into lysosomes. M. tuberculosis uses two different strategies to 
block this trafficking event regulated by PI3P. The mycobacterial cell wall component 
lipoarabinomannan (LAM) interferes with the activity of PI3 kinase hVP34 and 
subsequently, prevents PI3P production on phagosomal membranes and phagosomal 
maturation into lysosomes. Additionally, M. tuberculosis prevents PI3P accumulation on 
phagosomal membranes via secreting SapM phosphatase into the host cell cytosol. SapM 
hydrolyzes PI3P accumulated on phagosomal membranes (Pieters, 2008).  
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Figure 1-3. Intracellular lifestyle of Mycobacterium tuberculosis. Following engulfing by 
alveolar macrophages, bacilli will end up in phagosome that has a very harsh 
environment. In order to survive, mycobacterium needs to arrest the phagosome 
maturation and subsequent fusion with preformed lysosomes. See section 1.4.3 for more 
details. However, some phagosomes mature and fuse with preformed lysosomes. 
Phagosomal maturation more likely happens in activated macrophages, producing IFN-γ 
interferon. Adopted from Kaufmann, 2001, with permission.  
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PknG is also, another protein secreted by M. tuberculosis that is involved in preventing 
phagosome-lysosome fusion. PknG is one of the several Ser/Thr kinases encoded by M. 
tuberculosis and one of two kinases (the second soluble kinase is PKnK) that is located in 
the cytosol and is not anchored into the membrane by a transmembrane helix (Pieters, 
2008). PknG is necessary for growth in vivo and is highly conserved in the genome of all 
pathogenic mycobacteria (Pieters, 2008). The exact mechanism of PknG in blocking host 
trafficking machinery is not well known but probably as a kinase phosphorylates a host 
molecule that is involved in phagosome maturation into lysosomes (Pieters, 2008).  
 
However, mycobacterium cannot always prevent phagosomal maturation and some 
phagosomes will succeed to mature and merge with endosomes prior to fusion with 
lysosomes. Phagosomal maturation more likely happens in activated macrophages, 
producing IFN-γ interferon. IFN-γ can stimulate anti-microbial mechanisms, notably 
reactive oxygen intermediates ROI and reactive nitrogen intermediates RNI, in 
macrophages (Kaufmann, 2001). 
 
In vitro analysis of infected macrophages grown in culture indicates that the bacterium 
inside the phagosome is not isolated from the extracellular environment and can 
communicate with extracellular environment through fusion with recycling endosomes 
(Russell, 2007). For instance, mycobacterium obtains the iron, which is essential for 
intracellular survival, from endosomes using specialized iron-scavenging molecules 
(Kaufmann, 2001).  
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1.4.4 Beyond	  phagocytes	  
 
 
Mycobacterial components can increase the success of bacterium by manipulating the 
inflammatory response and causing persistence and subsequently late stage damage and 
transmission (Russell, 2007). It has been shown that cell wall components 
lipoarabinomannan and arabinomannan are released inside the infected macrophages and 
trafficked into the uninfected cells. Following the release of cell wall components into the 
M. tuberculosis vacuole, they accumulate in multilamellar vesicles. Multilamellar bodies 
come together in the multivesicular lysosomes know as major histocompatibility complex 
(MHC) class II-enriched compartments, which are released from infected macrophages 
into the extracellular environment through exocytosis. Exosomes are taken up by 
neighboring cells. If these lipids have biological activities, then their release can enhance 
the mycobacterium influence without instant prevention by host cells.  
 
1.5 Current	  treatment	  of	  TB	  and	  rise	  of	  MDR	  and	  XDR	  strains	  	  	  
 
The current treatment for tuberculosis is based on using a cocktail of drugs, isoniazid, 
rifampicin, ethambutol and pyrazinamide, known as first line anti-TB drugs for duration 
of six month (Table 1-1 and 1-2). You can find a comprehensive list of anti-TB drugs 
with their targets in the Supplements section (Table S9-1). The regimen starts by using all 
four drugs everyday for two month and continues by using isoniazid and rifampicin for 
additional four month. This regimen has proved to be efficient in more than 95% of 
cases, especially in patients under directed observed therapy (DOT) and is prescribed to 
both pulmonary and extrapulmonary TB patients (Zumla, Nahid and Cole, 2013). 
However, there are some disadvantages attached to this regimen including: drug 
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intolerance and toxicities, causing interruptions in the treatment or changing the regimen; 
increasing the treatment duration in cases with reoccurrence TB and potential drug-drug 
interactions, especially in patients co-infected with HIV (Zumla, Nahid and Cole, 2013).  
 
The concern about TB is on rise as some stains of M. tuberculosis have developed 
resistance against current anti-TB drugs (Koul et al., 2011). Strains resistant to isoniazid 
and rifampicin are known as multi-drug resistant (MDR) and those resistant to first line 
drugs as well as one or more fluoroquinolones (such as ciprofloxacin, levofloxacin, 
moxifloxacin and ofloxacin) and injectables (amikacin, capreomycin, kanamycin) are 
referred to as extensively drug resistant (XDR) (Dye, 2009). It is estimated that there are 
650,000 new cases of MDR-TB annually (Zumla, Nahid and Cole, 2013). The treatment 
duration for MDR patients with no history of previous TB is about 20 month and for 
those with previous records of MDR-TB treatment is 28 month. The treatment includes a 
combination of four second-line drugs everyday and under DOT (Zumla, Nahid and Cole, 
2013). Treating XDR-TB is more challenging than MDR, as it requires administering 
third-line anti-TB drugs, which are more expensive and usually have more side effects. 
The most recent categorization of TB includes a new generation of strains that are 
resistant to all first and second-line anti-TB drugs known as totally drug-resistant 
tuberculosis or TDR (Zumla, Nahid and Cole, 2013). Although the rate of TDR incidence 
is low, it illustrates the importance and urgency of developing new anti-TB drugs.  
 
It has been shown, however, that incidence of MDR can be halted and reversed by good 
programmed management, including prompt diagnosis and appropriate treatment of drug-
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resistant TB, as it has been illustrated in counties such as Estonia, Hong Kong and USA 
(Dye, 2009). Also, introducing new anti-TB drugs in recent years have increased our 
chance in combat against M. tuberculosis (Table S9-2). Developing new drugs that 
suppress new essential targets in M. tuberculosis can also help to overcome the TB 
resistance problem (Lamichhane, 2011). You can find list of recently identified targets in 
M. tuberculosis in supplements table S9-3.  
 
Table 1-1. Classification of anti-TB drugs according to their efficacy in TB treatment. 
They are used to treat susceptible and resistant strains of tuberculosis. First line anti-TB 
drugs are used to treat drug-susceptible tuberculosis in a regimen consists of four drugs 
for duration of six month. Second line drugs are prescribed for drug-resistant TB and 
third line anti-TB drugs are not well defined in terms of efficacy and target.  
Classification  Drugs 
First line anti-TB drugs 
(oral) 
Ethambutol, isoniazid, pyrazinamide, rifampicin/rifampin, 
rifambutin, rifapentine 
 
Second line anti-TB 
drugs (injectables) 
Amikacin, kanamycin, capreomycin, streptomycin, viomycin 
 
Second line anti-TB 
drugs (oral and 
injectable 
fluoroquinolones) 
Ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and 
ofloxacin 
 
Third-line anti-TB drugs Amoxicillin plus clavulanate, clarithromycin, clofazimine, 
imipenem plus cilastatin and linezolid 
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Table 1-2. Approved drugs to treat tuberculosis. Most commonly used drugs in TB treatment. You can find comprehensive list of all 
approved anti-TB drugs in Appendix Table 1 (Brennan, Young and Robertson, 2008).  
Drug name  Drug target/mechanism Drug resistance mechanism  In vitro activity  
Ethambutol (ETH) Inhibits cell wall biosynthesis 
through inhibiting arabinosyl 
transferase 
Mutations in M. tuberculosis 
embA or embB 
Active against M. tuberculosis 
(H37Rv) with MIC 0.5 µg/ml 
Isoniazid (INH) A prodrug activated by KatG 
Inhibits fatty acid synthesis by 
inhibiting InhA 
Mutation in inhA and activating 
enzyme KatG 
MIC against M. tuberculosis 
(H37Rv) 0.025 µg/ml 
Rifampicin Inhibits transcription by binding to 
RNA polymerase β-subunit 
Mutations in rpoB gene  
Pyrazinamide (PZA) It is not well understood but 
experimental evidence suggests that 
PZA converts to pyrazinoic acid 
(POA) by pyrazinamidase (PZAase). 
POA can inhibit major processes 
within the cell, for instance fatty 
acid synthase and membrane 
transport, through acidifying the cell  
Mutations in PZAase MIC against M. tuberculosis 
(H37Rv) 6-50 µg/ml at pH 5.5 
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Continued from last page. Second line anti-TB drugs. 
Drug name  Drug target/mechanism Drug resistance mechanism  In vitro activity  
Amikacin (AMI) Inhibits protein synthesis by binding 
to the A site of 16S rRNA in the 30S 
ribosomal subunit  
Ribosomal changes in the 16S 
rRNA 
Bactericidal activity against all 
the drug-sensitive clinical 
isolates of M. tuberculosis at 2 
µg/ml 
Capreomycin (CAP) Inhibits protein synthesis  Ribosomal changes in the 16S 
rRNA 
Active against M. tuberculosis 
(MIC 2µg/ml) and M. avium  
Cycloserine (CYS) Inhibits peptidoglycan synthesis Overexpression of the alanine 
racemase gene in M. smegmatis 
Active against M. tuberculosis 
(H37Rv) with MIC 25 µg/ml 
    
Ethionamide (ETA) Inhibiting enoyl-ACP reductase 
encoded by inhA gene 
Mutation in inhA gene Active against M. tuberculosis 
(H37Rv) with MIC 0.25 µg/ml 
Kanamycin (KAN) Inhibits protein synthesis by binding 
to the A site of 16S rRNA in the 30S 
ribosomal subunit 
Ribosomal changes in the 16S 
rRNA 
MIC against M. tuberculosis 
(H37Rv) 2 µg/ml 
Para-aminosalicylic acid 
(PAS) 
Inhibits thymidylate synthase, ThyA Mutations in thyA gene MIC against M. tuberculosis 
(H37Rv) 0.3-1 µg/ml 
Streptomycin (STR) Similar to amikacin and kanamycin, 
inhibits protein synthesis through 
binding to the A site of 16S rRNA in 
the 30S ribosomal subunit 
 
Ribosomal changes in the 16S 
rRNA and ribosomal protein 
S12 
MIC against M. tuberculosis 
(H37Rv) 1 µg/ml 
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1.6 The	  mycobacterial	  cell	  envelope	  	  
 
1.6.1 Peptidoglycan	  	  
 
The unique cell envelope of M. tuberculosis composed of plasma membrane, cell wall 
and capsule protects the bacilli against the antibiotics and is involved in pathogenesis 
(Brennan, 2003) (Figure 1-4). The plasma membrane is a typical bacterial membrane but 
paramount to the mycobacterium survival (Daffe and Etienne , 1999). The cell wall core 
represents the hallmark of mycobacterial cell envelope and consists of mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex (Figure 1-4). Like peptidoglycan (PG) 
in Gram-negative bacteria, M. tuberculosis peptidoglycan is responsible for maintaining 
the cellular shape and osmotic stability and is composed of N-acetyl-α- D -glucosamine 
(GlcNAc) and a modified muramic acid (Mur) cross linked with L-alanyl- D -
isoglutaminyl-meso-diaminopimelyl- D -alanine (L-Ala- D -Glu-A2pm- D -Ala) with the 
Glu being further amidated (Figure 1-5). However, the main distinct feature of M. 
tuberculosis peptidoglycan, compare to other bacteria, is that some or all of the Mur 
residues are N-acetylated with glycolic acid (MurNGlyc) rather than N-acetylated 
(MurNAc). Peptide cross-links are composed of cross-links between two A2pm residues 
or between A2pm of MurNGlyc from one strand and D -Ala from MurNGlyc from a 
second strand (Brennan, 2003 and Kaur et al., 2009). A specific linker, a rhamnosyl 
residue attached to a N-acetylglucosaminosyl-1-phosphate residue, attaches 
peptidoglycan to the galactan domain of arabinogalactan (Kaur et al., 2009).  
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Figure 1-4. The Mycobacterium tuberculosis cell envelope. The envelope is composed of 
plasma membrane, cell wall core and capsule. Peptidoglycan, arabinogalactan and 
mycolic acids are the major constituents of the cell wall. Peptidoglycan contains N-acetyl 
muramic acid and N-acetyl glucosamine cross-linked by short peptides. Arabinogalactan 
is composed of arabinan chains attached to a linear galactan chain. A linker connects the 
peptidoglycan to the galactan part of arabinogalactan. The most outer layer of cell 
envelope is capsule that plays key roles in pathogenicity and resistance of mycobacterium 
to antibiotics. Adopted from (Kaur et al., 2009), with permission.   
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Figure 1-5. Structure of M. tuberculosis peptidoglycan before cross-linking. R1 and R2 
represent N-glycolylmuramic acid and N-acetylglucosamine residues of adjacent 
monomers; R3, H or the linker unit of arabinogalactan; R4, H, CH3 (N-acetyl) or CH2OH 
(N-glycolyl); R7, H or cross-link to last D -Ala or to the D -center of another meso-DAP 
residue; R5, R6, R8 OH, NH2 or OCH3. Picture from (Kaur et al., 2009), with 
permission.  
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1.6.2 Arabinogalactan	  	  
 
 
The function of arabinogalactan (AG) is not well understood but apparently it produces a 
thick hydrophilic region between the PG and mycolic acid layer (Kaur et al., 2009). AG 
is composed of two domains, a galactan domain and one arabinan domain (Figure 1-4). 
The galactan domain is made of 30 β-(1→5) and β-(1→6) linked galactofuranose (Galf) 
residues attached to three arabinan chains at position 8, 10 and 12, each containing 31 β-
(1→2), α-(1→5) and α-(1→3) linked arabinofuranose (Araf) residues (Tam and Lowary, 
2009) (Figure 1-4 and 1-6). The molecular mechanism of AG biosynthesis has been well 
studied. Linker, galactan and arabinan domains of AG are synthesized on decaprenyl 
phosphate (Dec-P) and transferred to PG by an unknown ligase (Kaur et al., 2009). The 
first Galf residues are attached to the linker unit by galactosyltransferase Rv3782 (GlfT1) 
and the subsequent Galf residues are added by Rv3808c (GlfT2). Membrane-associated 
glycosyltransferases (GTs) are responsible for elongation of the arabinan domain of AG. 
So far seventeen GTs have been identified (Kaur et al., 2009). AftA (Rv3792) catalyzes 
the addition of first Araf residue to the galactan chain. AftB (Rv3805c) and Aftc 
(Rv2673) catalayze the addition of β-(1→2) and α-(1→3) linked Araf units to the non-
reducing termini of the arabinan domain of AG, respectively. EmbA and EmbB act as α-
(1→5) arabinofuranosyl transferases that extend the arabinan chain after the first Araf 
residue (Figure 1-6).  
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Figure 1-6. Chemical structure of arabinogalactan (AG) from M. tuberculosis and role of 
AftA, AftB, AftC, EmbA and EmbB in its synthesis. From Birch et al., 2008. For more 
information see section 1.6.2, with permission.    
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1.6.3 Mycolic	  acids	  	  
 
Mycolic acids composed of long chain (C70-C90) α-alkyl, β-hydroxy fatty acids, are a 
major component of the cell wall in M. tuberculosis (Takayama, Wang and Besra, 2005) 
(Figure 1-7). Mycolic acids are highly insoluble and along with free glycolipids called 
trehalose dimycolate (TDM), are responsible for impermeability of the mycobacterial cell 
envelope. They protect mycobacterium against antibiotics and the host immune system 
(Takayama, Wang and Besra, 2005 and Sani et al., 2010).  The cyclopropane rings of 
mycolic acids protect bacillus against oxidative stress (Takayama, Wang and Besra, 
2005).  
 
Recent cryo-transmission electron microscopy (EM) data has shown that mycolic acids, 
referred to as mycomembrane, form a structure similar to the outer membrane of Gram-
negative bacteria around the arabinogalactan-peptidoglycan layer (Sani et al., 2010). 
Mycolic acids can be divided into three groups α, methoxy and keto mycolic acids 
(Figure 1-7). More than 70% of mycolic acids are α-mycolic acids and only 10 to 15% of 
mycolic acids are methoxy and keto-mycolic acids.  
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Figure 1-7. Chemical structure of mycolic acids from M. tuberculosis. For more 
information see section 1.6.3. Adopted from (Takayama, Wang and Besra, 2005). With 
permission.  
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1.6.4 Capsular	  layer	  
 
 
The term capsule was used for the first time by Chapman and colleagues in 1958 
(Chapman, Hanks and Wallace, 1959). Using ultrathin sectioning and electron 
microscope they observed a loose disposed membrane around the cell wall in M. 
lepraemurium. They proposed that tissue cells are likely responsible for producing 
capsule since this layer is in remote distance from bacterial cells and often two or three 
bacteria can be found within one membrane. (Chapman, Hanks and Wallace, 1959). 
Visualizing capsular layer and determining its nature was abandoned since Chapman 
study until recently when Sani and colleagues reasoned that growing the cells without 
detergent and agitation might be the key to detect the capsule in an intact form (Sani et 
al., 2010). They also used Gram-negative bacterium Shigella flexneri as a control (Figure 
1-8A). M. smegmatis cells grown in the presence of Tween-80 and agitation (to prevent 
clumping) showed a cell envelope structure similar to S. flexneri (Figure 1-8B). But M. 
smegmatis and other mycobacterial species cells grown without perturbation showed an 
extra layer surrounding their mycomembrane (Figure 1-8 C-F).  
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Figure 1-8. Visualization of capsule in native-state using electron microscope. (A) Cryo-
electron micrographs of intact S. flexneri cells, (B) M. smegmatis cells grown in the 
presence of detergent with agitation, which show a cell envelope similar to S. flexneri.  
(C) M. smegmatis cells grown without perturbation showing the presence of an extra 
layer (bracket) around cell wall. Observing capsule around the mycomembranes of M. 
tuberculosis (D), M. marinum (E) and M. bovis BCG (F). From Sani et al., 2010, with 
permission.   
 
In order to support this observation that the extra layer is capsule, they immuno-labeled 
one of the mycomembrane proteins, OmpATb porin on M. smegmatis cells 
overexpressing this protein. Antibody efficiently labeled mycomembrane in both 
perturbed and non-perturbed conditions, but in latter condition, the capsular layer was 
distinct from the mycomembrane. This study revealed that both pathogenic and non-
pathogenic strains contain a capsular layer around the cell wall and the capsule is distinct 
from the mycomembrane (Sani et al., 2010).  
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1.6.4.1 Capsular	  functions	  	  
 
In an earlier study by Cywes and colleagues, it was shown that capsular D-glucan 
mediates the direct (nonopsonic) binding of bacilli to the phagocytic receptor CR3 in the 
absence of serum (Cywes et al., 1997). In other words, capsular polysaccharides can act 
as ligands for direct binding to CR3 receptors. Binding to the CR3 lectin site leads to 
receptor activation and stimulation of phagocytosis (Cywes et al., 1997). Interestingly, 
phagocytosis via CR3 is considered as a safe portal of entry for M. tuberculosis because 
phagocytosis through this receptor leads to inhibition of respiratory burst and production 
of interleukin 12 (IL-12) (Ehlers and Daffe, 1998). Daffe and Etienne also demonstrated 
that capsule mediates the adhesion and penetration of bacilli into the host cells, since 
capsule removal significantly reduces the bacterial binding to the macrophages (Daffe 
and Etienne, 1999 and Sani et al., 2010).  
 
Capsule removal by treating the M. bovis BCG culture with detergent significantly 
reduced the amounts of IL-12p40, IL-6 and TNFα (about 30%) indicating the role of 
capsule in diminishing the pro-inflammatory responses (Sani et al., 2010). Moreover, 
Sambou and his group showed that reduction in capsular glucan level, by disrupting α-
glucan biosynthesis enzyme GlgA, diminishes the ability of bacilli to persist in mice 
(Sambou et al., 2008). In a more recent study, Geurtsen found that the C-type lectin DC-
SIGN acts as a cellular receptor for M. tuberculosis α-glucan (Geurtsen, et al., 2009). 
This binding induces the production of cytokine IL10. IL10 production prevents dendritic 
cells (DCs) maturation (during maturation DCs convert from antigen capturing to antigen 
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presenting mode) and subsequently eliminates the antigen-presenting function of DCs 
and initiating the immune response (Geurtsen, et al., 2009).  
 
Several distinct proteins have been detected in the capsular extracts of M. marinum 
including EspB (MM5457), EspF (MM5440), fatty acid synthase Fas (MM3962), iron-
regulated elongation factor Ef-tu Tuf (MM1014), chaperonin GroEL1 (MM1126), KatG 
(MM2914), ESAT-6, CFP-10 and PPE68_1 (Sani et al., 2010). The majority of these 
proteins are secreted by ESX-1, which is a type VII secretion system, known for its role 
in mycobacterial pathogenicity (Figure 1-9) (Stoop, Bitter and van der Sar, 2012).  
 
In a recent study Weerd and colleagues investigated the epitope specificity of the anti-
glycogen IgM antibody (Mab, IV58B6) against α-glucan polymers and glycogen using 
saturation transfer difference NMR (STD NMR) technique (Weerd et al., 2015). They 
showed that Mab is able to bind glycogen and capsular α-glucan and identifies the inner 
α-(1-4)-linked glucose as epitope.  Additionally, they used Mab to create a transposon-
library based screening technique to determine putative genes involved in capsular α-
glucan biosynthesis. To achieve this, they cultured the transposon mutant libraries over 
nitrocellulose filters set on Middlebrook 7H10 agar plates. Then, they generated a back 
up by transferring the nitrocellulose filters on top of new filters (second filters) and 
cultured them on fresh Middlebrook 7H10 agar plates. In this way the capsular α-glucan 
diffused to the second filters and first filters were kept aside as back up. The second 
filters were immunostained with Mab to detect the amount of capsular α-glucan and 
compared with the level of capsular α-glucan in wild type strain determined by the same 
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technique. Using this approach they identified 140 transposon mutants participating in 
biosynthesis of capsular α-glucan including well-known enzymes in α-glucan production, 
GlgB, GlgC and GlgP (Weerd et al., 2015).  
 
1.6.4.2 Capsular	  composition	  	  
 
Capsular layer is mainly composed of polysaccharides and proteins (about 97% of the 
total material) and small amount of lipids. The main polysaccharide is α-D-glucan with a 
molecular weight of about 100 kDa.  Glucan has a similar structure to intracellular 
glycogen, -->4-α-D-Glcp-1--> core substituted at some six positions with short chains, 
though, former has higher molecular weight and is more compact than the glycogen 
(Dinadayala, et al. 2008). Arabinomannan and mannan with 13 kDa and 4 kDa molecular 
weights, respectively, are also frequently found in the capsule. The mannan segment of 
arabinomannan and mannan consisted of >6-α-D-Manp-1> core substituted with a α-D-
mannosyl residue at some positions 2 (Daffe and Etienne , 1999).  
 
The outermost capsule is a complex mixture of proteins including secreted proteins, 
exported to the extracellular medium, cell envelope-associated or cytoplasmic proteins. 
Since the secreted proteins are limited around the bacilli and in contact with the host 
membrane, it is very difficult to distinguish between secreted proteins and surface-
associated proteins. Some of the main capsular proteins of M. tuberculosis are 
summarized in Table 1-3. Capsular proteins, such as β-lactamase Y49, are involved in the 
resistance of bacilli to β-lactam antibiotics, or other capsular proteins, especially 
catalase/peroxidase and superoxide dismutase protect the bacilli against the host’s 
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microbicidal mechanisms by detoxification of reactive oxygen intermediates (Daffe and 
Etienne , 1999). Capsular lipids form only a small fraction of the capsule and located 
either on the cell surface, e. g. phospholipids, species specific lipids (dimycocerosate of 
phthiocerol) and type specific lipids of M. tuberculosis (PGL), or present in the inner 
parts of the capsule, such as trehalose dimycolates (Daffe and Etienne , 1999).  
 
α-D-glucan. Glucan as the main constituent of the mycobacterium capsule is synthesized 
inside the cytoplasm and is transported to the cell surface by as yet unknown transporters. 
Several secretion systems and porins, such as ESX-1 and OmpATb have been identified 
in the mycobacterium cell wall that are involved in the transportation of macromolecules 
through cell wall, but their roles in the glucan translocation is not still determined (Figure 
1-9). ESX-1 is a type VII secretion system located on the plasma membrane and 
responsible for secretion of potent T cell antigens such as ESAT-6 and CFP-10. In        
M. marinum a large amount of capsular proteins are in fact secreted by ESX-1 pathway 
(Sani et al., 2010). OmpATb is a porin present in the mycomembrane of M. tuberculosis 
and is essential for the passage of small hydrophilic molecules through the cell wall 
(Senaratne, et al. 1998).  
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Figure 1-9. Schematic of the spatial organization of mycobacterial cell envelope layers 
and localization of the ESX-1 secretion system. The size and relative position of different 
layers of cell envelope including plasma membrane, arabinogalactan, mycolic acids and 
capsule has been depicted. The majority of proteins in the capsule are secreted by ESX-1 
secretion system. Generated using ChemBioDraw.  
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Table 1-3. Some of the main capsular proteins of M. tuberculosis (Daffe and Etienne, 
1999). 
Protein (synonym) Gene  Function 
β-lactamase Y49 
(Gen Bank 1370234) 
blaC  β-lactam antibiotics resistance  
FAP-TB  apa Fibronectin-binding protein (antigen)  
MPT53  mpt53 15 kDa antigen  
MPT63 mpt63 16 kDa antigen 
MPT64 mpt64 23.5 kDa antigen 
Mycoloyl transferase A, B, C fbpA 
fbpB 
fbpC1 
Cell wall synthesis  
Fibronectin-binding protein 
T-cell antigens  
Catalase/Peroxydase (MPT35) katG Survival in host cells, Reactive oxygen 
intermediates detoxification  
CFP 29  Cfp29 T-cell antigen  
ESAT-6 Esat-6 T-cell antigen  
Heat Shock Protein Acr 
(16 kDa alpha-crystallin HSP) 
hspX Resistance to oxygen limitation  
Nicotinamidase  
(pyrazinamidase)  
pncA Activation of pyrazinamide  
Superoxide dismutase 
(MPT58) 
sodA Reactive oxygen intermediates 
detoxification 
Thioredoxine (MPT46)  trxA Reactive oxygen intermediates 
detoxification 
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Mycobacteria produce three α-glucans; cytosolic glycogen, capsular α-glucan and 
methylglucose lipopolysaccharide in three interlinked pathways (Chandra, Chater and 
Bornemann, 2011) (Figure 1-10). The classical GlgC-GlgA pathway generates cytosolic 
glycogen in a series of reactions from glucose 1-phosphate. Diphosphoglucose 
pyrophosphorylase (GlgC) phosphorylates glucose 1-phosphate to glucose diphosphate. 
Subsequent polymerization of latter monosaccharide is mediated by glycogen synthase 
(GlgA) followed by introducing branches at some positions 6 by GlgB. The final 
glycogen is highly soluble and is used by bacterial cells as a carbon/energy storage 
molecule. In situations that glucose is needed two enzymes, glycogen phosphorylase 
(GlgP) and debranching enzyme (GlgX) breakdown glycogen to glucose 1-phosphate 
(Figure 1-10). Orthologous genes of GlgC-GlgA have been identified in M. tuberculosis 
(Sambou et al., 2008). In order to study the role of glgC, glgA and treZ genes in capsule 
biosynthesis and subsequently its impacts on persistence, Sambou and colleagues 
generated mutants of orthologous of these genes in M. tuberculosis and labeled them as 
H37RvΔglgC, H37RvΔglgA and H37RvΔtreZ, respectively. They observed two fold 
decrease in glucan production in H37RvΔglgC and H37RvΔglgA but glucan production 
was not affected in H37RvΔtreZ. Mice infected with H37RvΔglgC and H37RvΔtreZ 
showed similar results to those mice infected with wild type H37Rv strain in terms of 
virulence and persistence. However, the ability of H37RvΔglgA mutants to persist in 
mice was significantly reduced indicating a direct role for the capsular glucan in 
persistence (Sambou et al., 2008). 
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Figure 1-10. Three interlinked pathways involved in the α-glucan biosynthesis. Adapted from (Chandra, Chater and Bornemann, 
2011). 
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The production of glycogen is highly connected to trehalose metabolism. Trehalose, α, α-
1, 1- glucosyl-glucose, is also another abundant source of carbon in bacterial cells that 
protects membrane and cellular proteins against environmental stresses such as cold, 
dehydration, heat and oxygen radicals.  Trehalose, also, is involved in regulating glucose 
metabolism and is a component of various cell wall glycolipids in mycobacteria and other 
related organisms (Elbain et al., 2003 and Elbein, et al. 2010). Trehalose dimycolate 
(cord factor) composed of a trehalose core with the unusual fatty acid mycolic acid 
esterified at some position 6 is the most toxic lipid produced by M. tuberculosis and 
responsible for impermeability of the cell wall to different antibiotics (Zhang et al., 
2011). There are two different pathways involved in the trehalose biosynthesis. The first 
pathway referred to as TPS/TPP or OtsA/OtsB uses UDP-glucose to make trehalose 
(Figure 1-11). Trehalose phosphate synthase (TPS, OtsA) initially transfers glucose from 
UDP-glucose to glucose 6-phosphate to make trehalose phosphate and releases UDP and 
then trehalose phosphate phosphatase (TPP, OtsB) removes the phosphate group to form 
trehalose and an inorganic phosphate (Elbain et al., 2003). Unlike to glycosyltransferases 
from many organisms that are very specific for the donor nucleotide-glucose, TPS from 
M. smegmatis and M. tuberculosis can utilize any type of ADP-glucose, UDP-glucose, 
TDP-glucose, CDP-glucose or GDP-glucose to make trehalose, suggesting the 
importance of trehalose biosynthesis for these organisms (Elbain et al., 2003). The 
second pathway also uses two enzymes to convert glycogen to trehalose. The first 
enzyme, maltooligosyl trehalose synthase (TreY), changes the α- 1,4 linkage at the 
reducing end of glycogen to α, α, 1, 1 linkage and the second enzyme, maltooligosyl 
trehalose trehalohydrolase (TreZ), cleaves the trehalose from glycogen chain (Elbain et 
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al., 2003 and Pan et al., 2008). Breaking glycogen branches is mediated by debranching 
enzyme TreX (also known as GlgX).  
 
 
 
Figure 1-11. The most widely demonstrated pathway responsible for trehalose 
biosynthesis in most organisms. During this pathway trehalose phosphate synthase (TPS 
or OtsA) transfers glucose from UDP-glucose to glucose-6-phosphate to form trehalose-
6-phosphate and then the phosphate group is removed by trehalose phosphate 
phosphatase (TPP or OtsB) to make free trehalose (generated with ChemBioDraw).  
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Methylglucose lipo-polysaccharide is produced in a two-enzymatic pathway known as 
Rv3032. The first enzyme, α-1,4 glucosyltransferase (Rv3032), turns over UDP-glucose 
or ADP-glucose to linear glucan and the second enzyme, Rv3031, introduces branches to 
the linear glucan. Methylglucose lipo-polysaccharides are composed of about 20 glucose 
residues attached by α-1,4 links and 10% branching at positions 6. Although these 
molecules were discovered several decades ago, their function is not still clear but recent 
studies suggest that they are likely involved in fatty acid biosynthesis regulations within 
the cells (Chandra, Chater and Bornemann, 2011).   
 
The fact that disruption of Rv3032 pathway has no effects on capsular glucan levels 
convinced Chandra and his colleagues to conclude that the newly discovered GlgE 
pathway should be responsible for capsular α-glucan biosynthesis in mycobacteria 
(Chandra, Chater and Bornemann, 2011). However, Sambou and his group’s efforts in 
studying the role of GlgC and GlgA from first pathway on capsular glucan production 
showed a complicated link between these two pathways. They observed that while in 
glgC knockout mutants both capsular glucan and glycogen production levels are reduced, 
in ΔglgA mutants only capsular glucan production is affected. Moreover, latter mutants 
show lower persistence in mice cells,  indicating the presence of a functional link 
between GlgA, capsular glucan production and immune system responses (Sambou et al., 
2008).    
 
The newly discovered pathway, GlgE pathway, involves a novel enzyme, 
maltosyltransferase GlgE, which transfers maltose from maltose 1-phosphate (M1P) to 
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maltooligosaccharides and genetically validated as a novel anti-tuberculosis target 
(Kalscheuer et al., 2010). The pathway also consists of three other enzymes as follows: 
trehalose synthase (TreS), maltokinase (Pep2) and GlgB. TreS catalyzes the reversible 
conversion of trehalose to maltose (MTase activity) and Pep2 converts the latter 
disaccharide into maltose 1-phosphate.  
 
1.7 GlgE	  pathway	  enzymes	  
 
1.7.1 Trehalose	  synthase	  	  
 
By sequence similarity, trehalose synthase (TreS) is a member of glycoside hydrolase 
family GH13 that catalyzes the reversible interconversion of maltose and trehalose 
(Caner et al., 2013). However, it has been shown that TreS does not contribute 
significantly in the de novo production of trehalose in mycobacteria and mainly works in 
the direction of α-maltose production, except in organisms that have access to the large 
amounts of cytosolic maltose from intracellular or extracellular sources (Miah, et al. 
2013). Compare to other members of the GH13 family, which are monomeric, the crystal 
structure of TreS shows that this protein is a tetramer (Figure 1-13A) (Caner et al., 2013 
& Roy et al., 2013). The members of this family have two conserved domains: a TIM 
barrel fold and a C-terminal β-sandwich domain (Figure 1-13B). TIM barrel, also known 
as triosephosphate isomerase, is composed of 8 β-sheets surrounded by 8 α-helices. The 
TIM barrel core is decorated with a few loops that play different functional roles. For 
instance, the β3- β4 loop forms a calcium binding site, β7- β8 loop folds over the central 
β-barrel in chain A but is disordered in chain B and β6- β7 loop encompasses a helix-
turn-helix motif (Figure 1-13B). The C-terminal domain consists of seven-stranded anti-
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parallel β-sheets (Figure 1-13C). The function of this domain is not very clear but other 
members of the GH13 family harbor a carbohydrate-binding domain in this part of the 
enzyme (Caner et al., 2013).  
 
Glycoside hydrolases are a group of enzymes that catalyze the hydrolysis of glycosidic 
bond between two or more carbohydrates using two different mechanisms, retaining or 
inverting (McCarter and Withers, 1994). Inverting glycoside hydrolases utilize a one step, 
single displacement mechanism, to change the anomeric configuration of substrate. 
During this process the general acid first attacks the hydrogen of water and in turn the 
oxygen, which now has a negative charge, attacks the anomeric carbon (Figure 1-12A). 
General acid aids this process by providing hydrogen during the transition state for 
glycosidic oxygen. On the other hand, retaining mechanism is a two step, double 
displacement process, in which the nucleophile amino acid attacks the anomeric center 
and forms a covalent glycosyl-enzyme intermediate (Figure 1-12B). At the same time, the 
second amino acid participates as an acid and protonates the glycosidic oxygen. In the 
second step, water attacks the glycosyl-enzyme intermediate and the second residue 
deprotonates the water molecule by acting this time as a base. As it will be explained 
later TreS catalyzes the interconversion of trehalose and maltose via a double 
displacement process (retaining) (Figure 1-15).  
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Figure 1-12. Schematic mechanisms of glycoside hydrolases. (A) Inverting and (B) 
retaining mechanisms. Adapted from (McCarter and Withers, 1994).  
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The active site of TreS is situated at the top (C-terminal) rim of the β-barrel, composed of 
Asp238 (nucleophile), Glu280 (general acid) and Asp350 (unknown function) (Figure 1-13). 
The structure of MtbTreS catalytic site is consistent with the catalytic mechanism of 
MsmTreS proposed by Zhang and colleagues (2011) (Figure 1-15). Asp238 attacks the 
glycosidic bond and forms a covalent-β-glucosyl-enzyme intermediate. The released 
glucose remains within the active site and reorients in such a way that 1-hydroxyl group 
or the 4-hydroxyl group is ready for re-attack in a productive complex. Although 
glucosyl-enzyme intermediate is protected in an enclosed site, it goes under some transfer 
to water and about 10% hydrolysis occurs. In Pseudomonas mesoacidophila two aromatic 
residues, Phe256 and Phe280, form a clamp at the entrance of the enzymatic active site 
(Zhang et al., 2011). Mutation of any of these clamping phenylalanines increases the 
enzymatic hydrolysis and double mutant leads to exclusive hydrolysis. In MtbTreS, β7- 
β8 loop acts as a clamp to obstruct the diffusion of glucose moieties (Roy et al., 2013).  
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Figure 1-13. The crystal structure of trehalose synthase (TreS) from M. tuberculosis. (A) 
The crystal structure of TreS with two 2-fold rotational symmetry axes, chain A maps to 
chain A’ and B into B’ and subsequently chain A symmetrically superimposes to chain B. 
(B) Illustrating the TIM barrel fold as the conserved core of the TreS structure. (C) 
Representing an antiparallel β-sandwich domain at the C-terminus. This domain mediates 
intersubunit contacts. Adopted from Roy et al., 2013, with permission.  
 
 
 
 
A 
B 
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Figure 1-14. Position of active site and topology of solvent channel formed between 
chains A and B of MtbTreS. (A) Illustrates the position of active site of TreS at the top 
rim of β-barrel. Asp238 and Glu280 constitute the catalytic residues of active site. (B) 
Molecular surfaces of chains A and B in the TreS tetramer. β7- β8 loop is shown as a 
yellow ribbon. (C) Close up view of the solvent channel formed between active sites of 
chains A and B. The chain A is shown transparent so it can illustrate the catalytic 
residues of active site and putative substrate. Adapted from Roy et al., 2013. Panel A of 
this figure was generated with MacPyMOL software, with permission.   
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Figure 1-15. The catalytic mechanism of TreS proposed by Miah et al., 2013 (generated 
with ChemBioDraw). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
HOHO
OH
OOH
O
HO
OH
OH
OH
O O
Asp
OO
Glu
H
O
HOHO
OH
OH
O OH
OH
OH
O O
Asp
OO
Glu
OH
HO
O
HOHO
OH
OH
O O
Asp
OO
Glu
Rotate inside the
active side
O
HOHO
OH
OH
O O
Asp
OO
Glu
H
O
HO
HO
HO
OHO
O
OH
HO
HO
OH
HO
!"#$%&'(#)
*%&+'(#)
 45 
Pan and colleagues (2008) suggested that TreS has also α-amylase activity, in addition to 
maltose to trehalose interconversion activity (referred to as MTase), and can convert 
glycogen to maltose and subsequently to trehalose, suggesting this enzyme is providing 
another pathway to convert glycogen to trehalose. However, solving the MsmTreS 
structure co-crystallized by acarbose, a potent α-glucosidase inhibitor, has casted doubt 
on this model (Caner, et al. 2013). Although, a binding site was identified well remote 
from the active site, it didn’t contain any catalytic residues required for amylase activity. 
Even in case that TreS has minor amylase activity, it is not physiologically significant, 
since it has been shown that wild type M. smegmatis accumulates large amounts of 
glycogen when grown in high concentrations of trehalose but treS mutants do not 
accumulate glycogen, supporting the dominant anabolic role of TreS (Kalscheuer et al., 
2010).  
 
According to PISA (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) molecular 
assembly analysis data, it is suggested that TreS forms a tetramer in the solution. Roy and 
his colleagues using analytical ultracentrifugation in sedimentation equilibrium mode and 
solution X-ray scattering, confirmed the self-assembly of MtbTreS into a tetrameric state, 
consistent with the crystal structure (Roy et al., 2013 & Caner et al., 2013).   
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1.7.2 Maltokinase	  Pep2	  
 
 
The crystal structure of Pep2 from M. tuberculosis (Li et al., 2014) and M. vanbaalenii 
(Fraga et al., 2015) was published recently. Li and colleagues described the structure of 
MtbPep2 as two lobes architecture, with the N-terminal lobe mainly made up of β-strands 
and the C-terminal lobe mainly composed of α-helices (Figure 1-16 A). The N-terminal 
lobe contains two sheets. The sheet close to the N-terminus of protein embraces five anti-
parallel β-strands (β1- β5) while the second sheet is formed of seven anti-parallel strands 
(β6- β7, β9- β11, β8'- β9'). The strands β8 and β9 from second sheet protrude out of the 
protein, enter into the adjacent monomer and form an unusual homotypic dimer (Figure 
1-15 B).  
 
Structural alignment of MtbPep2 with homologous kinases, using DALI (Holm and 
Rosenstrom, 2010), revealed that some parts of N-terminal lobe (β1- β3 strands) are 
unique to M. tuberculosis and are missing from other homologue structures (Li et al., 
2014). In contrast, C-lobe architecture is similar to the C-lobes of most other kinases (Li 
et al., 2014). However, they could not show the function of this unique β sheet in the 
structure of MtbPep2. Moreover, unlike other kinases where C-lobe is involved in 
dimerization, in MtbPep2 only N-lobe forms a dimer with adjacent molecule (Figure 1-16 
B).    
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Figure 1-16. The crystal structure of MtbPep2. (a) Cartoon representation of Pep2 in 
monomeric state with two distinct lobes, N and C-lobes. The N-lobe, depicted in red, is 
mainly composed of β-sheets while C-lobe, depicted in blue, is primarily made up of α-
helices. (B) Cartoon representation of homotypic dimer of Pep2. The strands β8 and β9 
from each monomer protrude into the adjacent monomer and form a dimer. Adopted from 
(Li et al., 2014), with permission.  
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Solving the crystal structure of MtbPep2 in complex with maltose demonstrated that 11 
residues, W222, D322, H324, P344, S367, Y370, K426, Y429, E430, Y433 and R438, 
interact with maltose (Li et al., 2014) (Figure 1-17 A-B). Alanine mutagenesis of these 
amino acids revealed that 9 residues are essential for phosphorylation of maltose (except 
P344 and K426).  In addition, in order to identify the ATP-binding site of MtbPep2, the 
nucleotide-binding site of amino glycoside phosphotransferase (APH; PDB code 1J7U, 
RMSD of 2.6 Å for 90 aligned Cα positions) was compared with MtbPep2, revealing that 
three amino acids E142, Q143 and S144 from the EQS loop are interacting with ATP 
(Figure 1-17 C).  
 
Before solving the structure of Pep2 by Li and colleagues, Mendes and colleagues 
characterized Pep2 from M. bovis BCG, an homologue species of M. tuberculosis 
(Mendes, et al. 2010). They showed that Pep2 is dependent on maltose and ATP, 
although GTP and UTP can also be used to produce M1P. They determined its KM as 
2.52 ± 0.40 mM for maltose and 0.74 ± 0.12 mM for ATP. Divalent cations are essential 
for enzyme activity and Mg2+ is the best activator. Pep2 has its maximal activity at 60 oC, 
between pH 7 and 9 (at 37 oC) and is unstable on ice and upon freeze/thawing (Mendes, 
et al. 2010).  
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Figure 1-17. Maltose and nucleotide binding sites of MtbPep2. (A) Maltose binding site 
in C-terminal lobe and in close contact with the conserved motifs essential for catalysis. 
(B) An illustration of maltose in contact with catalytic residues. Catalytic residues and 
P344 from the activation loop are shown in blue and magenta, respectively. Maltose is 
shown in sticks in both panels. (C) Cartoon representation of nucleotide binding pocket at 
the junction of N- and C-lobes. The activation loop (shown in black), α-C helix (red 
color) and catalytic loop (magenta color) are highly conserved between kinases.  The 
EQS loop (cyan sticks) contains the amino acids necessary for ATP binding and catalysis. 
Adopted from Li et al., 2014, with permission.  
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1.7.3 Maltosyltransferase	  GlgE	  
 
GlgE has become the focus of attention as a potential new class of drug targets as it is a 
part of pathway, which has never been targeted by antimicrobials and especially doesn’t 
have any homologues in humans (Kalscheuer et al., 2010). Studying GlgE (encoded by 
Rv1327c) represents two novel bactericidal mechanisms, which can lead to death in M. 
tuberculosis. In first mechanism, inactivation of glgE leads to self-poisoning and death 
due to accumulation of M1P. Hyperaccumulation of M1P triggers the DNA damage 
responses, indicating DNA damage is likely the main factor causing death in Mtb. It is 
also possible that M1P is indirectly involved in toxicity through some complex 
mechanisms such as unidentified degradation or side products. The second mechanism is 
based on synthetic lethality with the glucosyltransferase Rv3032. Synthetic lethal 
interaction occurs when disrupting two non-essential genes can lead to death, while 
inhibiting neither of these genes on its own is lethal. This shows that these two pathways 
generate similar products and disturbing one pathway can be compensated by the activity 
of other pathway (Kalscheuer et al., 2010).  
 
Kalscheuer and colleagues in a detailed study in 2010 showed there is a functional link 
between TreS, Pep2, GlgE and GlgB (Kalscheuer et al., 2010). To achieve this, they 
deleted glgE in M. smegmatis and subjected the mutant to the different concentrations of 
trehalose. They found MsmΔglgE mutant is sensitive to the trehalose. Although this sugar 
is abundant in mycobacteria, even small amount of trehalose, 0.5 mM, can completely 
inhibit the growth of the mutant. This growth inhibition in MsmΔglgE correlates to the 
M1P hyperaccumulation. Deletion of either trehalose synthase gene (tres) or pep2 gene 
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confers trehalose resistance and suppresses M1P accumulation (Kalscheuer et al., 2010). 
The glgE gene clusters with glgB gene (encoded by Rv1326c), an essential gene in Mtb 
H37Rv which introduces α-1,6-linked branches into linear α-1,4-glucans. Deletion of 
glgB gene in M. smegmatis also, confers sensitivity to trehalose. This sensitivity in 
MsmΔglgB can be suppressed by deletion of treS (Kalscheuer et al., 2010). 
 
Trehalose synthase (TreS) and Pep2 catalyze the interconversion of trehalose and maltose 
and phosphorylation of maltose to M1P using ATP, respectively. Exploring the genomes 
of different organisms indicates that these two genes are clustered together in many cases, 
suggesting they catalyze two consecutive reactions, trehalose is first converted to maltose 
and latter is then turns over to M1P. In order to support this, Kalscheuer and his 
colleagues monitored the metabolism of 14C-labeled trehalose in MsmΔglgE mutant. 
Radiolabeled trehalose was immediately consumed and converted to M1P (Kalscheuer et 
al., 2010). On the other hand, they showed that perturbing treS or pep2 hinders M1P 
production in the ΔglgE mutant. Moreover, deletion of pep2 leads to accumulation of 
large amounts of radiolabeled maltose, implying the role of Pep2 in rapid conversion of 
maltose to M1P. These findings together represent the direct connection between TreS, 
Pep2, GlgE and GlgB in M. smegmatis (Kalscheuer et al., 2010).  
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Structure of Streptomyces GlgE 
 
The crystal structure of Streptomyces coelicolor GlgE has shown that this protein is a 
homodimer composed of five domains, A, B, C, N and S (Figure 1-18) (Syson et al., 
2011). Domain A is a (β/α)8 barrel and acts as the catalytic domain. The role of domain 
B, involves a pair of anti-parallel strands and one short helix, is not clear but in other 
members of GH13 family is responsible for Ca2+ ion binding. The C-terminal domain C 
possesses a β-sandwich fold and contributes in stabilizing domain A and is involved in 
substrate binding. The N-terminal domain N, which also contains a β-sandwich, forms 
the core of the dimer interface. The final domain, referred to as domain S, is unique to 
GlgE and participates in dimer interface by interacting with domain B of the next subunit.  
M1P enters into the donor pocket, situated in the center of domain A, in such a way that 
its reducing end sits between Asp394 and Glu423 as nucleophile/base and proton donor, 
respectively (Figure 1-19). Asp394 attacks the reducing end of M1P and forms a maltosyl-
enzyme intermediate, and phosphate group is released as an inorganic phosphate (Figure 
1-20). The non-reducing end of acceptor is deprotonated and attached to the C-1 position 
of maltose. A pair of anti-parallel β-strands of domain B and Pro353 and Pro357 form a lid 
at the entrance of donor pocket and control the access to this pocket (Syson et al., 2011).  
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Figure 1-18. The crystal structure of Streptomyces coelicolor GlgE. (A) Shows the 
protein as a homodimer with 5 domains. (B) A space-filling representation showing 
different features of the protein. Adopted from Syson et al., 2011, with permission.  
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Figure 1-19. Co-crystallization of maltose and GlgE. Adopted from Syson et al., 2011, 
with permission. 
 
 
 
 
 
 
 
Figure 1-20. Double displacement mechanism of GlgE proposed by Syson et al. 2011, 
with permission.    
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1.7.4 Branching	  enzyme	  GlgB	  
 
 
GlgB has also shown to be essential for Mtb viability through having a secondary effect 
on GlgE (Kalscheuer et al., 2010). In the absence of branching enzyme GlgB, the 
produced linear glucan has fewer non-reducing ends and become insoluble by reaching 
the degree of polymerization (DP) of about 20. In this case GlgE will not be able to 
extend the glucan, and reducing the GlgE activity similarly leads to toxic accumulation of 
M1P (Kalscheuer et al., 2010). MtbGlgB is a member of glycoside hydrolase family 
GH13 composed of four main domains: N1, N2, central (β/α)8 domain and C domain. N1, 
N2 and C domains have a similar structure consist of a β-sandwich and central domain 
with a (β/α)8 structure harbors the catalytic site (Pal et al., 2010) (Figure 1-21). Based on 
the structure of active site a substrate-binding model has been proposed (Figure 1-21). 
Asp411 attacks the 1-4 glycosidic bond and forms a glucosyl-enzyme intermediate and 
Glu464 protonates the 4th glycosidic oxygen. The substrate fragment is then transferred to 
the hydroxyl group at C6 of a glucose unit on the same or another chain to form 1-6 bond 
(Figure 1-22).  
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Figure 1-21. The crystal structure of M. tuberculosis GlgB. The N1 β-sandwich domain 
(residues 1-105), the N2 β-sandwich domain (residues 106-226), the central (β/α)8 
domain (residues 227-630) and the C-terminal β-sandwich (residues 632-731) are shown 
in brown, magenta, green and red, respectively. Adopted from Pal et al., 2010, with 
permission.    
 
 
 
 
Figure 1-22. The substrate-binding model for Mycobacterium tuberculosis GlgB 
proposed by Pal et al., 2010, with permission.    
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1.8 Rv3032	  pathway	  
 
 
Mycobacteria produce two classes of cytoplasmic polymethylated polysaccharides 
(PMPS) including 6-O-methylglucosyl containing lipopolysaccharides (MGLP) and 3-O-
methylmannose polysaccharides (MMP) (Stadthagen et al., 2007) (Figure 1-23). The role 
of these molecules is not very clear but they are proposed to be involved in regulating 
fatty acid biosynthesis and protecting latter molecules from degradation (Stadthagen et 
al., 2007). PMPS might also act as general lipid carriers to facilitate the synthesis of very 
large and insoluble mycolic acid esters (Stadthagen et al., 2007). In order to identify the 
genes encoding PMPS in mycobacteria, Stadthagen and colleagues searched for putative 
glucosyltransferases that use ADP-D-Glc or UDP-D-Glc as substrates in Carbohydrate-
Active enZYmes database (CAZy). Out of seven potential NDP-sugar-dependent 
glucosyltransferases found, they chose Rv3032 and Rv1212c for further experimentation 
due to greatest level of sequence similarity with E. coli GlgA. Scrutinizing the genes in 
close vicinity to Rv3032 on the M. tuberculosis genomic DNA revealed two putative S-
adenosyl-methionine-dependent methyltransferase genes (Rv3030 and Rv3037c) and a 
putative branching enzyme gene (Rv3031).  
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Figure 1-23. Structures of mycobacterial polymethylated polysaccharides (PMPS). (A) 
Structure of methylmannose polysaccharides (MMP) composed of 10-13 α-(1-4) linked 
3-O-methylmannoses terminated at the non-reducing end by a single α-(1-4) linked 
unmethylated D-mannose and an α-methyl group at reducing end. (B) Structure of 
methylglucosyl lipopolysaccharides (MGLP) composed of 10 α-(1-4)-linked 6-O-
methylglucosyl residues with a non-reducing end made of tetrasaccharide glucosyl 
residues methylated at position 3. Reducing end consists of 4 α-(1-4) and one α-(1-6) 
linked glucose residues linked to the position 2 of D-glyceric acid. Position 3 of the 
second and fourth α-D-glucosyl residues are substituted by single β-D-glucosyl residues. 
Adopted from Stadthagen et al., 2007, with permission.   
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Inhibiting Rv3032 in M. tuberculosis reduced lipopolysaccharides and glycogen contents 
by ~50%, indicating the involvement of this gene in MGLP synthesis. It is noteworthy to 
mention that Stadthagen and colleagues were able to detect only MGLP in the extracts or 
in the purified PMPS fractions of M. tuberculosis, but not MMP. Rv3032 deletion, 
however, did not affect capsular glucan synthesis in M. tuberculosis. Likewise, knocking 
out the orthologous of Rv3030 in M. smegmatis (MSMEG2349) significantly reduced the 
production of PMPS in M. smegmatis, confirming the participation of this gene in the 
biosynthesis of MGLP.  Furthermore, based on sequence similarity to GH-57 family 
branching enzyme from Thermococcus kodakaraensis, Stadthagen suggested that Rv3031 
should be involved in generating α-(1-6) glycosidic bonds in MGLP molecules. Rv3032 
and Rv3030 are proposed to catalyze the elongation and 6-O-methylation of MGLP 
respectively in M. tuberculosis (Mendes et al., 2011) (Figure 1-24).  
 
In another attempt to identify other genes involved in MGLP synthesis, Kaur and 
colleagues identified Rv1208 (GpgS) in the vicinity of Rv1212c as a glucosyl-3-
phosphoglycerate catalyzing the transfer of the first glucosyl residue of MGLPs (Figure 
1-24) (Kaur et al., 2009). The crystal structure of GpgS, which is essential for the 
survival of M. tuberculosis, was solved as apo enzyme and in complex with both UDP 
and 3-phosphoglycerate by Jose Barbosa Pereira et al. (2008). Mendes showed that 
Rv2419c (encoding a glucosyl-3-phosphoglycerate phosphatase) is responsible for 
converting glucosyl-3-phosphoglycerate to glucosylglycerate (Mendes et al., 2011) 
(Figure 1-24).  
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Figure 1-24. Proposed pathway for the biosynthesis of MGLP in M. tuberculosis. Genes 
highlighted in red are essential genes for M. tuberculosis growth and dashed arrows 
represent putative biosynthetic steps. GpgS: glucosyl-3-phosphoglycerate synthase, 
GpgP: glucosyl-3-phosphoglycerate phosphatase, DggS: diglucosylglycerate synthase, 
GT: glucosyltransferases, MeT: methyltransferase, AcT: acyltransferase, 3-PGA: 3-
phosphoglyceric acid, GPG: glucosyl-3-phosphoglycerate, GG: glucosylglycerate, DGG: 
diglucosylglycerate. Adopted from Mendes et al., 2010, with permission.    
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A comparative genomic study indicated that unlike GlgC-GlgA and GlgE pathways, 
which are relatively abundant between bacterial genomes, Rv3032 pathway is unique 
with a few exceptions only to mycobacteria (Chandra, Chater and Bornemann, 2011).  
 
1.9 Aims	  and	  objectives	  
 
 
GlgE has been genetically validated as a new anti-TB drug target; especially lack of 
homologous of this gene from humans make it even more attractive (Kalscheuer et al., 
2010). The primary aim of this project was to solve the crystal structure of GlgE from 
Mtb using X-ray crystallography and exploiting the structural information of this protein 
to find its inhibitors. Moreover, given that the accumulation of M1P is toxic to bacilli, we 
hypothesized that mycobacterium might facilitate the turn over of this substrate into α-
glucan chain through forming a complex between Pep2 and GlgE. Probing this complex 
formation could provide us with new information about the metabolic flux in GlgE 
pathway.  
 
The second aim of this project was to describe the crystal structure of Pep2 on its own or 
in complex with TreS. Prior to this study there was not any information on the crystal 
structure of Pep2 and modeling predictions of tertiary structure of this protein would 
strongly suggest that this protein has a novel structure. In particular, solving the crystal 
structure of Pep2 in complex with TreS could explain the Pep2 rate-enhancement effects 
following complex formation with TreS.  
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Finally, we were interested to explain the synthetic lethal interactions between GlgA and 
Rv3032 in Mtb. Synthetic lethal interactions have also been reported for a dozen of other 
genes and explaining this effect could provide us with new insights into the biochemistry 
of mycobacteria and subsequently new therapeutic agents. We thought that solving the 
crystal structure of both proteins might be a good start to better understand this effect.  
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2 Materials	  and	  methods	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2.1 Cloning	  of	  Mtb	  and	  MsmglgE	  and	  glgB	  
 
 
The M. tuberculosis Rv1327c gene was cloned from a pET28a vector containing 
Rv1327c gene (provided by Dr. Rana Roy) using the Phusion High-Fidelity DNA 
Polymerase kit (New England Biolabs, UK) and forward and reverse primers (Table 2-1), 
followed by PCR amplification (Table 2-2). The PCR products were analyzed on a 1% 
agarose gel stained with SYBR Safe DNA gel stain (Invitrogen, USA). The PCR 
products were purified from gel using QIAquick Gel Extraction protocol using a 
microcentrifuge. NdeI and HindIII restriction enzymes were used to digest purified PCR 
products to generate overhang ends. The reaction was set up in a final volume of 75 µL as 
50 µL PCR products, 7.5 µL 10x FastDigest Buffer, 3 µL of each NdeI and HindIII 
restriction endonucleases, for 3 hour at 37 oC. The reaction sample was loaded on a 1% 
agarose gel and purified using QIAquick Gel Extraction protocol using a microcentrifuge.  
 
Overhang PCR products were ligated into pET28a vectors digested with NdeI and 
HindIII restriction enzymes as explained earlier. Ligation reactions were set up with 2 µL 
T4 DNA Lygase buffer, 1 µL T4 DNA Lygase (New England Biolabs, UK) and 
sufficient amount of insert and plasmid in a final volume of 20 µL at room temperature 
for 30 minutes. The required amount of insert to plasmid was calculated using 
www.insilico.uni-duesseldorf.de/Lig_Input.html program in a molar ratio of 3:1. 2 µL of 
ligation reaction was transformed into the Top10 cells using heat-shock protocol and 
cultured on LB-Kan plates (25 µg/mL kanamycin) overnight at 37 oC. The colonies were 
screened using restriction enzyme digestion and DNA sequencing. 
 
 65 
Cloning of MsmglgE and glgB and MtbglgB using In-Fusion HD cloning kit. The M. 
smegmatis MSMEG_4916 gene, MSMEG_4918 and Rv1326c were amplified from M. 
smegmatis and M. tuberculosis genomic DNAs using the Phusion High-Fidelity DNA 
Polymerase kit (New England Biolabs, UK) and forward and reverse primers (Table 2-1), 
followed by PCR amplification (Table 2-2). The primers were designed in such a way 
that would contain 15 nucleotides extensions homologous to pET28a ends. The PCR 
products were analyzed and purified as explained earlier, followed by setting up the 
ligation reaction as 1 µL pET28a vector digested with NdeI and HindIII, 1 µL purified 
PCR product, 2 µL 5X In-fusion HD enzyme premix (Clontech) and 6 µL water in a final 
volume of 10 µL at 50 oC for 15 minutes. 2.5 µL of each cloning reaction were 
transformed into Top10 cells using heat-shock protocol and cultured on LB-Kan plates 
(25 µg/mL kanamycin) overnight at 37 oC. The colonies were screened using gel 
electrophoresis and DNA sequencing. 
 
Truncating MsmPep2. M. smegmatis MSMEG_6514 gene was cloned from a pET28a 
vector containing MSMEG_6514 gene using the Phusion High-Fidelity DNA Polymerase 
kit (New England Biolabs, UK) and seven forward and one reverse primers, as explained 
earlier (Table 2-1 and 2-2).  
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Table 2-1. Sequence of primers for cloning.  Underlined and bold sequences represent 
extensions homologous to pET28a ends and restriction sites, respectively.  
Gene  Primer  Sequence  
M. tuberculosis 
glgE cloned in 
pET28a 
Forward GATCCATATGGTGAGTGGCCGGGCAATCGGAAC 
Reverse GATCGATCAAGCTTTCACCTCCTGCGCAGCAGCGTGTTTC 
M. smegmatis 
glgE cloned in 
pET28a 
Forward CGCGCGGCAGCCATAGTGGCCGGTCGTATCGGA 
Reverse GTGCGGCCGCAAGCTTCATTCCCTGCGTAGCAAG 
M. tuberculosis 
glgB cloned in 
pET28a 
Forward CGCGCGGCAGCCATAATGAGTCGATCCGAGAAAC 
Reverse GTGCGGCCGCAAGCTCTAGGCGGGCGTCAGCCA 
M. smegmatis 
glgB cloned in 
pET28a 
Forward CGCGCGGCAGCCATAATGACGAGAAGCAGCAATC 
Reverse GTGCGGCCGCAAGCTCTAAGCCGGCTCGAACCA 
M. tuberculosis 
treS cloned in 
BACTH 
plasmids 
Forward GATCTCTAGAATGAACGAGGCAGAACACAGCGTC 
Reverse  GATCGGTACCTCATAGGCGCCGCTCTCCCCCGCA 
M. tuberculosis 
pep2 cloned in 
BACTH 
plasmids 
Forward GATCTCTAGAATGACTCGGTCGGACACGCTGGCA 
Reverse GATCGGTACCTCAGCTAGCGGTCAGGCGGGCGA 
M. tuberculosis 
glgE in cloned in 
BACTH 
plasmids 
Forward GATCTCTAGAGTGAGTGGCCGGGCAATCGGAAC 
Reverse GATCGGTACCTCACCTCCTGCGCAGCAGCGTGTTTC 
M. tuberculosis 
glgB in cloned in 
BACTH 
plasmids 
Forward GATCGGATCCATGAGTCGATCCGAGAAAC 
Reverse GATCGGTACCCTAGGCGGGCGTCAGCCA 
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Table 2-1 continued.  
Gene  Primer  Sequence  
MsmPep2 Δ10 Forward GATCCATATGCAGCAGCGCTGGTACGCCGGACG 
MsmPep2 Δ20 Forward GATCCATATGGAATTGGTCTCGGCCACAACCG 
MsmPep2 Δ30 Forward GATCCATATGGTGCGGCTGCGCGACGGGCTGG 
MsmPep2 Δ40 Forward GATCCATATGCTGCTGCAGGCGAATTACGCCGACG 
MsmPep2 Δ50 Forward GATCCATATGGATGAGCGTTACCAGGTGATCGTCG 
MsmPep2 Δ60 Forward GATCCATATGGGAAGCGGACCGATCGACGAGTAC 
MsmPep2 Δ70 Forward GATCCATATGGTCGCCACGATCGGCATCGCCGAC 
MsmPep2 Δ10- 
Δ70 
Reverse GATCAAGCTTTCACTCCAGAAGACGTGCGATGGAGCC
CAG 
Rv3031 Forward GATCCATATGTTGAACACGTCCGCAAGCCCGGTG 
 
 Reverse GATCAAGCTTTCACTTGGGCAGCCTCCGAGCGTC 
 
Rv3032 Forward GATCCATATGATGAGGATCCTCATGGTGTCGTGGGA 
 
 Reverse GATCAAGCTTCTACCGATCGGGAAGAGCGTGCTCGAC 
Rv1212c (GlgA) Forward GATCCATATG ATGCGGGTGGCGATGTTGACTCG 
 Reverse GATCAAGCTT TTACGCGCACACCTTCCGGTAG 
Rv1213 (GlgC) Forward GATCCATATG ATGAGAGAAGTGCCGCACGTGCTG 
 Reverse GATCAAGCTT CTAGATCCAAACACCCTTGCCCAC 
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Table 2-2. Thermocycler settings for PCR amplifications.  
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Initial denaturation 98 oC/2 min 98 oC/2 min 98 oC/2 min 98 oC/2 min 
Denaturation 98 oC/30 s 98 oC/30 s 98 oC/30 s 98 oC/30 s 
Annealing  - 64 oC/30 s 72 oC/30 s - 
Extension 72 oC/1 min 72 oC/1 min 72 oC/90 s 72 oC/90 s 
Final extension  72 oC/20 min 72 oC/20 min 72 oC/10 min 72 oC/10 min 
Number of cycles 34 34 35 35 
 
2.2 Testing	  the	  expression	  and	  solubility	  of	  recombinant	  proteins	  	  
 
The recombinant plasmid of protein of interest was transformed into different competent 
cells, BL21 (DE3), BL21 (DE3) pLysS, C41 (DE3) or Rosetta using heat-shock protocol. 
Recombinant plasmid of Rv3031 was co-transformed with 60.1 GroES and 60.2 GroES 
plasmids. 1 µL of miniprep DNA sample was added to the 50 µL of competent cells and 
incubated on ice for 20-30 minutes. Cells were heat-shocked by placing them in a 42 oC 
water bath for 45 seconds, followed by incubation on ice for 3 minutes. Cells were 
recovered by adding 350 µL of room temperature S.O.C Medium and placing them in a 
shacking incubator at 200 rpm for 1 hour at 37 oC. 50 µL of transformed cells were plated 
on LB agar plates containing the appropriate antibiotics (Table 2-3) and incubated 
overnight at 37 oC.  
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Table 2-3. List of competent cells/plasmids used during transformation with appropriate 
antibiotics.  
Competent cells/ Plasmid  Antibiotic  Final concentration  
pET28a plasmid Kanamycin  50 µg/mL 
BL21 (DE3) pLysS Chloramphenicol 25 µg/mL 
Rosetta  Chloramphenicol 25 µg/mL 
60.1 GroES plasmid Ampicillin  100 µg/mL 
60.2 GroES plasmid Ampicillin 100 µg/mL 
 
Next day 5 mL of overnight culture was prepared using a single colony from LB agar 
plate in LB broth with appropriate antibiotics (Table 2-3) and incubated at 37 oC. 
Glycerol stocks were prepared by adding 500 µL of overnight culture to 500 µL of 50% 
glycerol and stored at -80 oC. 2 mL of overnight culture was added to 100 mL LB broth 
supplemented with appropriate antibiotics and allowed to grow at 37 oC until the OD600 
of 0.4-0.6. In this stage the culture was induced with ∼ 1 mM IPTG and allowed to grow 
for additional 3 hours at 37 oC; or incubated at 16 oC for additional 3 hours and then 
induced with IPTG, followed by overnight growth at 16 oC. Cells were harvested (7000 
g, 10 min at 4 oC), re-suspended in lysis buffer, 25 mM Hepes-NaOH pH 7.6, 500 mM 
NaCl and 10% (v/v) glycerol, and lysed by a sonicator (10 cycles, 20 seconds on, 40 
seconds off). Recombinant protein was purified as explained in section 2.3.   
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2.3 Protein	  expression	  and	  purification	  
 
 
All the proteins used during this thesis were purified as described below unless it is 
stated. 10 mL of overnight culture was prepared using glycerol stock of protein of interest 
in LB broth with appropriate antibiotics (Table 2-3) and 1% glucose (only for Pep2 and 
TreS) and incubated at 37 oC.  
 
The overnight culture was centrifuged and the pellet was re-suspended in fresh Terrific 
Broth (TB) or LB with appropriate antibiotics (Table 2-3). The culture was allowed to 
grow at 37 oC until the OD600 of 0.6-0.8, cooled down to 16 oC for 3 hours and protein 
expression was induced with 0.1 mM  (MsmPep2), 0.6 mM (MsmTreS), 1 mM IPTG 
(MsmGlgE and GlgB) followed by further incubation at 16 oC overnight. Cells were 
harvested (7000 g, 10 min at 4 oC), washed with phosphate buffered saline (PBS), re-
suspended in 30 mL lysis buffer, 25 mM Hepes-NaOH pH 7.6, 1 M NaCl and 10% (v/v) 
glycerol for Pep2 and 25 mM Hepes-NaOH pH 7.6, 300 mM NaCl and 10% (v/v) 
glycerol for TreS, and frozen at -80 oC until needed.   
 
The cells were lysed using a French Press (Thermo Spectronic FA-078). Protease 
inhibitor cocktail (Roche), 1 mM PMSF, 10 mM MgCl2 and 10 µg/mL DNase I were 
added to the re-suspended cell pellets prior to French Press. The lysed solution was 
centrifuged at 20,000 rpm for 30 min at 4 oC and clear lysate was diluted 4 times with 
lysis buffer, filtered with 0.45 µm Millipore filter and loaded into a pre-equilibrated Ni-
NTA column (1 mL, GE Healthcare) in room temperature. The column was eluted with a 
gradient of imidazole from 0 mM to 500 mM. The fractions were tested with SDS-PAGE. 
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The Pep2 and TreS eluates were diluted with enough 50 mM MES pH 5.8, 10% (v/v) 
glycerol; and 20 mM Bis-Tris pH 6.0, 10% (v/v) glycerol, respectively, to reduce the 
NaCl concentration to 50 mM prior to load into the HiTrap Q-column (1 mL, GE 
Healthcare Life Sciences). The protein was applied into the HiTrap Q-column pre-
equilibrated with 50 mM MES pH 5.8, 10% (v/v) glycerol, 50 mM NaCl for Pep2 and 20 
mM Bis-Tris pH 6.0, 10% (v/v) glycerol, 50 mM NaCl for TreS. The protein was eluted 
with a gradient of NaCl from 0 mM to 500 mM NaCl. Fractions were analyzed with 
SDS-PAGE and concentrated using Amicon Ultra-4 centrifugal filter units prior to load 
onto the gel filtration column.   
 
Purification of MsmPep2(Δ70). This mutant protein was overexpressed as mentioned 
earlier with 0.2 mM IPTG and 25 mM Hepes-NaOH pH 7.6, 1 M NaCl and 10% (v/v) 
glycerol as lysis buffer. Fractions containing Pep2 Δ70 from Ni-NTA chromatography 
column were mixed together and diluted with enough 50 mM MES pH 6.0 and 10% (v/v) 
glycerol to reduce NaCl concentration to 300 mM prior to load into the HiTrap Q-column 
pre-equilibrated with latter buffer. The protein was eluted with a gradient of NaCl from 
150 mM to 1 M NaCl.  
 
Purification of Rv3032 and Rv3031 
Rv3032 and Rv3031 were grown in TB media and LB media, respectively, using 1 mM 
and 0.2 mM IPTG. Lysis buffer was 25 mM Hepes-NaOH pH 7.6, 500 mM Nacl, 10% 
(v/v) glycerol (for Rv3032) and 25 mM Hepes pH 7.6, 1 M NaCl, 10% (v/v) glycerol (for 
Rv3031) supplemented with 33 µM ADP-Glucose (A0627- Sigma-Aldrich). Fractions 
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containing either Rv3032 or Rv3031 were pulled down from Ni-NTA column, mixed 
together and diluted with enough 25 mM Tris/HCl pH 8.2, 10% (v/v) glycerol to reduce 
the NaCl concentration to 50 mM prior to load into the HiTrap Q-column pre-
equilibrated with latter buffer. Both proteins were eluted from the Hi-Trap Q-column 
using a gradient of NaCl from 100 mM to 1 M NaCl.  
 
2.4 Size	  exclusion	  chromatography	  
 
 
Size exclusion chromatography column was calibrated using albumin (1 mg/mL) as a 
standard protein, prior to running other proteins, and the graph containing void volume 
and elution volumes of both dimer and monomer peaks was recorded. Mtb and MsmPep2 
and Pep2 (Δ70) were applied to a pre-equilibrated HiPrep Sephacryl 26/60 S300 HR (GE 
Healthcare) column. Equilibration was carried out with 50 mM MES pH 5.8, 200 mM 
NaCl and 10% (v/v) glycerol. In case of Pep2 Δ70 column was equilibrated with 50 mM 
MES pH 6.0, 500 mM NaCl and 10% (v/v) glycerol. Proteins were eluted at a flow rate 
of 0.5 mL/min and monitored by UV absorbance at 280 nm. Collected fractions were 
analyzed with SDS-PAGE. For the elution of MsmegGlgE and GlgB from the same size 
exclusion matrix, the proteins were in 50 mM Bis-Tris propane pH 7.0 (GlgE) or 20 mM 
Tris/HCl pH 8.0 (GlgB), 150 mM NaCl, 10% (v/v) glycerol.  
 
In order to study the complex formation between TreS and Pep2 under different pH 
conditions, both proteins dialyzed against 50 mM Na-phosphate pH 6.0-9.0 in 0.5 unit 
intervals, 300 mM NaCl and 10% (v/v) glycerol. TreS and Pep2 were mixed together in 
1:1 molar ratio (30 µM each) in 2 mL final volume and loaded onto the pre-equilibrated 
 73 
HiPrep Sephacryl 26/60 S300 HR (GE Healthcare) column. Proteins were eluted and 
analyzed as explained earlier.  
 
The interaction between Pep2 and GlgE was explored using 20 mM Bis-Tris pH 6.0, 10% 
Glycerol and 300 mM NaCl buffer. 
Rv3032 and Rv3031 were eluted from SEC using 25 mM Tris/HCl pH 8.2, 150 mM 
NaCl, 10% v/v glycerol and 25 mM Tris/HCl pH 8.2, 500 mM NaCl, 10% v/v glycerol, 
respectively.  
 
2.5 Checking	  the	  nature	  of	  MsmTreS	  and	  MsmPep2	  degradation	  with	  western	  
blot	  
 
 
Three different fractions of MsmTreS and Pep2 eluted from HiTrap Q HP column were 
reduced in sample buffer and electrophoresed on a 10% SDS-PAGE gel. For western 
blotting, protein bands were transferred from gel to a hydrophobic polyvinylidene 
difluoride (PVDF) membrane (Amersham Hybond-P, GE Healthcare). The membrane 
was washed with PBS (two times, each 10 min) and PBST (0.1% Tween 20 in PBS) and 
blocked overnight at 4 oC in 3% albumin in PBST buffer on a shaker. The membrane was 
washed once with PBST, two times with PBS (each 10 min) and incubated with anti-His6 
(1:1000 added into the 3% albumin in PBS) for 1.5 h at room temperature on a shaker. 
Membrane was washed once with PBST, and two times with PBS. Membrane was 
incubated with secondary antibody, Anti Mouse IgG alkaline phosphate, (1:25000 added 
into the 3% albumin in PBS) for 1.5 h at room temperature on a shaker. Membrane was 
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washed three times with PBST and PBS as mentioned earlier and developed in 10 ml of 
SigmaFast BCIP/NBT in a dark room.  
 
2.6 M1P	  purification	  from	  MsmΔglgE	  
 
 
4 mL of overnight culture was prepared using a loopfull of MsmΔglgE in 3.6 mL of 
Middlebrook 7H9 (MB7H9) supplemented with 0.5% glycerol, 0.25% Tween 80 and 
10% OADC (Oleic Albumin Dextrose Catalase). Two shake flasks each containing 250 
mL of MB7H9, were inoculated with 2 mL of overnight culture, followed by adding 
0.25% Tween 80 into each. The cells were incubated at 37 oC with 120 rpm for 24 h (OD 
≈ 0.8), harvested at 5000 rpm, 10 min, 4 oC, and kept at -80 oC until purification.  Each 
pellet was re-suspended in 25 mL of PBS and 0.05% Tween 80, centrifuged for 10 min at 
4000 rpm. The pellets were re-suspended in 4 mL of mili-Q water and boiled at 95 oC for 
4 hrs. The samples were centrifuged at RT at 4000 rpm for 15 min, the supernatant was 
transferred to a new tube and dried overnight using a vacuum dryer (GeneVac, EZ-2, 
Suffolk, UK). Each sample was re-suspended in 400 µl of mili-Q water and spotted on 
two Silica gels 60 F254, TLC plastic sheets (MERCK) and developed three times using 
solvent system butanol: ethanol: water (5:3:2). A thin layer (about 2 cm) of each TLC 
plate was cut and visualized using α-naphtol sulfuric acid stain ad used as a guideline to 
determine the M1P position on the TLC plates. M1P was scratched from TLC plates 
using a sharp blade and re-suspended in 3 ml of mili-Q water on a circular rotator for 15 
min. Each sample was re-suspended and centrifuged three times at 4000 rpm at RT for 10 
min and each time the supernatant was collected. The total volume (36 mL) was dried 
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overnight by vacuum dryer (GeneVac, EZ-2, Suffolk, UK) and re-suspended in 400 µl of 
mili-Q water.  
 
2.7 Activity	  assay	  
 
Reaction mixtures probing TreS and Pep2 activity were prepared as 10 µL of TreS (1 
mg/mL), 100 mM trehalose or maltose, 50 mM Hepes buffer pH 7.5, 75 µL H2O and 5.7 
µL of Pep2 (0.5 mg/mL), 100 mM maltose, 50 mM Hepes-KOH pH 7.5, 10 mM MgCl2, 
5 mM ATP and H2O to reach the final volume of 100 µL, respectively. The reaction 
mixture for each protein was incubated at 37 oC for 1 hour. The reactions were stopped 
by adding 100 µL of ice cold acetone to each tube. Each tube was kept at -20 oC for at 
least 30 min, centrifuged at 14,000 rpm for 10 min at 4 oC, supernatant was collected and 
dried using a speed vacuum. The dried reaction product was re-suspended in 200 µL of 
H2O, and 2 µL of the solution applied on silica gel plate (Merck, Darmstadt, Germany) 
and developed using solvent system butanol: pyridine: water (7:3:1 v/v) for TreS and in 
butanol:ethanol:water (5:3:2 v/v) for Pep2. The plate containing Pep2 and M1P was 
developed three times in the same solvent system. Plates were visualized using α-naphtol 
sulfuric acid stain and dried using a heat gun.  
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Figure 2-1. Measuring phosphorylation of maltose to maltose 1-phosphate using an 
enzymatically coupled reaction between ATP to ADP conversion and NADH to NAD+ 
oxidation in the presence of pyruvate kinase and lactate dehydrogenase. PEP: 
phosphoenol pyruvate.     
 
In order to measure the phosphorylation of maltose by Pep2, conversion of ATP to ADP 
was enzymatically coupled to the oxidation of NADH to NAD+ in the presence of 
pyruvate kinase and lactate dehydrogenase (Figure 2-1). Pyruvate kinase catalyzes the 
transfer of one phosphate group from phosphoenol pyruvate (PEP) to ADP, generating 
one molecule of ATP and one molecule of pyruvate, which in turn is converted to lactate 
by lactate dehydrogenase (LD). NADH is fluorophore and its oxidation to NAD+ can be 
monitored fluorimetrically by measuring its excitation at 340 nm and emission at 450 nm.  
The experiment was performed in duplicates in 96 well plates, using a BMG PHERAstar 
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  1-­‐phosphate Pep2 
 ATP ADP 
 
PEP 
ATP Pyruvate	  kinase 
Pyruvate 
Lactate	  dehydrogenase	  (LD) 
 
Lactate 
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FS microtiter plate reader. Data were recorded and analyzed using MARS and GraphPad 
Prism softwares, respectively.  
 
The activity of Pep2 was monitored in a series of reactions where Pep2 concentration 
varied, from 0 to 2 µM, at a fixed ATP concentration (0.2 mM). The reaction was set up 
as 50 mM Hepes-NaOH pH 7.5, 100 mM NaCl, 10% (v/v) glycerol, 10 mM MgCl2, 0.1 
mM NADH, 0.2 mM ATP, 4 mM phosphoenolpyruvate and 2 mM pyruvate kinase: 
lactate dehydrogenase couple (Sigma) at a final volume of 100 µL and initiated with 20 
mM maltose. In order to reduce the effect of dilution on pH, the buffer was prepared 
three times more concentrated. The effect of pH (6.0 to 7.5 in 0.5 unit increments) on the 
activity of Pep2 in the presence and absence of TreS (in 1:0.5, 1:1 1:2 and 1:4 molar 
ratios, respectively) was measured using the same set up and 0.02 µM Pep2. When 
varying ATP (0 mM – 0.2 mM), maltose was present at 20 mM and when varying the 
maltose concentration (0 mM – 20 mM), the reaction was initiated by adding 0.3 mM 
ATP.  
 
2.7.1 Enzymatic	  activity	  of	  Pep2	  (∆70)	  	  
 
Reaction mixtures contained 50 mM Na-phosphate, pH 6.5, 300 mM NaCl, 10% (v/v) 
glycerol, 10 mM MgCl2 and Pep2 (0.45 µM – 1.0 µM) or Pep2 (Δ70) (0.45 µM – 1.0 
µM), 4 mM phosphoenolpyruvate, 2 units pyruvate kinase, 2 units lactate dehydrogenase 
and 0.1 mM NADH.  When varying ATP (0 mM - 0.4 mM), maltose was present at 20 
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mM. Furthermore, the activity of both proteins were measured in the presence of 0.5 mM 
ATP and maltose varied from 0.1 mM – 3 mM.  
 
2.8 Crystallization	  and	  data	  collection	  	  
 
 
Crystals of MsmPep2 were grown by vapor diffusion in 96-well plates, using a Mosquito 
liquid handling system (TTP Labtech) to set up crystallization drops containing 100 nL of 
MsmPep2 (40 mg/mL) and 100 nL of reservoir solution. JCSG+, Morpheus, MIDAS and 
Structure Screen (Molecular Dimensions) were used as reservoir solutions. In order to 
crystallize MsmPep2 in complex with MsmTreS, both proteins were purified and 
concentrated separately and mixed in 1:1 (400 µM each) and 1:2 (400 µM: 200 µM) 
molar ratios, respectively, just before crystallization. In addition to above screening 
solutions, Proplex was also included in the crystallization trials of MsmTreS-Pep2 
complex.  
 
MsmPep2 crystals were obtained from 2.1 M malic acid pH 7.0 and 2.4 M malonic acid 
pH 7.0. MsmPep2 crystals were frozen in liquid nitrogen and transported in Unipuck 
cassettes to Diamond Light Source, beamline I03 (Oxford, UK) for data collection. 
MsmTreS:Pep2 complex crystals were obtained from a reservoir of 9-10% polyethylene 
glycol 8000, 4% v/v glycerol, 200 mM MgCl2 and 0.1 M Tris-HCl pH 6.7-7.0. 
MsmTreS:Pep2 crystals were briefly immersed in a cryoprotectant solution (the same 
mother liquor supplemented with 15% - 20 % glycerol in final concentration) and flash 
frozen in liquid nitrogen. Diffraction data were collected and processed using 
XDS/XSCALE.  Phases were calculated using PHASER (McCoy et al., 2007) by 
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molecular replacement (MR) using PDB entry 3ZO9 (Caner et al., 2013) as the initial 
search model.  
 
The first copy of TreS tetramer was placed using a tetrameric search model for PHASER 
(with a Z score > 30 after translation function). In order to place the second TreS 
tetramer, the TreS monomer was used as a search model and the three other monomers 
were found by performing NCS operations. The individual monomers were adjusted to 
the electron density map using rigid body fitting in COOT. Similarly, the first copy of 
MsmPep2 was placed using molecular replacement (MR) and PDB entry 4O7O 
(MtbPep2) (Li et al., 2014). Additional copies of Pep2 were placed by performing NCS 
operations, real space rigid body fitting in COOT, refining the combined model in 
REFMAC5 and repeating the cycle.  
 
2.9 Checking	  the	  expression	  and	  solubility	  of	  C-­‐terminal	  his-­‐tagged	  MsmPep2	  
 
The recombinant C-terminal his-tagged Pep2 cloned into the pET23b vector (provided by 
Dr. Rana Roy) was expressed as explained earlier with 100 µg/mL ampicillin in place of 
kanamycin. The N-terminal his-tagged MsmPep2 was also expressed with 1 mM IPTG as 
a positive control.  
 
2.10 Overexpression	  of	  Pep2	  in	  M.	  smegmatis	  
 
pSD26 plasmid carrying M. smegmatis pep2 gene was transformed into the M. smegmatis 
mc2155 cells by electroporation (Roy et al., 2013). 500 µL of LB media was added to the 
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transformation mixture and incubated at 37 oC for 4 hours. Transformation mixture was 
cultured on LB-hygB+ plates (50 µg/mL hygromycin B) at 37 oC for four days. Several 
colonies (8-10 colonies) were used to inoculate a 4 mL culture (50 µg/mL hygromycin B 
and 0.05% Tween80) and grown for two days at 37 oC. The culture was propagated (1% 
v/v inoculation) into 50 mL LB (50 µg/mL hygromycin B and 0.05% Tween80) and grew 
for two days (OD600 of 0.3-0.6). 5 mL of this culture was used to inoculate 1 L of LB (50 
µg/mL hygromycin B and 0.05% Tween80) and further growth to the OD600 of 0.3-0.6. 
The protein expression was induced with 0.2% w/v acetamide and further incubated at 16 
oC overnight. Cells were harvested (7000 rpm, 10 min at 4 oC), washed with phosphate 
buffered saline (PBS), re-suspended in 30 mL lysis buffer, 25 mM Hepes-NaOH pH 7.5, 
1 M NaCl and 10% (v/v) glycerol and frozen at -80 oC until needed.  The cells were lysed 
by sonication (12 cycles of 60 s on, 90 s off at maximum amplitude). Protein purification 
was carried out at it was explained earlier.  
 
2.11 Limited	  proteolysis	  of	  MsmPep2	  
 
Stocks of trypsin, α-chymotrypsin and proteinase K were prepared as 1 mg/mL in 1 mM 
HCl or 50 mM Tris/HCl pH 8.5 (for proteinase K). Limited proteolysis using trypsin (in 
molar ratios of trypsin: Pep2 as 1:20, 1:40 and 1:80), α-chymotrypsin (0.2-2*10-6 mg/mL) 
and proteinase K (0.2-2*10-5 mg/mL) was carried out for 1 hour at 37 oC. Pep2 
concentration was about 3 mg/mL. Protease activity was inhibited by adding protease 
inhibitor cocktail and PMSF. Digestion of Pep2 was tested on SDS-PAGE.  
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2.12 Thermal	  shift	  assay	  	  
 
The thermal shift assay protein-dye solution was prepared using 35 µg/mL of protein of 
interest, 8x SYPRO Orange (Life Technologies) and appropriate amount of buffer 20 
mM MES pH 5.8, 300 mM NaCl and 10% glycerol (for Pep2) and 20 mM Bis-Tris 
propane pH 7.0, 250 mM NaCl and 10% glycerol (for GlgE). 10 µL of thermal shift assay 
protein-dye solution was mixed with 20 µL of each screen (Table 2-4), to provide a final 
concentration of 100 mM Buffer and either 100 mM or 250 mM NaCl. Controls were 
included in the experiment and using water instead of reaction solution.  The resulting 
solutions were loaded into a 96 well PCR plate. The plate was sealed with Optical-
Quality Sealing Tape (Bio-Rad) and centrifuged at 2000 rpm for 4 min, followed by 
heating in a QPCR instrument (Mx3005P, Agilent Technologies) from 25 oC to 85 oC in 
1 oC increments and staying at each temperature for 1 minute. The excitation and 
emission wavelengths for SYPRO Orange are 490 and 575 nm, respectively. Melting 
temperatures of each protein were calculated from cycle thresholds using Agilent 
software (Mx3005P Software).  
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Table 2-4. List of the buffers and their pH values used in the screen 
Number  Buffer (150 mM) pH 
1 Sodium citrate/citric acid 4.0 
2 Sodium acetate  4.2 
3 Sodium acetate 4.8 
4 Sodium citrate/citric acid 5.0 
5 Sodium acetate 5.4 
6 MES 5.7 
7 Sodium citrate/citric acid 6.0 
8 Bis-Tris 6.0 
9 MES 6.1 
10 Imidazole 6.4 
11 MES 6.5 
12 Bis-Tris 6.5 
13 Bis-Tris 7.0 
14 Hepes 7.0 
15 Imidazole 7.1 
16 Tris 7.2 
17 Hepes 7.5 
18 Imidazole 7.6 
19 Hepes 8.0 
20 Tris 8.0 
21 Tris 8.6 
22 CHES 8.6 
23 CHES 9.1 
24 CHES 9.6 
 
2.13 Small	  Angle	  X-­‐ray	  Scattering	  	  
 
Solution scattering data of MsmTreS, MsmPep2 and the complex of these two proteins 
were recorded on beamline BM29 at ESRF, Grenoble. The protein samples were dialyzed 
against 50 mM Na-phosphate buffer (pH 6.5), 300 mM NaCl and 10% (v/v) glycerol. 
SAXS data were collected on five different concentrations for each protein sample (1.25, 
2.5, 5, 7.5 and 10 mg/mL). The data for each protein concentration was collected in the 
following order, buffer measurement, protein solution and final buffer measurement. 
Each exposure contained 10 frames, each for 2 s in flow mode. The detector images were 
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averaged and reduced to 1-dimentional scattering curves, and buffer contributions to 
scattering subtracted using the beamline software BsxCuBE.  
 
All SAXS data were analyzed using programs of ATSAS suite (www.embl-
hamburg.de/biosaxs/software.html). Global parameters (Rg and Dmax) and pair 
distribution were calculated using PRIMUS (Konarev et al., 2003). Fitting curves were 
calculated using CRYSOL (Svergun, Barberato and Koch, 1995). Molecular envelopes 
were generated by both DAMMIF (Franke and Svergun, 2009) and DAMAVER (Volkov 
and Svergun, 2003).  
 
2.14 Analytical	  ultracentrifugation	  
 
Sedimentation equilibrium was carried out in a Beckman Optima XL-A analytical 
ultracentrifuge equipped with absorbance optics. Protein samples were dialyzed overnight 
in 50 mM NaPO4 pH 6.5, 300 mM NaCl and 10% glycerol (Table 2-5). Equilibrium 
experiment was performed using 6-channel Epon centerpieces with quartz windows at a 
rotor temperature of 4 oC for a total duration of 116 hours. The data were recorded at the 
UV of 280 nm at 8000, 9000, 10000 and 11000 rpm. At each rotation speed, the sample 
was allowed to reach equilibrium during a 24 hours period. Finally, the sample was run at 
25,000 rpm for 20 hours. The data were analyzed using SEDPHAT. Parameters for 
solvent density and viscosity and for the partial specific volume of the proteins were 
calculated using SEDNTERP.  
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Table 2-5. The concentrations of MsmTreS, TreS-Pep2 complex in 1:1 and 2:1 molar 
ratio before loading on analytical ultracentrifuge.  
TreS TreS: Pep2 (1:1 molar ratio) TreS: pep2 (2:1 molar ratio) 
2 µM 1.25 µM: 1.25 µM 1.5 µM: 0.75 µM 
4 µM 2.5 µM: 2.5 µM 3 µM: 1.5 µM 
6 µM 3.75 µM: 3.75 µM 4.5 µM: 2.25 µM 
	  
 
2.15 Bacterial	  two-­‐hybrid	  screen	  
 
 
The Mtb Rv0126, Rv0127, Rv1327c and Rv1326c genes encoding TreS, Pep2, GlgE and 
GlgB, respectively, were amplified by PCR (primers in Table) from M. tuberculosis 
H37Rv genomic DNA. The PCR amplification was carried out during 35 cycles: initial 
denaturation at 98 oC for 2 min, denaturation at 98 oC for 30 s, extension at 72 oC for 90 s 
(for pep2) and 59 oC for 1 min (for glgB) and final extension at 72 oC for 10 min. The 
PCR products were analyzed on a 1% agarose gel stained with 2% ethidium bromide. 
The PCR products were purified from gel using QIAquick Gel Extraction protocol using 
a microcentrifuge. XbaI and KpnI restriction enzymes (for treS, pep2 and glgE) and 
BamHI and KpnI (for glgB) were used to digest purified PCR products to generate 
overhang ends. The reaction was set up in a final volume of 50 µl as 40 µL PCR 
products, 5 µL 10x FastDigest Buffer, 1 µL of each restriction endonucleases, for 1 h at 
37 oC. The reaction sample was loaded on a 1% agarose gel and purified using QIAquick 
Gel Extraction protocol using a microcentrifuge.   
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Overhang PCR products were ligated into pKT25, pKNT25, pUT18 and pUT18C vectors 
digested with appropriate restriction enzymes. Ligation reaction was set up different 
amounts of digested plasmids and PCR products (the ratio between vector and insert was 
calculated using Insilico.uni-dusseldorf.de/lig_input.html online program), 2 µL T4 DNA 
Lygase buffer and 1 µL T4 DNA Lygase (New England Biolabs, UK) in a final volume 
of 20 µL incubated at room temperature for 10 minutes. One µL of each ligation reaction 
was used to transform 50 µL of XL1-Blue cells using heat-shock protocol and cultured on 
LB plates with appropriate antibiotics (50 µg/mL kanamycin for pKT25 and pKNT25; 
100 µg/mL ampicillin for pUT18 and pUT18C) overnight at 37 oC. The colonies were 
screened using gel electrophoresis and DNA sequencing. 
 
The test of interaction between two pairs of proteins was performed as described by 
Battesti and Bouveret (2012). BTH101 and DHM1 competent cells were co-transformed 
with 0.5 µL of two recombinant plasmids. One plasmid carring the first gene fused to 
pKT25 or pKNT25 and second plasmid carring the other gene of interest fused to pUT18 
or pUT18C (8 plasmid combinations). 60 µL of transformation reaction was cultured on 
LB plates supplemented with 100 µg/mL ampicillin and 50 µg/mL kanamycin and 
incubated at 30 oC for 48 hours. 5 mL overnight culture was prepared from 
transformation plates (several colonies were picked in order to reduce heterogeneity) with 
appropriate antibiotics and 0.5 mM IPTG, incubated at 30 oC with shaking. Next day, the 
interaction between two proteins of interest was measured using β-galactosidase assay on 
the same overnight liquid using Miller protocol. A loopfull from overnight culture was 
streaked on the LB plate containing appropriate antibiotics, 40 µL X-gal and 0.5 mM 
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IPTG. Plates initially incubated overnight at 30 oC but next day transferred to room 
temperature for another 72 hours. Positive and negetive controls included throughout the 
assay using two empy plasmids as negative control and plasmids pKT25-zip and 
pUT18C-zip as positive control.  
 
2.16 β-­‐galactosidase	  activity	  assay	  	  
 
The overnight culture was diluted 1 to 5 with M63 medium and the optical density at 600 
nm of each culture was recorded. Bacterial cells were permeabilized with 30 µL of toluen 
and 0.1% SDS solution per 2.5 mL of the diluted cells in a Falcon tube. Tubes were 
vortexed for 10 seconds and left open at 37 oC for one hour to allow the toluen to 
evaporate. In a glass tube, 0.5 mL of the permeabilized cells were mixed with 0.5 mL of 
PM2 buffer, followed by incubation in water bath at 28 oC for 5 minutes. A tube 
containing 1 mL of PM2 buffer was also prepared and used as blank. The enzymatic 
reaction was started by adding ONPG substrate, prepared in PM2 buffer without ?-
mercaptoethanol, in 0.4% final concentration. After 10 minutes the reaction was stoped 
by adding 500 µL of 1 M Na2CO3 stop solution. The optical density of each reaction was 
measured at 420 nm. The enzymatic activity of each sample was calculated using this 
equation: A= (200 × OD420 of each sample / min of incubation) × dilution factor. The 
results were recorded as units/ mL that one unit represent hydrolysis of 1 nmol of ONPG 
in 1 min at 28 oC (BACTH System Kit, Euromedex).  
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2.17 Isothermal	  titration	  calorimetry	  assay	  
 
Isothermal titration calorimetry (ITC) experiments were performed using a VP-ITC 
Microcalorimeter from MicroCal, LLC (Northampton, MA). Both proteins, MsmTreS and 
MsmPep2, were dialysed against 50 mM NaPO4 pH 6.5, 7.5 and 8.5, 300 mM NaCl and 
10% v/v glycerol and degassed at 2 oC below the experimental temperature prior to use. 
Around 290 µL of MsmPep2 (500 µM) was titrated into 1.4 mL of MsmTreS (75 µM as 
monomer) during 29 injections (10 µL each time) and 300 seconds time intervals between 
each injection. The experiment was conducted at 25 oC. The data were analyzed using 
Origin 7.0 software (Microcal, Northampton, MA) provided by the company. The 
experimental data were fitted to a theoritical titration curve using single and two sets of 
sites. The results were shown as n (Stoichiometry), Ka (association constant, in M-1), ΔH 
(enthalpy change, in kcal mol-1) and ΔS (entropy change, kcal K-1 mol-1).  
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3 Crystallization	  of	  Pep2	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3.1 Crystallization	  of	  maltokinase	  
 
 
Maltokinase (Pep2) is a member of GlgE pathway that catalyzes the phosphorylation of 
maltose to maltose 1-phosphate in the presence of ATP. Although Pep2 from M. 
tuberculosis H37Rv is considered to be important for optimum growth (Sassetti, Boyd 
and Rubin, 2003), the crystal structure of this protein wasn’t characterized prior to the 
start of this project.  Roy and colleagues showed that MtbPep2 forms a complex with 
MtbTreS and, surprisingly, this complex formation increases the activity of Pep2 in a 
dose-dependent manner (Roy et al., 2013). Due to lack of a crystal structure of Pep2 with 
TreS, we were not able to explain this rate enhancement. In order to answer these 
questions, I decided to attempt the crystallization of Pep2, initially working with the 
orthologue from M. tuberculosis, then that of M. smegmatis.  
 
3.2 Expression	  and	  purification	  of	  MtbPep2	  and	  MsmPep2	  
 
 
Both MtbPep2 and MsmPep2 were purified using immobilized metal ion affinity 
chromatography (IMAC) and anion-exchange chromatography (Figure 3-1 A-B). SDS-
PAGE analysis of fractions collected from anion-exchange Q-Sepharose column showed 
that MsmPep2 is amenable to degradation (Figure 3-1B). Degradation appears as lower 
bands with smaller molecular weights on the SDS-PAGE gel. In order to determine the 
nature of degradation, MsmPep2 was analyzed with western blot using an antibody 
directed against the His-tag, demonstrating that degradation occurs from the C-terminal 
side (Figure 3-1D).  
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Figure 3-1. Purification of recombinant MsmPep2. (A-B) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography, 
respectively.  L: crude lysate, CL: clear lysate, FT: flow through, AP: applied. Ni-NTA 
elution fractions (25 mM Hepes pH 7.5, 1 M NaCl, 10% (v/v) glycerol) supplemented 
with 0 to 300 mM imidazole and anion-exchange elution fractions (50 mM MES pH 5.8, 
10% (v/v) glycerol) supplemented with 0 to 400 mM NaCl as indicated above the gels. 
(C) The size exclusion chromatogram of MsmPep2 and SDS-PAGE analysis of the peak 
fractions from size exclusion chromatography. (D) Western blot analysis of MsmPep2 
(three protein-rich fractions from anion-exchange Q-Sepharose column) using an anti-His 
tag antibody. Arrows indicate His6-tagged Pep2 bands on the gel (∼ 51 kDa with the His6 
tag). 
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Size exclusion chromatography (SEC) was used to enhance the purity of MtbPep2 and 
MsmPep2 and also to determine the oligomeric state of each protein. MsmPep2 was 
eluted as a dominant monomer peak at 151 mL, while MtbPep2 showed a continuous size 
distribution with three major peaks at 108, 147 and 162 mL (using a Sephacryl S200 HR 
column) (Figure 3-2). Compare to the albumin standard, three peaks could represent the 
tetrameric, dimeric and monomeric state of MtbPep2. On a Sephacryl S300 column, 
MsmPep2 elutes at 188 mL.  
 
3.3 Verifying	  activity of MsmPep2 
 
In order to probe the activity of MsmPep2, the reaction products were monitored in an 
end point assay using thin layer chromatography (TLC) (Figure 3-3). Incubating Pep2 
with maltose led to the production of maltose 1-phosphate, while neither trehalose nor 
sucrose were turned over.  
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Figure 3-2. The size exclusion chromatogram of MtbPep2 and MsmPep2 from a 
Sephacryl S200 column. Comparing the elution pattern of each protein with albumin 
demonstrates MtbPep2 is in a dimer-tetramer configuration, while MsmPep2 is monomer. 
The albumin double peak corresponds to masses of 133 and 66.5 kDa, respectively.  
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Figure 3-3. Thin layer chromatography of reaction mixtures probing the activity of 
MsmPep2. A volume of 2 µL of the reaction mixture containing maltose, trehalose and 
sucrose, spotted on the lanes 5-7, respectively. Lane 1 represents maltose 1-phosphate 
and lanes 2-4 are the same activity reactions but without Pep2 enzyme and used as a 
control to determine the place of saccharides on the plate. Arrows indicate the position of 
maltose on the plate.  
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3.4 X-­‐ray	  diffraction	  of	  MsmPep2	  
 
MsmPep2 crystals formed over a reservoir containing 2.1 M malic acid pH 7.0 and 2.4 M 
malonic acid pH 7.0 and diffracted to 7.5 Å. The unit cells parameters were determined 
as 123.2 Å, 123.2 Å, 265.9 Å (90.0O, 90.0O, 120.0O) (Figure 3-4). In order to improve the 
diffraction quality of the crystals, Pep2 protein was screened in a 2D screen 
(concentration of malic acid or sodium malonate vs. pH). In another attempt, available 
crystals were used as seeds against this optimization screen (streak seeding). In addition, 
Pep2 was also screened against the screening solutions supplemented with 20% (v/v) of 
2.1 M malic acid pH 7.0 to promote crystallization, though, neither had any effects on the 
diffraction quality of MsmPep2 crystals. In order to co-crystallize MsmPep2 with 
maltose, the concentrated protein (33 mg/mL) was mixed with maltose (30 mM) and 
AMPPNP (5 mM) and crystal trays were set up. The resultant crystals diffracted very 
poor or did not diffract at all.   
 
3.5 Expression	  and	  purification	  of	  C-­‐terminally	  tagged	  MsmPep2	  
 
In an attempt to generate higher diffraction-quality crystals of MsmPep2, C-terminally 
tagged and M. smegmatis overexpressed Pep2 were purified using IMAC and anion-
exchange chromatography (Figure 3-5A-B). Both proteins were concentrated to 27 
mg/mL and 22 mg/mL, respectively, and used to set up crystallization screens. However, 
neither of these proteins was able to generate any crystals.  
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Figure 3-4. The diffraction pattern of MsmPep2 crystals grown in 2.1 M malic acid pH 
7.0 and frozen in liquid nitrogen. Crystals diffracted to 7.5 Å. 
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Figure 3-5. Purification of recombinant C-terminally tagged MsmPep2 (A) and Pep2 
overexpressed in M. smegmatis (B). (A-B) SDS-PAGE analysis of the fractions from 
affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography.  L: crude lysate, 
CL: clear lysate, FT: flow through, AP: applied. Ni-NTA elution fractions (25 mM Hepes 
pH 7.5, 1 M NaCl, 10% v/v glycerol) supplemented with 0 to 500 mM imidazole and 
anion-exchange elution fractions (50 mM MES pH 5.8, 10% v/v glycerol) supplemented 
with 0 to 500 mM NaCl as indicated above the gels. Arrows indicate His6 tagged Pep2 
bands on the gel (∼ 51 kDa with the His6 tag). 
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3.6 Limited	  proteolysis	  of	  MsmPep2	  
 
In order to improve the crystallization of MsmPep2 by removing potential unstructured 
fragments from either side of protein, limited proteolysis was carried out using three 
different proteases, trypsin, α-chymotrypsin and proteinase K (Figure 3-6). Limited 
proteolysis of MsmPep2 using trypsin led to the formation of two major smaller 
fragments with molecular weights of about 25 and 19 kDa, while digesting this protein 
using α-chymotrypsin (final concentration of 0.2 mg/mL) led to formation of several 
smaller fragments with molecular weights ranging from 7 to 30 kDa. Similar to trypsin, 
proteinase K (final concentration of 0.002 mg/mL) produced two major smaller 
fragments with molecular weights of 25 and 30 kDa. In principle we were interested to 
generate only one or two fragments with a MW very similar to the undigested one but 
probably better folded or more stable. We stopped continuing with α-chymotrypsin since 
it generated several fragments with small MWs. Although trypsin produced only two 
fragments during digestion (similar to proteinase K), it also failed to meet our criteria, as 
those two fragments were smaller than half of the size of undigested protein. Thus, we 
chose the proteinase K for further experimentation.  
 
During anion-exchange chromatography of digested products with proteinase K, the two 
fragments 25 and 30 kDa pulled down together in one fraction but they appeared as two 
bands on the SDS-PAGE gel, suggesting these two fragments are linked together by non-
covalent bonds. Furthermore, western blot using an anti-his6 tag antibody demonstrated 
that the cleavage site should be somewhere in the middle of protein as only the 30-kDa 
fragment contained his tag but not 25-kDa fragment.  
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Figure 3-6. SDS-PAGE analysis of MsmPep2 digested with trypsin (A) α-chymotrypsin 
(B) and proteinase K (C); anion exchange chromatography (D) and western blot (E) of 
proteinase K digested products. Ctrl in all figures represent undigested MsmPep2 as 
control. Lanes 1-3 in (A) represent reaction mixtures of MsmPep2 with trypsin in 20:1, 
40:1 and 80:1 rations, respectively. Lanes 1-6 in (B) represent reaction mixtures of 
MsmPep2 (2.6 mg/mL) with different concentrations of α-chymotrypsin from 0.2-2*10-6 
mg/mL. Lane 1-5 in (C) represent reaction mixtures of MsmPep2 (2.6 mg/mL) with 
different concentrations of proteinase K from 0.2-2*10-5 mg/mL. (D) Fractions from 
anion-exchange (Q-Sepharose) chromatography eluted with 50-250 mM NaCl as 
indicated above the gel, AP: applied, FT: flow through.  (E) Western blot analysis of 
proteinase K digested MsmPep2 using an anti-His6 antibody. 
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proteinase K digested MsmPep2 (both fragments 25 and 30 kDa) was concentrated to 27 
and 54 mg/mL and exposed to crystallization screens but failed to produce any crystals.  
 
3.7 Increasing	  pH	  promotes	  MsmPep2	  stabilization	  
 
In order to probe thermal stability of MsmPep2 as a function of buffer composition, a 
thermal shift assays was performed using a qPCR thermal cycler and changes in melting 
temperature (Tm) of this protein were monitored (Niesen, Berglund and Vedadi, 2007). 
Improving the buffer composition can increase homogeneity, stability and solubility of a 
protein and therefore, promoting the crystallization rate of a protein (Ericsson et al., 
2006). This method is based on fluorescent properties of the dye SYPRO Orange in non-
polar environments. SYPRO Orange is intrinsically a fluorescent dye, but its fluorescence 
emission significantly increases when it is exposed to non-polar environments. 
 
Gradual rise in temperature causes the protein to start unfolding, which exposes 
hydrophobic amino acids, valine, leucine, isoleucine, phenylalanine and tryptophan, to 
the dye and increases the intensity of fluorescence. Fluorescence intensity starts 
decreasing after reaching a maximum point. This could be due to precipitation of the 
complex of SYPRO Orange and the denatured protein (Ericsson et al., 2006). The 
melting temperature correlates with stability of the protein, as higher melting temperature 
represents that the protein is better folded and therefore is in a more stable state.  
 
The Tm value of MsmPep2 was measured as 20 oC and its changes (ΔTm) were monitored 
throughout the experiment. An increase in Tm could suggest an elevation in structural 
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order of MsmPep2, whereas a decrease in Tm might represent a disordered conformation 
or a sign of misfolding. Large variation in stability was observed in different screens.  
Some buffers had a higher impact on MsmPep2 stability, mainly sodium citrate/citric acid 
pH 6.0, Bis-Tris pH 6.5 and 7.0, imidazole pH 7.1 and 7.6 with a ΔTm of about 10. The 
most destabilizing buffers are sodium acetate pH 4.8 and sodium citrate/citric acid pH 5.0 
with a ΔTm of about -4 and -8, respectively. However, it is apparent that increasing the 
pH from 4.8 towards more basic pH values, up to 8.0, increases the melting temperature 
and promotes the stability of MsmPep2. In most screens there is not a significant 
difference between 100 mM and 250 mM NaCl on the stability of MsmPep2. MsmPep2 
was dialyzed against two buffers, Hepes pH 7.0 and 8.0; supplemented with 250 mM 
NaCl and 10% (v/v) glycerol and exposed to crystallization screens. Unfortunately, 
neither of these buffers improved the crystallization of MsmPep2 protein.  
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Figure 3-7. MsmegmPep2 stability versus buffer type determined using thermal shift assay. Stability was measured at 100 mM NaCl 
() and 250 mM NaCl (). Stars above the bars indicate the buffers that were tested in the crystallization screenings. Error bars 
represent standard deviation. Abbreaviations on X axis are explained  in Table 2-4 of materials and methods.  
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3.8 Summary	  
 
Pep2 was successfully purified to more than 95% purity (single band on the SDS-PAGE 
gel) from Mtb and M. smegmatis (Figure 3-1). Oligomeric state of this protein in the 
solution was determined using size exclusion chromatography (Figure 3-2). MtbPep2 was 
eluted from SEC column as a continuous size distribution (multimer) at 108, 147 and 162 
mL, while MsmPep2 appeared as a dominant monomer peak at 151 mL. Given that 
MsmPep2 behaves as a monomer in the solution, this protein was chosen for 
crystallization trials. MsmPep2 crystallized over a reservoir containing 2.1 M malic acid 
pH 7.0 and 2.4 M malonic acid pH 7.0 and diffracted to 7.5 Å. In order to improve the 
diffraction of MsmPep2 and to find the best condition for crystallizing this protein, 
folding and stability of Pep2 were further characterized by limited proteolysis and 
thermal shift assay. Limited proteolysis of MsmPep2 by proteinase K produced two major 
smaller fragments with MWs of 25 and 30 kDa. Anti-His6 blotting of these two fragments 
indicated that cleavage occurs in the middle of Pep2 and two fragments are linked 
together by non-covalent bonds (two fragments eluted together from anion-exchange 
chromatography column). However, attempts to crystallize these two fragments together 
were not successful. The thermal stability of MsmPep2 as a function of buffer 
composition was explored in a thermal shift assay (Figure 3.7). The assay suggested that 
elevating the pH increases the melting temperature and therefore promotes the stability of 
MsmPep2, with the most pronounced impact at sodium citrate/citric acid pH 6.0, Bis-Tris 
pH 6.5 and 7.0, imidazole pH 7.1 and 7.6 (Figure 3.7). Nevertheless, neither of these 
buffers were able to improve the crystallization of MsmPep2.  
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4.1 Crystallization	  of	  MsmTreS:Pep2	  complex	  
 
The crystal structures of MtbTreS (Roy et al., 2013), MtbPep2 (Li et al., 2014) and M. 
vanbaalenii Pep2 (Fraga et al., 2015) were determined by others prior and during the 
course of this project. Roy and colleagues demonstrated complex formation between 
MtbTreS and MtbPep2, using size exclusion chromatography (SEC) and analytical 
ultracentrifugation (AUC). Using AUC in sedimentation equilibrium mode they 
determined the stoichiometry, but not the affinity of complex formation and were not able 
to solve the structure of neither Pep2 nor complex. In addition, they were not able to 
explain the MtbPep2 rate enhancement, since having structure of the complex was 
necessary. During this study I aimed to solve the structure of MsmTreS:Pep2 complex, 
determine the affinity of binding and how complex formation affects the activity of 
MsmPep2.  
 
4.2 Protein	  expression	  and	  purification	  of	  MsmTreS	  and	  MsmPep2	  
 
Both MsmPep2 and MsmTreS were purified using immobilized metal ion affinity 
chromatography (IMAC) and anion-exchange chromatography (Figures 3-1 and 4-1). 
SDS-PAGE analysis of fractions collected from anion-exchange Q-Sepharose column 
showed that, similar to MsmPep2, MsmTreS is susceptible to degradation (Figure 4-1B). 
Degradation appears as lower bands with smaller molecular weights. In order to 
determine the nature of degradation, both proteins were analyzed with western blot using 
an antibody directed against the His6 tag, demonstrating that degradation occurs from the 
C-terminal side (Figure 4-1D).  
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Figure 4-1. Purification of recombinant MsmTreS. (A-B) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography, 
respectively.  L: crude lysate, CL: clear lysate, FT: flow through. Ni-NTA elution 
fractions (25 mM Hepes pH 7.6, 300 mM NaCl, 10 % (v/v) glycerol) supplemented with 
0 to 250 mM imidazole and anion-exchange elution fractions (20 mM Bis-Tris pH 6.0, 
10% (v/v) glycerol) supplemented with 150 to 400 mM NaCl as indicated above the gels. 
(C) The size exclusion chromatogram of MsmTreS vs. albumin and SDS-PAGE analysis 
of the peak fractions from size exclusion chromatography. The albumin double peak 
corresponds to masses of 133 and 66.5 kDa, respectively. (D) Western blot analysis of 
MsmTreS (three protein-rich fractions from anion-exchange Q-Sepharose column) using 
an anti-His6 tag antibody. Arrows indicate His6-tagged MsmTreS bands on the gel (∼ 70 
kDa with the His6 tag). 
!"#
$!#
%&#
'"#
($#
)*#
)*$#
!"#
$!#
!##
!##
!"
#"
+,#
-./01#
+,#
-./01# 230.#4506789:#
;# <;# =>#
?@A789:#
BCDB>E#
=>#
?@A789:#
"# $"# )""# )$"#(""#($"# )$"# (""# ($"# '""# '$"# %""#
FD:3GH058:3#
E97DIC:&#J@8K#
#
$"
$!#
%&#
'"#
($#
*#
+,#
-./01#
%"
D"L(#
"#
"L(#
"L%#
"L&#
"L!#
)#
)L(#
$"L""# )""L""# )$"L""# (""L""# ($"L""# '""L""#&
'(
)
*+
+,-
./
"*
01
'(
0*
23
."
*4
"
56
7"
2)
"8!
9
:"
;+<='2">'+<)."8)+:"
+:M>53N#
ONE#
 107 
MsmTreS eluted as a single peak from size exclusion chromatography at 144 mL, 
representing tetrameric state of this protein in the solution (Figure 4-1C). Likewise, 
MsmPep2 was eluted as a dominant monomer peak at 188 mL from size exclusion 
column (Figure 3-2).  
 
 
4.3 Verifying	  activity of MsmTreS	  	  
 
In order to probe the activity of recombinant MsmTreS, the reaction products were 
analyzed in an end point assay using thin layer chromatography (TLC) (Figure 4-2). 
Incubation of MsmTreS with trehalose or maltose interconverted the substrates. Also, a 
third molecule was observed on the TLC plate, which is likely glucose (glucose and 
fructose have similar positions on the TLC plate) suggesting hydrolysis also happens in 
addition to the catalysis reaction. Incubating sucrose, α-1,4 glucosyl fructose, with 
MsmTreS produced trehalose as well as fructose consistent with the data for TreS from 
M. smegmatis (Zhang et al., 2011).   
 
4.4 MsmTreS	  forms	  a	  complex	  with	  MsmPep2	  
 
 
MsmTreS and MsmPep2 eluted individually as a single peak from size exclusion 
chromatography at 144 and 188 mL, respectively, representing tetrameric and monomeric 
state of these proteins in solution (Figure 4-3), consistent with published data (Roy et al., 
2013). However, combining MsmTreS and MsmPep2 in 4:1, 2:1, 1:1, 1:4 and 1:6 molar 
ratios, respectively, changed the elution pattern of both TreS and Pep2 proteins (Figure 4-
3). They eluted as a single peak at lower elution volume indicating complex formation 
 108 
between these two proteins. Nevertheless, the excess amounts of Pep2 as free molecules 
in the solution eluted at the same elution volume as Pep2 (Figure 4-3). Adding MsmPep2 
to MsmTreS from 0.25 up to 0.5:1 molar ratio led to a shift of the MsmTreS tetramer peak 
towards shorter retention times (Table 4-1). Adding additional amounts of MsmPep2 (up 
to 1:1 molar ratio) slightly shifted the peak (from 136 mL to 134.6 mL) but the free 
MsmPep2 (not bound to MsmTreS) appeared as a second peak at 188 mL.  
 
4.5 MsmTreS:Pep2	  complex	  formation	  is	  pH	  dependent	  
 
 
MsmTreS:Pep2 complex formation was examined under different pH conditions, from 
6.0-9.0, using size-exclusion chromatography in sodium phosphate buffer (Figure 4-5). 
At pH 9.0, MsmTreS:Pep2 complex eluted at 142 mL. At pHs below 9.0, the complex 
peak shifted towards lower elution volumes (134 mL at pH 6.0). Moreover, the peak 
height of the complex in acidic pH is higher than basic pH, demonstrating a distinct 
preference of complex formation at acidic pH. Plotting elution volume of complex (mL) 
vs. different pH values would indicate a sigmoidal relationship between these two 
parameters.  
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Figure 4-2. Thin layer chromatography analysis of reaction products probing the activity 
of MsmTreS. 2 µL of the reaction mixture containing fructose, sucrose, maltose and 
trehalose, respectively, spotted on the lanes 5-8. Lanes 1-4 are the same activity reactions 
but without MsmTreS enzyme and used as a control to determine the place of saccharides 
on the plate.   
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Figure 4-3. Exploring complex formation between MsmTreS and MsmPep2 in a range of 
molar ratios using size-exclusion chromatography.  
 
 
Table 4-1. Size exclusion chromatography data of complex formation between MsmTreS 
and MsmPep2.   
Molar ratio  
MsmPep2:MsmTreS 
0.25:1 0.5:1 1:1 4:1 6:1 
Elution volume 
(mL) 
139.5 136 134.6 134 134.6 
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Figure 4-4. Exploring complex formation between MsmTreS and MsmPep2 under 
different pH values using sephacryl S300-HR size exclusion resin. (Top section) Traces 
of absorbance (at 280 nm) vs elution volume. (Bottom section) The elution volume of 
each complex is plotted against corresponding pH value, demonstrating the shift of 
complex peak elution volume. Proteins were dialyzed against Na-phosphate buffer at 
specified PH values.  
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4.6 Assessing	  binding	  affinity	  of	  the	  complex	  by	  isothermal	  titration	  
calorimetry	  
 
 
Isothermal titration calorimetry (ITC) is a useful technique capable of determining the 
thermodynamic parameters (stoichiometry, affinity and enthalpy) of an interaction 
between macromolecule and ligand just in one single experiment (Pierce, Raman and 
Nall, 1999). The calorimeter is composed of two cells; a reference cell containing water 
and a sample cell containing the sample protein. Ligand is added in small aliquots to the 
sample cell with an automated syringe and due to its interaction with macromolecule heat 
will be released, exothermic reaction, or heat will be absorbed, endothermic reaction. ITC 
can measure this heat changes in sample cell by determining the electrical power required 
to keep both cells at the same temperature. As the ligand concentration increases the 
macromolecule becomes saturated and less heat is released or absorbed. Then the area of 
each peak is integrated and plotted against molar ratio of ligand to protein. A binding 
model (e.g., one set of binding site or two sets of binding sites) (equations 4-1 and 4-2) 
will be fitted into the data using a nonlinear regression procedure. The model is a 
mathematical description that helps to understand the actual physical, chemical or 
biological process taking place in the calorimeter (Freyer and Lewis, 2008). The molar 
ratio at the center of binding gives stoichiometry of the protein and ligand and Kd can be 
calculated from the model.  
!" =    ! !"1+ ! !" 
!" = ! +   !" (!"#")!!!!  
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Θj is the fraction of site j occupied by ligand, [L] is the free ligand concentration, Kj is the 
binding constant of process j, Lt is the total ligand concentration, Pt is the total 
macromolecule concentration and nj is the total stoichiometric ratio for process j.  
 
In order to determine the affinity between MsmTreS and Pep2, I measured the binding 
between these two proteins using ITC. MsmPep2 (initial concentration of 500 µM) was 
loaded into the syringe and titrated into the MsmTreS solution in the sample cell (initial 
concentration of 75 µM) (Figure 4-6). The experiment was performed in Na-phosphate 
buffer and three different pH values, 6.5, 7.5 and 8.5 at 25 oC. Following each titration 
heat was released and as MsmTreS became saturated the amount of heat released 
decreased, suggesting that MsmTreS was interacting with MsmPep2. If the heat change 
was simply due to reagent mixing, the amount of heat change should have remained 
constant throughout the experiment. The area of each peak is integrated and plotted 
against molar ratio of MsmPep2 to MsmTreS. One set of binding site or two sets of 
binding sites models were fitted very well into the data points (using equations 4-1 and 4-
2) and binding parameters, the stoichiometry of MsmTreS and Pep2 (n), association 
constant (Ka), the enthalpy change (ΔH) and the entropy change (ΔS) were determined 
from theoretical fit (Figure 4-5 and Table 4-2). The strongest affinity was measured at pH 
6.5 with a Kd of 3.5 µM. By increasing the pH the affinity of binding decreased. 
Therefore, the lowest affinity was measured at pH 8.5 with a Kd of 34.8 µM. The 
stoichiometry (n) at pH 6.5 was measured as 0.5, which indicates the MsmTreS tetramer 
binds 2 copies of MsmPep2. Likewise to affinity, by increasing pH the n dropped to 0.22 
at pH 8.5, suggesting only one copy of MsmPep2 binds to the MsmTreS tetramer.  
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The crystal structure of MsmTreS:Pep2 suggested that the previously observed rate 
enhancement of Pep2 in MtbTreS:Pep2 complex might be due to conformational changes 
in Pep2 upon binding to TreS. In order to explore this we decided to measure the affinity 
of complex formation in the presence of trehalose and maltose using ITC. The binding 
measurement between two proteins was performed as explained earlier but 10 mM of 
each maltose and trehalose was included in the dialysis buffer. Similarly, the n was 
measured as 0.5, suggesting the binding of one TreS tetramer to 2 Pep2 monomers. But 
the affinity was increased to the Kd of 1.8 µM, half of the affinity measured earlier (Table 
4-2).  
 
Figure 4-5. Schematic representation of the essential components of an ITC system. The 
stoichiometry of ligand and macromolecule (n), association constant (Ka), the enthalpy 
change (ΔH) and the entropy change (ΔS) can be calculated from the theoretical curve. 
Adopted from Malvern website.  
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Figure 4-6. Isothermal titration calorimetry (ITC) graphs of titration of MsmTreS with 
MsmPep2. Prior to experiment both proteins were dialyzed against Na-phosphate buffer 
at pH values of 6.5, 7.5 and 8.5, supplemented with 300 mM NaCl and 10% (v/v) 
glycerol. The initial concentration of MsmTreS in the reaction chamber was 75 µM that 
was titrated with 500 µM MsmPep2. The experimental data were fitted into the 
theoretical titration curves using one set of binding sites (A) and two sets of binding sites 
(B).  
 
 
 
 
 
 
 
 
 
 
 
 
!" #"
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Table 4-2. Thermodynamic parameters of MsmTreS:Pep2 interaction determined using 
isothermal titration calorimetry. The data are represented as an average of triplicate 
experiments. 
 
 Pep2 (wild type) Pep2 (wild 
type) in the 
presence of 
substrates 
Pep2 
(Δ70) 
pH 6.5 7.5 8.5 6.5 6.5 
T (K) 298 298 298 298 298 
 Single-site binding model   
n 0.574 ± 
0.007 
0.459 ± 
0.008 
0.22 ± 0.04 0.536 ± 
0.003 
0.681 ± 
0.004 
Ka (105 M-1) 2.87 ± 0.26 1.6 ± 0.12 0.287 ± 
0.03 
5.31 ± 2.82 0.35 ± 0.08 
Kd (µM) 3.48 6.25 34.8 1.88 26.8 
ΔH (104 kcal 
mol-1)  
-3.12 -1.81 -1.96 -3.39  
ΔS (kcal K-1 
mol-1) 
-79.7 -36.7 -45.9 -87.7  
 Two-site binding model   
Ka1 (105 M-1) 19.7 ± 3.2     
Ka2 (105 M-1) 0.55 ± 0.08     
Kd1, Kd2  
(µM) 
0.5, 18     
n1, n2  0.445±0.004 
0.457±0.055 
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4.7 Complex	  formation	  increases	  the	  activity	  of	  MsmPep2	  in	  acidic	  pH	  
 
 
 
In order to test the effects of complex formation on catalytic activity of MsmPep2 
activity, a continuous enzyme assay was developed based on this fact that 
phosphorylation of maltose to maltose 1-phosphate is proportional to the conversion of 
ATP to ADP (Figure 2-1). The conversion of ATP to ADP was enzymatically coupled to 
the oxidation of NADH to NAD+. Varying ATP at fixed MsmPep2 concentration (0.02 
µM) at different pH values, in the absence of MsmTreS, resulted in Michaelis-Menton 
type kinetics (Figure 4-7 and Table 4-3). The assay indicated that the activity of 
MsmPep2 is pH dependent, as lowering the pH from 7.5 to 6.0 dramatically reduced the 
activity of MsmPep2 (Vmax was measured at pH 7.5 and 6.0 as 1901 and 687 µmol min-1 μg-1, respectively) (Table 4-3). Then, I probed the activity of MsmPep2 in the presence of 
MsmTreS in 1:1 molar ratios (Pep2: TreS). Adding MsmTreS to MsmPep2 increased the 
Vmax of latter at pH 6.0 from 687 to 912 µmol min-1 μg-1. Consistent with ITC results, 
which measured the highest and lowest affinity at pH 6.5 and 8.5 with a Kd of 3.5 and 35 
µM, respectively; we expected to see this rate enhancement only at acidic pH. As the 
affinity drops at basic pH, adding MsmTreS may not have a distinct effect on the activity 
of MsmPep2. To confirm this rate enhancement at pH 6.0, I explored the activity of Pep2 
in the presence of four different concentrations of TreS at either fixed maltose or ATP 
concentrations (Figure 4-7 and Table 4-3). At fixed maltose concentration, adding TreS 
to Pep2 in 0.5:1, 1:1, 2:1 and 4:1, respectively, increased the activity of Pep2 (Vmax) from 
352 µmol min-1 μg-1 (in the absence of TreS) to 2040 µmol min-1 μg-1 (in the presence of 
four fold TreS concentration). However, at fixed ATP concentration, adding TreS didn’t 
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affect the activity of Pep2, 754 µmol min-1 μg-1 (in the absence of TreS) to 733 µmol min-
1
 μg-1 (in the presence of four fold TreS concentration). It is evident from Michaelis-
Menton plots that in several cases the concentration of substrate is not enough to saturate 
the enzyme and the as a result the calculated KM value is more than the highest 
concentration of substrate titrated to the assay (Figure 4-7). Therefore, it is necessary to 
repeat those activity assays with higher concentration of substrates to reach closer to 
equilibrium point and to be able to calculate KM values with higher confidence of 
accuracy.  
  
   
Figure 4-7. Michaelis-Menton kinetics of MsmPep2 activity under different pH 
conditions, in absence and presence of MsmTreS, and measured by an enzyme-coupled 
assay (for details see section 2.7). Error bars represent standard deviation.  
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Table 4-3. Michaelis-Menton parameters of MsmPep2-catalyzed phosphorylation of 
maltose in absence and presence of MsmTreS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pH MsmPep2 MsmTreS: Pep2 (1:1) 
 
Vmax	  (μmol	  min-­‐1	  μg-­‐1)	  
KM (mM) kcat	  (sec-­‐1)	   Vmax	  (μmol	  min-­‐1	  -­‐	  μg	  1)	   kcat	  (sec-­‐1)	   KM (mM) 
6.0 687.2 0.15 224.5 912 298 0.2274 
6.5 1291 0.11 421.9 1173 383.3 0.09601 
7.0 1993 0.01 651.3 1389 453.9 0.07218 
7.5 1901 0.08 621.2 1716 560.8 0.09139 
MsmTreS: 
Pep2  
(Molar ratio)  
Titrating with ATP at pH 6.0 Titrating with maltose at 
pH 6.0 
 
Vmax	  (μmol	  min-­‐1	  μg-­‐1)	   KM 
(mM) 
kcat	  
(sec-1) 
Vmax	  (μmol	  min-­‐1	  -­‐	  μg	  1)	   KM 
(mM) 
kcat	  
(sec-1) 
No TreS 352.1	   0.2456 115 754.7	   1.511 246.6 
0.5 : 1 1306 0.3759 426.8 717.6 1.562 234.3 
1 : 1 1515 0.3874 495 752.9 1.240 246 
2 : 1 1697 0.4100 554.6 655.3 1.457 214.2 
4 : 1 2040 0.5528 666.6 733.4 1.534 239.6 
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4.8 MsmTreS	  forms	  a	  complex	  with	  inactive	  mutant	  MsmPep2-­‐K145A	  
 
 
 
In order to test the effects of complex formation on MsmTreS activity, Roy and 
colleagues measured the enzymatic activity of MsmTreS by monitoring the conversion of 
trehalose to glucose (the hydrolysis side reaction) coupled to the oxidation of NADH to 
NAD+ in the presence of hexokinase, pyruvate kinase and lactate dehydrogenase (Figure 
4-8) (Roy et al., 2013). Since the coupling reactions involved conversion of ATP to ADP, 
it was necessary to prevent the consumption of ATP by Pep2 and subsequently 
phosphorylation of maltose to maltose 1-phosphate. Therefore, they generated an inactive 
mutant of MsmPep2, K145A, designed to abrogate ATP binding to Pep2. Using size 
exclusion chromatography Roy et al. showed that inactive mutant was still able to form a 
complex with MsmTreS, though, surprisingly; the complex eluted at very low elution 
volumes very close to the void volume (Figure 4-9 A).  
 
In order to confirm this complex formation and determine its elution volume, both 
proteins were mixed together in 1:1 molar ratio (75 µM each) and run at a pre-
equilibrated Sephacryl S300 column (GE Healthcare) as explained in section 2.4. 
Equilibration was carried out using 50 mM Na-phosphate pH 6.5, 300 mM NaCl and 
10% (v/v) glycerol. Two peaks appeared on the chromatogram at 137 and 193 mL, 
corresponding to the elution volumes of TreS:Pep2 complex and Pep2, respectively, 
indicating that Pep2-K145A mutant is still able to form a complex with MsmTreS and 
elutes at the same elution volume, contrary to Roy et al. findings (Figure 4-9 B).  
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Figure 4-8. Measuring the enzymatic activity of TreS using an enzymatically coupled 
reaction between trehalose to glucose conversion and NADH to NAD+ oxidation in the 
presence of hexokinase, pyruvate kinase and lactate dehydrogenase. PEP: 
phosphoenolpyruvate.  
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Figure 4-9. Exploring complex formation between MsmTreS and mutant Pep2-K145A. 
The size exclusion profile of complex between TreS:Pep2-K145A from (A) Roy et al, 
2013 paper and (B) in a second study in order to validate the Roy et al. data. This 
confirmed that MsmTreS and mutant Pep2-K145A form a complex together, though, 
complex elutes at higher elution volume (138 mL).  
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4.9 Crystallization	  of	  the	  MsmTreS:Pep2	  complex	  	  
 
In order to co-crystallize MsmTreS and Pep2 together, both proteins were purified 
separately and mixed together in three different molar ratios of MsmPep2 to TreS (1:1, 
2:1 and 1:2) respectively, just before setting up crystal trays. Initial crystals appeared in 6 
different conditions (Table 4-4). SDS-PAGE analysis of the four crystals selected from 
different conditions demonstrated that these crystals are formed from both TreS and Pep2 
proteins (Figure 4-10). However, most of these crystals did not diffract using the in-house 
X-ray source. Only crystals grew in 0.2 M MgCl2, 0.1 M Tris pH 7.0 and 10% w/v PEG 
8K (JCSG-plus B8 condition) diffracted (~8.5 Å). Using extensive screening and a very 
narrow pH range (pH 6.7 to 7.0) I was able to generate higher diffraction quality crystals. 
The structure was phased by molecular replacement and refined to a resolution of 3.6 Å 
(Table S9-4).  
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Table 4-4. List of conditions generating crystals of MsmTreS:Pep2 complex. 1 NPS: 
NaNO3, Na2HPO4, (NH4)2SO4; 2 Ethylen glycol, PEG 8K; 3 NaF, NaBr, NaI; 4 D-glucose, 
D-mannose, D-galactose, L-fucose, D-xylose, N-acetyl-D-glucosamine.   
Salt Buffer pH Precipitant 
0.2 M MgCl2 0.1 M Tris 7.0 10% w/v PEG 8K 
0.3 M C2H2MgO4 0.1 M Bis-Tris 5.5  
0.09 M NPS1 0.1 M imidazole-MES 
(acid) 
6.5 30.0% EDO_P8K2 
0.09 M Halogens3 0.1 M Tris (base)-Bicine  8.5 30.0% EDO_P8K2 
0.12 M Ethylene glycols 0.1 M Tris (base)-Bicine 8.5 30.0% EDO_P8K2 
0.12 M 
Monosaccharides4 
0.1 M Tris (base)-Bicine 8.5 30.0% EDO_P8K2 
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Figure 4-10. SDS-PAGE analysis of crystals harvested from MsmTreS:Pep2 crystal 
trays. Crystals initially were washed in cryoprotectant solution, boiled in sample buffer 
for 5 minutes and ran on the SDS-PAGE. Crystals in (A) harvested from Lanes (1) 0.1 M 
Morpheus buffer system 3 pH 8.5, 0.09 M Halogens and 30.0% EDO_P8K, (2) 0.1 M 
Morpheus buffer system 3 pH 8.5, 0.12 M monosaccharides and 30.0% EDO_P8K, (3) 
0.1 M Bis-Tris (pH 5.5) and 0.3 M C2H2MgO4 conditions. Lanes in B represent (1) TreS 
(2) crystals obtained from 0.2 M MgCl2, 0.1 M Tris pH 7.0 and 10% w/v PEG 8K 
(JCSG-plus B8 condition) and (3) Pep2. These gels confirm that crystals grew in these 
conditions contain both MsmTreS and Pep2 proteins. Morpheus buffer system 3 is made 
of a mixture of imidazole and MES in a way to give the appropriate pH. Halogens: NaF, 
NaBr, NaI. Monosaccharides: D-glucose, D-mannose, D-galactose, L-fucose, D-xylose, 
N-acetyl-D-glucosamine. EDO_P8K: Ethylen glycol, PEG 8K.  
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4.10 X-­‐ray	  crystal	  structure	  of	  the	  MsmTreS:Pep2	  complex	  
 
 
The structure of MsmTreS:Pep2 complex was phased by molecular replacement, and 
refined to a resolution of 3.6 Å (Table 9.3). There are two copies of the MsmTreS:Pep2 
complex in the asymmetric unit of the crystal lattice, which display differences in terms 
of subunit orientation and level of disorder. Each copy of the complex is composed of 4 
TreS subunits bound to 4 Pep2 monomers (4 + 4 assembly). Except Ca2+ sites in TreS, no 
other ligand was observed in the crystal structure of TreS:Pep2 complex. The backbone 
of the MsmTreS tetramer of the first complex of the asymmetric unit (chains A – D) 
superimposes well with the tetramer of the stand-alone TreS (PDB entry 3ZO9) with 
minimal root mean square deviation (RMSD) of 0.45 Å for 2243 aligned Cα positions 
(Figure 4-11). In contrast, the TreS tetramer from the second complex (chains E-H) do 
not superimpose well with either MsmTreS from the first complex or the stand-alone 
MsmTreS structure. However, if we superimpose chain H of complex 2 to chain A of 
complex 1, the three other subunits can be mapped accordingly (i.e. G → B, F → D, E → 
C), leading to an RMSD of 3.4 Å for 2175 aligned Cα positions (Figure 4-11). This 
mismatch can be explained as a result of rotation of the MsmTreS protomers against each 
other.  
 
There are eight Pep2 protomers in the asymmetric unit, which show different levels of 
disorder. In first complex, three Pep2 chains I – L (Figure 4-12B) are completely folded 
but in fourth Pep2 subunit (chain K) residues 1 to 86 are largely disordered. In second 
 127 
complex (Pep2 chains M – P) only one copy of Pep2 (chain M) could be traced fully, 
while in other three chains the disorder extends to about residue 195 in N-terminus.  
 
The core of MsmTreS:Pep2 complex is previously described diamond shaped TreS 
tetramer (Figure 4-12A), which can be described as a dimer of dimers (Caner et al., 2013 
and Roy et al., 2013). The β-sandwich domains, composed of seven-stranded anti-parallel 
β-sheets, (see section 1-7-1 for more information) of each dimer join together and form 
the top and bottom apex of the diamond (Figure 4-12A). Pairs of Pep2 monomers bind to 
each apex of the diamond in a clamp-like assembly (Figure 4-12 B), demonstrating an 
assembly of 4 + 4 complex. It might appear that Pep2 form dimers on TreS core but 
considering this fact that the contact surface between Pep2 monomers is small compared 
to than the contact surface between TreS and Pep2 implies that Pep2 binds as a monomer 
(Figure 4-12 C). More importantly, in those copies of Pep2 that contain disorded N-
turmini, the Pep2:Pep2 interface is absent.  
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Figure 4-11. The superimposition of the TreS tetramer of complex 1 (chains A – D, in 
hues of blue) to the TreS tetramer of the complex 2 (chains E- H, in gray). The 
superposition was performed such that chain A matches chain H, therefore, there is only 
minimal displacement between chains A and H. Spheres in the magenta indicate the 
location of the active sites. 
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Figure 4-12. Crystal structure of the MsmTreS:Pep2 complex. (A) Crystal structure of 
MsmTreS tetramer that can be described as a dimer of dimer. Magenta ribbons show the 
interaction between C-terminal β-sandwich domains of the TreS subunits. (B) Assembly 
of the MsmTreS: Pep2 complex with the TreS tetramer at the core and pairs of Pep2 on 
each end of the diamond shaped TreS. Spheres indicate the location of active sites 
derived by superposition with homologous structures. (C) Contact surface between TreS 
and Pep2 in top view, illustrating that the contact surface between Pep2 monomers is 
smaller than the contact surface with TreS. (D) Illustration of location of TreS and Pep2 
active sites in proximity of each other. The dashed line that connects TreS active site 
(chain A) and Pep2 active site (chain J) traverses through the hydrophobic core of Pep2, 
indicating there is no substrate channel between two protein’s active sites.  
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4.11 The	  structure	  of	  MsmPep2	  
 
 
During the course of this project the crystal structure of Pep2 from M. tuberculosis (Li et 
al., 2014) and M. vanbaalenii (Fraga et al., 2015) were published. The structural model of 
MsmPep2 in the current complex is completely defined by electron density except for 
two residues at the N-terminus and 4-5 residues at the C-terminus. We were able to dock 
the amino acid sequence of Pep2 onto the backbone structure by using the coordinates 
from Pep2 structures of M. tuberculosis and M. vanbaalenii. However, in some positions 
where the corresponding density was missing, we were not able to dock the side chains.  
 
Pep2 is a member of Pfam family PF01636, a database that classifies proteins according 
to their sequence homology (Finn et al., 2014). The main characteristic of the members of 
this family is having a two-lobe architecture, N-terminal and C-terminal lobe (Figure 4-
13A). Comparing the structure of MsmPep2 with closest structural neighbor (apart from 
the mycobacterial orthologues) Bacillus subtilis methylribose kinase (PDB code 2PUL, 
RMSD 3.9 Å, 262 aligned Cα) demonstrates a good match between the C-terminal lobe 
and parts of the N-terminal lobe of Pep2 (Figure 4-13). However, some parts of N-
terminus, β1- β3, appear to be unique to mycobacterial Pep2 and are missing from 
homologue structures identified by DALI. In contrast, the consecutive 7-stranded β-sheet 
(β6-β12) is conserved. Here, we refer to it as the canonical β-sheet (Figure 4-13A).  
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Figure 4-13. Structure of MsmPep2. (A) Cartoon representation of MsmPep2 in 
monomeric state with conserved and unique regions in the N-terminal lobe shown in blue 
and teal, respectively. Spheres depict the active sites of nucleotide and maltose obtained 
by superposition with GDP-bound aminoglycoside 2-phosphotransferase IIIa (PDB code 
3TDW) and maltose-bound MtbPep2 (PDB code 4O7P), respectively (B) Cartoon 
representation of methylribose kinase from Bacillus subtilis (PDB code 2PUL), the 
closest structural neighbor of Pep2. 
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4.12 Truncating	  MsmPep2	  
 
Prior to experimental structures of Pep2 being available, predictions of the tertiary 
structure of this enzyme using the HHpred threading server 
(toolkit.tuebingen.mpg.de/hhpred) failed to predict the folding of the first 100 amino 
acids of the Pep2 sequence, while high-confidence models for the remainder of the 
sequence were obtained. This observation suggested that either the N-terminal sequence 
encodes a unique structure or this sequence is intrinsically disordered. In order to test the 
hypothesis of intrinsic disorder, we generated seven mutants and truncated the first 70 
amino acids from the N-terminus of MsmPep2. The first mutant was generated by 
removing the first 10 amino acids and the proceeding mutants lost additional 10 amino 
acids in each time. Probing the oligomeric state of these truncations using size exclusion 
chromatography showed that they are highly prone to aggregation but the tendency to 
aggregate do not systematically increase with the extent of truncation (Figure 4-14).  
 
Following solving the crystal structure of MtbPep2 (Li et al., 2014) and then MsmPep2 it 
became evident that the N-terminus of Pep2 is well folded but contains a unique 3-
stranded β-sheet that is exclusive only to mycobacterial species. In order to explore the 
functional role of this unique β-sheet I chose Pep2(Δ70) for further studies as it lost this 
region. In order to improve the solubility of this mutant the concentration of NaCl was 
increased from 200 mM to 500 mM. This improved the solubility of Δ70 mutant to some 
extent but it did not prevent the aggregation of this protein completely. However, size 
exclusion chromatography is quite useful in separating the aggregated from the non-
aggregated protein. Pep2(Δ70) was eluted from the SEC column as two major peaks at 
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100 mL and 188 mL representing aggregation and monomeric state of this protein, 
respectively. Although Pep2(Δ70) is 70 amino acids smaller than wild type Pep2, it elutes 
almost at the same elution volume as MsmPep2, suggesting that the shape of this mutant 
has been changed.  
 
In order to test whether Pep2(Δ70) is still able to bind MsmTreS, both proteins were 
mixed together in 1:1 molar ratio (50 µM each) and loaded onto the pre-equilibrated 
HiPrep Sephacryl S300 HR (GE Healthcare) column (Figure 4-14). The complex peak 
was eluted at higher elution volumes (144 mL) indicating that the mutant Pep2 is still 
able to bind to its partner MsmTreS but the interaction is weaker. In addition, the catalytic 
activity of Pep2(Δ70) was measured against the wild type MsmPep2 using the continuous 
enzyme assay explained earlier in section 4-7. Varying ATP at a fixed initial maltose 
concentration or varying maltose at a fixed ATP concentration resulted in Michaelis-
Menton type kinetics in both cases (Figure 4-15). Fixing maltose concentration at 20 mM 
and increasing ATP concentration up to 0.4 mM showed a reduction in Vmax from 2513 (± 
205) (for wild type Pep2) to 242 (± 41) µmol min-1 mg-1 (for Pep2Δ70). Similarly, fixing 
ATP concentration at 0.5 mM and increasing the concentration of maltose up to 25 mM, 
indicated ~ 36-folds reduction in the activity of Pep2(Δ70) (Table 4-5). This data 
suggests that the unique β-sheet region of Pep2 is essential for structural stability of the 
N-terminal lobe and perturbing this region can affect nucleotide binding and 
subsequently activity.   
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Figure 4-14. The size exclusion profile of MsmPep2 (Δ10- Δ70) and evidence of complex 
formation between mutant Pep2 (Δ70) and MsmTreS. Individual TreS, Pep2 (Δ70) and 
the complex containing both proteins were eluted from column at 147, 193 and 144 mL, 
respectively.  
 
 
 
 
!"#$%
"%
"#$%
"#&%
"#'%
"#(%
)%
)#$%
*"#""% +"#""% ,"#""% ))"#""% )-"#""% )*"#""% )+"#""% ),"#""% $)"#""% $-"#""% $*"#""%!
"#
$
%&
'(
)*
+,
("
#,
%-
.)
*%
/*0
12
*-
$
*3+
4
5*
6&78"-*9"&7$)*3$:5*
./012314$%%
314$5)"%
314$5*"%
314$5'"%
314$5+"%
67189314$5+"%
./0126718%
314$%%
0:;:017/%
6718%%
<1<7=017%>:04?1@% 314$5+"%%
%
 135 
 
Figure 4-15. Michaelis-Menton kinetics of MsmPep2 wild type and MsmPep2(Δ70) 
activity, measured by an enzyme-coupled assay (for details see section 2.7). Error bars 
are representing standard deviation.  
 
 
Table 4-5. Michaelis-Menton kinetics of MsmPep2 and Pep2(∆70) measured by an 
enzyme-coupled assay. 
 
Parameters  Pep2 titrated 
with ATP 
Pep2∆70 
titrated with 
ATP 
Pep2 titrated 
with maltose 
Pep2∆70 
titrated with 
maltose 
Vmax  
(µmol.min-1. µg-1) 
2513 ± 205 242 ± 41 1679 ± 162 49 ± 3.2 
KM (mM) 0.2 ± 0.03 0.16 ± 0.1 3.3 ± 0.87 1.7 ± 0.36 
kcat	  
(sec-1) 
821.2 79 548.7 16 
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4.13 TreS	  and	  Pep2	  active	  sites	  	  
 
 
Roy and colleagues showed that complex formation between TreS and Pep2 in M. 
tuberculosis increases the activity of Pep2 in a dose-dependent manner (Roy et al., 2013). 
Therefore, we thought there might be a tunnel between two enzyme active sites, which 
could potentially facilitate substrate channeling.  However, if we connect the active site 
of TreS to the active site of nearest Pep2 using a direct line we observe that the line 
passes through the hydrophobic core of complex and there is no substrate channel 
between the active sites of two proteins (Figure 4-12D). The linear distance between 
MsmTreS active site and the nearest MsmPep2 active site (chain J) is about 53 Å and the 
next nearest MsmPep2 active site (chain I) is 63 Å away. This fact that MsmTreS and 
MsmPep2 active sites do not face each other and also both active sites are exposed to 
solvents suggest that maltose, following release from TreS active site, dissolves in 
solvent and enters the Pep2 active site.  
 
4.14 The	  TreS-­‐Pep2	  contact	  interface	  	  
 
According to PISA, the contact surface between chain B of TreS and chain I of Pep2 is 
composed of 37 and 33 amino acids of each subunit, respectively (Figure 4-16 and Table 
4-6). However, only a few residues from each subunits, ASN199, SER200, ASP213, 
ALA216, GLY227, ASP228 and ARG235 (from Pep2) and ARG311, ARG312, 
ARG315, GLU360 and ARG534 (from TreS) are involved in interaction between two 
proteins, mainly by forming hydrogen bonds and salt bridges (Table 4-6).  
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Figure 4-16. Contact surface between TreS and Pep2. The interaction between chain I of 
MsmPep2 and chain B of MsmTreS is stabilized by hydrogen bonds and salt bridges. 
Residues involved in surface interaction between two proteins are colored in red.  
 
According to Figure 4-4, the complex formation is more likely affected by pH changes at 
pH 6.5 – 8.0. It has been well established that the charge of amino acids can change in the 
range of -1 to +1 by pH changes and therefore, it would affect the charge-charge 
interactions established between charged residues. It was speculated that Histidine by 
having a side chain with a pKa value of 6.1 is more likely responsible for charge-charge 
interactions between TreS and Pep2. However, analyzing the interface between these two 
proteins using PISA server represented no Histidine in the binding interface, referring to 
the role of other forces in governing the interactions between TreS and Pep2 at the 
interaction interface.  
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Table 4-6. List of TreS and Pep2 residues in binding interface.  
Pep2 residues at 
surface interface 
Formed bond  TreS residues at 
surface interface 
Formed bond  
ILE65  ARG311 Hydrogen bond 
GLU67  ARG312 Hydrogen bond/salt bridge 
TYR68  GLU313  
ALA122  SER314  
PRO124  ARG315 Hydrogen bond 
ARG125  PHE316  
VAL126  SER319  
PHE127  GLU320  
GLY139  ALA323  
GLU140  GLN324  
ALA198  TYR356  
ASN199 Hydrogen bond GLU360 Hydrogen bond/salt bridge 
SER200 Hydrogen bond LYS363  
ALA201  ASP364  
GLU202  PRO365  
ASP205  ARG496  
MET206  GLU497  
THR209  LEU498  
SER210  GLY499  
ARG212  GLY500  
ASP213 Hydrogen bond/salt bridge SER501  
ALA216 Hydrogen bond ASN502  
GLU217  PRO503  
GLU223  SER504  
GLU224  ARG534 Hydrogen bond/salt bridge 
VAL225  PHE535  
GLY226  GLN537  
GLY227 Hydrogen bond ASN542  
ASP228 Hydrogen bond/salt bridge GLN544  
GLY231  GLN545  
GLU232  GLN565  
ARG235 Hydrogen bond/salt bridge LEU566  
ARG312  PRO567  
THR313    
PRO314    
LYS315    
ARG382    
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4.15 Small	  Angle	  X-­‐ray	  Scattering	  	  
 
In order to obtain structural information and determine the stoichiometry of TreS:Pep2 
complex in the solution state, a small angle X-ray scattering (SAXS) was performed 
(Jacques and Trewhella, 2010). We first examined the scattering profiles of individual 
MsmTreS (1.25 to 10 mg/mL) and MsmPep2 (1.25 to 10 mg/mL). Guinier plots of the 
scattering curves indicated that both proteins are heavily aggregating in the solution with 
radii of gyration (Rg) of 4.51 (± 0.03) nm and 2.78 (± 0.32) nm, respectively. Then, we 
examined the solution profiles of MsmTreS:Pep2 complex in 1:1 and 4:2 molar ratios of 
TreS to Pep2. It resulted in a bigger Rg (5.60 ± 0.01 nm). Fitting various structural models 
derived from the crystal structure of the TreS:Pep2 complex to the solution scattering 
data using CRYSOL (Svergun, Barberato and Koch, 1995), indicated a clear preference 
for a model consisting of the TreS tetramer bound to two copies of Pep2, attached to 
apposite apices of the TreS tetramer, respectively (Figure 4-17). Molecular envelope of 
the complex generated using DAMMIF (Franke and Svergun, 2009) and DAMAVER 
(Volkov and Svergun, 2003) suggested that the TreS:Pep2 complex in the solution is 
formed of 4 TreS bound to 2 Pep2 monomers (4+2 configuration) where chains I and L 
of Pep2 participate.  
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Figure 4-17. Small-angle X-ray scattering (SAXS) analysis of the MsmTreS:Pep2 
complex. (A) Fitting the atomic structure of MsmTreS:Pep2 complex (4+2) into the 
experimental scattering curves from SAXS (using CRYSOL program). The magenta 
color depicts the fitting curve. (B) The ab initio model generated using DAMMIF 
(Franke and Svergun, 2009) and DAMAVER (Volkov and Svergun, 2003) and 
converted into a pseudo-density map using CCP4 software suite. See materials and 
methods for more information. It indicates that the model fits one TreS tetramer and 2 
Pep2 monomers.  
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4.16 Stoichiometry	  of	  the	  MsmTreS:Pep2	  complex	  
 
Molecular mass and stoichiometry of the complex between MsmTreS and MsmPep2 were 
determined using analytical ultracentrifugation (AUC) in sedimentation equilibrium 
mode (Cole et al., 2008) (Figure 4-18). Mixtures of MsmTreS: Pep2 at molar ratios of 1:1 
and 2:1 were analyzed at 3 different concentrations and 4 different rotation speeds. It had 
been previously established that MtbTreS forms a tetramer in the solution with a 
molecular weight of ∼280,000 Da (Roy et al., 2013) and was further confirmed during 
this project using size exclusion chromatography (SEC) and small angle X-ray scattering 
(SAXS). Knowing the molecular weight of TreS and considering that Pep2 behaves as a 
monomer in the solution, molecular weights obtained from AUC were analyzed. In 
MsmTreS:Pep2 in molar ratio of 2:1 the molecular weight was calculated as 324,367 Da, 
which suggests four TreS (monomer) bound to one Pep2 subunit. Mixing TreS and Pep2 
in a 1:1 molar ratio gave a molecular weight of 363,763 Da, which indicates a TreS 
tetramer with two bound monomers of Pep2. When TreS was analyzed on its own, it 
yielded a molecular mass of 257,019 Da, which demonstrates a tetramer, consistent with 
previous published data (Roy et al., 2013).  
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Figure 4-18. Sedimentation equilibrium analysis of the M. smegmatis TreS:Pep2 
complex. A 1:1 molar ratio of MsmTreS and Pep2 mixture was analyzed at three different 
protein concentrations ([TreS]= 3.75, 2.5 and 1.25 µM) at three rotation speeds (8,000, 
9,000 and 10,000 rpm) and fitted to a single sedimenting species. Data points are shown 
as open symbols, and solid lines represent the best fit (top panel) and residuals (lower 
panel), respectively.  
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4.17 Summary	  	  
 
MsmTreS and MsmPep2 were successfully overexpressed and purified (Figure 3-1 and 4-
1). Both proteins were eluted as single peaks from SEC column at 144 and 188 mL, 
representing the tetrameric and monomeric states of these proteins in the solution, 
respectively. Using SEC, it was shown that TreS forms a complex with Pep2 and this 
complex formation is highly pH dependent, as increasing the pH from 6.0 to 9.0 
diminishes the complex formation (Figure 4-3 and Figure 4-4). Isothermal titration 
calorimetry also, measured the highest and lowest affinities between TreS and Pep2 at pH 
6.5 and 8.5, respectively (Table 4-2). Consistent with these data, the highest activity of 
Pep2 in the presence of TreS was observed only at pH 6.0 (Figure 4-7 and Table 4-3).   
Solving the crystal structure of Pep2 in complex with TreS demonstrated a 4 + 4 
configuration, in which two pairs of Pep2 monomers are placed on each apex of a 
diamond shape TreS tetramer (Figure 4-12). Additionally, the Pep2 rate-enhancement is 
due to conformational changes occurring upon binding to TreS, not substrate channeling 
as proposed earlier (Figure 7-1). Pep2 is composed of two lobes, N-terminal lobe and C-
terminal lobe (Figure 4-13). The N-terminal lobe harbors a unique region (β1 – β3), 
which only can be seen in mycobacteria, and is involved in structural stability of N-
terminal lobe, as shown by removing this region (Pep2 Δ70 mutant) and probing the 
activity and the interaction of this mutant with TreS, and comparing the results with wild 
type Pep2.  
SAXS and AUC suggested that complex formation between TreS and Pep2 in the 
solution occurs in a 4 + 2 configuration (Figure 4-17 and 4-18), in contrast to 
stoichiometry in the crystal lattice.  
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5 Crystallization	  and	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5.1 Crystallization	  of	  MtbGlgE	  	  
 
GlgE and GlgB catalyze two consecutive reactions from GlgE pathway, the transfer of 
maltose from maltose 1-phosphate (M1P) to maltooligosaccharides and introducing 
branches to the linear glucan at some position 6, respectively. Kalscheuer and colleagues 
(2010) demonstrated the essentiality of both enzymes for Mtb survival. They showed that 
inactivation of either GlgE or GlgB in Mtb leads to hyperaccumulation of M1P and 
subsequently self-poisoning of bacilli. Both enzymes could be potentially new drug 
targets, however, the presence of a human ortholog of GlgB makes it less attractive than 
GlgE. In this study I attempted to crystallize MtbGlgE and explore its interactions with 
Pep2 and GlgB.   
 
5.2 Protein	  expression	  and	  purification	  of	  MtbGlgE	  and	  MsmGlgB	  
 
MtbGlgE and MsmGlgB were purified from bacterial cell extracts using immobilized 
metal ion affinity chromatography (IMAC) and anion-exchange chromatography (Figure 
5-1 and 5-2 A-B). Size exclusion chromatography was used to enhance the purity and to 
determine the oligomeric state of each protein in the solution (Figure 5-1 and 5-2 C-D). 
MtbGlgE and MsmGlgB were eluted as single peaks from size exclusion chromatography 
at 168 mL (∼120 kDa, estimated from column calibration) and 186 mL (∼66 kDa), 
representing dimeric and monomeric state of these proteins in the solution, respectively, 
consistent with the literature (Syson et al., 2011 and Pal et al., 2010). Albumin was also 
used as a standard. Albumin elution profile contained two major peaks at 164 and 187 
mL, representing the dimeric (133 kDa) and monomeric (66.5 kDa) state of this protein in 
the solution, respectively.  
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Figure 5-1. Purification of recombinant MtbGlgE. (A-B) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography.  L: 
crude lysate, CL: clear lysate, FT: flow through, AP: applied sample. Ni-NTA elution 
fractions (20 mM Na2HPO4 pH 7.2, 500 mM NaCl, 10 % v/v glycerol) supplemented 
with 20 to 500 mM imidazole and anion-exchange elution fractions (100 mM Bis-Tris 
propane pH 7.0, 10% v/v glycerol) supplemented with 100 to 300 mM NaCl as indicated 
above the gels. (C) The chromatogram of MtbGlgE (green) vs. albumin (red). (D) SDS-
PAGE analysis of the peak fractions from size exclusion chromatography. Arrows 
indicate His6 tagged MtbGlgE bands on the gel (∼ 81 kDa with the His6 tag). 
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Figure 5-2. Purification of recombinant MsmGlgB. (A-B) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography.  L: 
crude lysate, CL: clear lysate, FT: flow through, AP: applied sample. Ni-NTA elution 
fractions (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 % v/v glycerol) supplemented with 
20 to 500 mM imidazole and anion-exchange elution fractions (50 mM Tris-HCl pH 8.0, 
10 % v/v glycerol) supplemented with 150 to 500 mM NaCl as indicated above the gels. 
(C) The chromatogram of MsmGlgB (green) vs. albumin (red). (D) SDS-PAGE analysis 
of the peak fractions from size exclusion chromatography. Arrows indicate His6 tagged 
MsmGlgB bands on the gel (∼ 85 kDa with the His6 tag). 
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5.3 Expression	  and	  purification	  of	  MsmGlgE	  
 
First attempts to overexpress MsmGlgE proved the over-expression of this protein as a 
formidable task. In order to find the best host for producing MsmGlgE, the plasmid 
carrying glgE was transformed into three different strains of E. coli, BL21 (DE3), BL21 
(DE3) pLysS and BL21 (DE3) C41, and induced each of them with 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG). Visually testing the SDS-PAGE gels of uninduced and 
induced samples of BL21 (DE3) cultures transformed with glgE against those from BL21 
(DE3) C41 cultures didn’t show any significant difference (Figure 5-3A). Since the bands 
containing uninduced and induced samples of BL21 (DE3) pLysS cultures appeared as 
smeary on the SDS-PAGE gel and I was not able to compare them with other competent 
cells, I purified GlgE from these culture cells using IMAC and compared the intensity of 
bands from elution fractions with those from BL21 (DE3) cells on SDS-PAGE gel. 
Higher intensity of GlgE bands on BL21 (DE3) SDS-PAGE gel indicated that the amount 
of GlgE production in these cells should be relatively higher than BL21 (DE3) pLysS 
cells (Figure 5-3B). The MsmGlgE overexpressed in BL21 (DE3) was further purified 
using anion exchange chromatography and size exclusion chromatography (Figure 5-3 C-
D). MsmGlgE was eluted as a major peak at 171 mL (∼116 kDa, estimated from column 
calibration), representing the dimeric form of this protein in the solution, consistent with 
other literature (Syson et al., 2011).  
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Figure 5-3. Purification of recombinant MsmGlgE from bacterial cell extracts. (A) SDS-
PAGE analysis of MsmGlgE overexpressed in two different competent cells, BL21 (DE3) 
and BL21 (DE3) C41. MsmPep2 was also overexpressed in C41 and used as a positive 
control. (B) SDS-PAGE analysis of fractions from affinity (Ni-NTA) chromatography of 
MsmGlgE overexpressed in BL21 (DE3) and BL21 (DE3) pLysS. CL: clear lysate, FT: 
flow through. Ni-NTA elution fractions (20 mM Na2HPO4 pH 7.2, 500 mM NaCl, 10 % 
v/v glycerol) supplemented with 20 to 500 mM imidazole. (C) SDS-PAGE analysis of 
anion-exchange elution fractions (100 mM Bis-Tris propane pH 7.0, 10% v/v glycerol) 
supplemented with 100 to 300 mM NaCl as indicated above the gel. (D) The 
chromatogram of MsmGlgE (purple) vs. albumin (green). Arrows indicate His6 tagged 
MsmGlgE bands on the gel (∼ 80 kDa with the His6 tag). 
 
 
 
 
 
!"#
$!# !"#%&'(#
!"#)*+,#
-./# 01(/# -./#
!"#)*+,# %&'(#
!"#
$!#
-1# 23# ("#
,*45678#
9:;93<#6=#)*+,#6>&?&@'?&88&A#:7#01(/#BC,DE#
."# !"# /""#/$"#(""# $""#D""#
; ; ;F F F
GH#
BICJE#
GH#
BICJE#
K%3)#
!"#)*+,#
-1# 23# ("#
,*45678#
."# !"# /""# /$"#(""#D""#
9:;93<#6=#)*+,#6>&?&@'?&88&A#:7#01(/#BC,DE#'1L8M#
"#
"N(#
"N.#
"NO#
"N!#
/#
/N(#
"N""# $"N""# /""N""# /$"N""# (""N""# ($"N""# D""N""# D$"N""#!
"#
$
%&
'(
)*
+%
,-
"#
,%
./
)+
%0
+1
23
+
.$
+45
6
7+
8&9:".+;"&9$)+4$<7+
5+
=+
>+ ?+
P$#
Q(#
$$#
GH#
BICJE# 23#
,*45678#
/""# (""# ($"# D""#
R;8&'SJ?68&#
<%#
0M<#
!"#)*+,#
 150 
5.4 Crystallization	  of	  MtbGlgE	  
 
 
MtbGlgE was concentrated to about 6.2 mg/mL and screened for crystallization in four 
different sparse matrix screens (for more information see section 2-8). However, it did 
not generate any crystals. Addition of maltose (as substrate) or cyclodextrin (as inhibitor) 
did not also promote the crystallization of MtbGlgE.  
 
5.5 Probing	  stability	  of	  GlgE	  using	  thermal	  shift	  assay	  
 
 
In order to probe thermal stability of MtbGlgE as a function of buffer composition, a 
thermal shift assay was performed using a qPCR thermal cycler and monitored changes 
in melting temperature (Tm) of this protein by monitoring fluorescence of the 
hydrophobic dye (Niesen, Berglund and Vedadi, 2007). The Tm value of MtbGlgE was 
measured as 18 oC and its changes (ΔTm) were monitored throughout the experiment 
(Figure 5-4). An increase in Tm could suggest an elevation in structural stability of GlgE, 
whereas a decrease in Tm might represent a disordered conformation or a sign of 
misfolding. Large variation in stability was observed in different screens (Figure 5-4).  
Some buffers had a higher impact on MtbGlgE stability, mainly sodium acetate pH 5.4, 
MES pH 5.7 and 6.1, Hepes pH 7.0 and 8.0 with a ΔTm of about +8. The most 
destabilizing buffers are sodium citrate/citric acid pH 4.0 and sodium acetate pH 4.2 with 
a ΔTm of about -1 and some buffers with small effects on GlgE stability including sodium 
acetate pH 4.8, 250 mM NaCl and sodium citrate/citric acid pH 5.0, 250 mM NaCl. 
MtbGlgE was dialyzed against two buffers, Hepes pH 7.0 and 8.0, 250 mM NaCl and 
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10% glycerol and exposed to crystallization screens. Unfortunately, neither of these 
buffers promoted the crystallization of this protein.  
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Figure 5-4. Exploring MtbGlgE stability versus buffer type, determined using thermal shift assay. Thermal stability was measured at 
100 mM NaCl () and 250 mM NaCl (). Stars above the bars indicate the buffers that were tested in the crystallization screenings. 
Error bars represent standard deviation. Abbreaviations on X axis are explained  in Table 2-4 of materials and methods. 
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5.6 Testing	  the	  interaction	  of	  MsmGlgE	  with	  MsmPep2	  and	  GlgB	  using	  size	  
exclusion	  chromatography	  
 
In order to probe the putative interactions between MsmGlgE and MsmPep2, both 
proteins were mixed together in 1:1 molar ratio (20 µM of each proteins) and loaded into 
size exclusion chromatography (SEC) column. Three major peaks appeared at 189, 170 
and 133 mL elution volumes, corresponding to the elution volumes of MsmPep2, 
MsmGlgE and higher oligomers of GlgE, respectively (Figure 5-5). If Pep2 and GlgE 
were interacting in the form of a complex, we should see a peak at lower elution volume 
containing both proteins. But since each protein elutes separately, it implies that Pep2 and 
GlgE do not form a complex. Similarly, MsmGlgE (60 µM) was mixed with MsmGlgB 
(120 µM) and loaded into the SEC column. Two major peaks appeared at 186 and 131 
mL (Figure 5-6). The peak at 186 mL corresponds to GlgB, but the peak at 131 mL is not 
corresponding to elution volumes of neither GlgE nor GlgB. In order to determine the 
contents of this peak, the fractions pulled from SEC column were tested on SDS-PAGE 
gel. Fractions corresponding to the peak contained only GlgE, suggesting that adding 
GlgB changes the elution pattern of GlgE (from 170 mL to 131 mL). However, it does 
not provide enough evidence that GlgE and GlgB are forming a complex together. In 
order to support these results another technique, bacterial two-hybrid system, based on 
complementation between two subdomains, T25 and T18, of catalytic domain of 
Bordetella pertussis adenylate cyclase, was performed.  
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Figure 5-5. Exploring complex formation between MsmGlgE and MsmPep2. Fore more 
details see section 5.6.  
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Figure 5-6. Exploring complex formation between MsmGlgE and MsmGlgB. Two 
protein bands appear at close proximity of each other on the gel. Arrows indicate each 
protein on the gel. The molecular weight of MsmGlgE and MsmGlgB  (with the His6 tag) 
is 80 and 85 kDa, respectively. Fore more details see section 5.6.  
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5.7 Bacterial	  Two-­‐hybrid	  system	  
 
 
In spite of this fact that there is a functional link between TreS, Pep2, GlgE and GlgB, the 
interactions between these proteins barely have been studied. Roy and his colleagues 
showed that TreS and Pep2 form a hetero-octameric complex in M. tuberculosis (Roy et 
al., 2013) but the interaction between other members of the pathway still remains a 
mystery. In order to explore putative interactions, bacterial adenylate cyclase two-hybrid 
system (BACTH) was used (Karimova et al., 1998). This technique is based on 
complementation between two subdomains, T25 and T18, of catalytic domain of 
Bordetella pertussis adenylate cyclase. When T25 and T18 domains are together the 
enzyme is active and will synthesize cyclic adenosine 3,5-monophosphate (cAMP) from 
ATP. Calmodulin, a protein found only in eukaryotic organisms, acts as an intermediate 
in bringing two subdomains together. Newly produced cAMP interacts with catabolite 
activator protein (CAP) and cAMP-CAP complex elevates the transcription of lactose 
and maltose catabolic genes by binding to their promoters and acting as an inducer. 
Activation of these operons can be easily detected by measuring cAMP levels and β-
galactosidase activities in liquid cultures. In practice two proteins of interest are fused to 
T25 and T18 subunits. If fused proteins interact together, they fulfill the role of 
calmodulin in bringing together T18 and T25 and restore the activity of adenylate 
cyclase.  
 
Four enzymes involved in GlgE pathway, TreS, Pep2, GlgE and GlgB from M. 
tuberculosis were fused to T25 and T18 subdomains of adenylase cyclase on BACTH 
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vectors. Since the reporter strain lacks the endogenous adenylase cyclase, only interaction 
between two proteins fused to subdomains T25 and T18 can restore the activity of this 
enzyme. The interactions between two sets of proteins TreS and Pep2, Pep2 and GlgE 
were measured using β-galactosidase assay on overnight cultures of these proteins 
(Figure 5-7) (for more information see section 2.16). Negative control, two empty 
plasmids, and positive control, plasmids pKT25-zip and pUT18C-zip, were also included 
in the experiment. The β-galactosidase activities of negative and positive controls were 
measured as 12.8 and 180 units of activity per mL of overnight culture, respectively 
(Figure 5-7). Similar to negative control, the overnight cultures of both TreS:Pep2 and 
Pep2:GlgE combinations showed 14.8 units of β-galactosidase activity per mL, 
suggesting that these sets of proteins are not interacting together, contrary to published 
data on TreS:Pep2 interactions. It had been previously established that TreS and Pep2 
from M. tuberculosis are forming a complex together in both in vitro and in vivo (Roy et 
al., 2013). These results discouraged me from further exploring the interactions of GlgE 
with the rest members of GlgE pathway. However, size exclusion chromatography also 
failed to show the complex formation between MsmGlgE and Pep2 (Figure 5-5).  
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Figure 5-7. β-galactosidase activity of overnight cultures prepared from BTH101 
competent cells co-transformed with vectors carrying TreS and Pep2 (), Pep2 and GlgE 
(). Negative control () and positive control () also were included in this experiment. 
For more information see section 2.16. Error bars are representing standard deviation.   
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5.8 Summary	  	  
 
MtbGlgE and MsmGlgB were purified from bacterial cell extracts (Figure 5-1 and Figure 
5-2). MtbGlgE and MsmGlgB were eluted as single peaks at 168 and 186 mL from SEC 
column, representing dimeric and monomeric states of these proteins in the solution, 
respectively (Figure 5-1C and Figure 5-2C).  
 
The initial attempts to crystallize MtbGlgE were not successful. In order to probe thermal 
stability of MtbGlgE as a function of buffer composition, a thermal shift assay was 
performed. The most stabilizing buffers were determined as sodium acetate pH 5.4, MES 
pH 5.7 and 6.1, Hepes pH 7.0 and 8.0 (Figure 5-4) but none of them improved the 
crystallization of GlgE. 
 
The interactions of MsmGlgE with MsmPep2 and MsmGlgB were explored using SEC 
(Figure 5-5 and Figure 5-6) and BACTH systems (Figure 5-7). Together, these results 
suggest that the recombinant GlgE do not form a complex with either Pep2 or GlgB. 
However, it is obvious that adding MsmGlgB to MsmGlgE changes the elution pattern of 
GlgE towards lower elution volumes (Figure 5-6).  
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6.1 Crystallization	  of	  Rv3031	  and	  Rv3032	  
 
 
The third pathway involved in glucan biosynthesis in mycobacteria is Rv3032, composed 
of two key enzymes Rv3032 and Rv3031 (Mendes et al., 2010). Rv3032 is a (1→4)-
glycosyltransferase that catalyzes the transfer of glucose from ADP-glucose or UDP-
glucose to diglucosylglycerate (DGG) and Rv3031 serves as a α-(1→6)-branching 
enzyme and introduces new branches into the growing glucan (Stadthagen et al., 2007). 
Neither of these enzymes are essential for mycobacterium survival, however, Rv3032 
exhibits synthetic lethal interactions with both TreS and GlgA (Sambou et al., 2008 & 
Kalscheuer et al., 2010). Although, both enzymes, Rv3031 and Rv3032, have been 
known for several years and their roles in glucan synthesis has been investigated, but they 
are not still biochemically characterized. In addition, solving the crystal structure of both 
Rv3032 and GlgA might provide us with new insights into synthetic lethal interactions in 
mycobacteria.  
 
6.2 Expression	  and	  purification	  of	  Rv3031	  
 
In order to find the optimum conditions to overexpress Rv3031, it was transformed into 
two different competent cells, BL21 (DE3) and BL21 (DE3) pLysS (Figure 6-1 A). Both 
types of competent cells were induced with 0.2 mM IPTG, followed by incubation either 
at 37 oC for 3 hours or overnight at 15 oC. Visually checking the SDS-PAGE gels of 
uninduced and induced samples from all four cultures indicated the overexpression of 
recombinant Rv3031 in both competent cells at 37 oC as well as BL21 (DE3) overnight at 
15 oC but not in BL21 (DE3) pLysS at 15 oC (Figure 6-1 A). Between these two 
competent cells I chose BL21 (DE3) for further experimentation.  
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Figure 6-1. SDS-PAGE analysis of recombinant Rv3031 overexpression and solubility. 
(A) Testing the overexpression of Rv3031 using BL21 (DE3) and BL21 (DE3) pLysS 
competent cells at 37 oC for three hours or overnight at 15 oC. Odd and even numbers 
represent uninduced and induced samples, respectively. (B) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) column, Lane 1: crude lysate; Lane 2: clear lysate; Lane 
3: flow through and Lane 4-5: samples eluted with 20 and 500 mM imidazole, 
respectively. The fraction containing the protein was concentrated more than 20 fold. 
Arrows indicate His6 tagged Rv3031 bands on the gel (∼ 60 kDa with His6 tag). 
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In order to improve the solubility of Rv3031, this protein was coexpressed with M. 
tuberculosis Cpn60.1 and E. coli GroES or M. tuberculosis Cpn60.2 and E. coli GroES at 
37 oC for three hours or overnight at 15 oC (Figure 6-2A). Cultures grown overnight at 15 
oC produced relatively more proteins than cultures grown at 37 oC for three hours. Cells 
collected from overnight cultures were lyzed and Rv3031 was purified using Ni-NTA 
chromatography for further analysis (Figure 6-2B). In order to be able to see the protein 
bands on the gels, each fraction was 30 folds concentrated. However, coexpression of 
Rv3031 with chaperons also didn’t improve the solubility of this protein significantly. 
The highest amount of protein was obtained only when 3 liters of bacterial cultures was 
used and cultures were induced with lower amount of IPTG (0.2 mM) (Figure 6-3A).  
 
 
Size exclusion chromatography (SEC) was used to enhance the purity of Rv3031 and also 
to determine the oligomeric state of this protein. Rv3031 was eluted as three peaks at 98, 
119 and 163 mL elution volumes, representing aggregation, higher oligomeric and 
dimeric state of this protein in the solution, respectively (Figure 6-3B).  
 
 
 
 
 
 
 
 
 
 
 
 164 
 
 
Figure 6-2. SDS-PAGE analysis of recombinant Rv3031 overexpression and solubility in 
the presence of chaperones. (A) Testing the overexpression of Rv3031 in the presence of 
60.1 GroES and 60.2 GroES chaperones at 37 oC for three hours or overnight at 15 oC. 
Odd and even numbers represent uninduced and induced samples, respectively. (B) SDS-
PAGE analysis of the fractions from affinity (Ni-NTA) column, Lane 1: crude lysate; 
Lane 2: clear lysate; Lane 3: flow through and Lane 4-5: samples eluted with 20 and 500 
mM imidazole, respectively. Arrows indicate His6 tagged Rv3031 bands on the gel (∼ 60 
kDa with His6 tag). In order to be able to see the bands on the gel, each fraction was ~30 
folds more concentrated.  
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Figure 6-3. Purification of recombinant Rv3031 from three liters of bacterial cultures. 
(A) SDS-PAGE analysis of anion-exchange elution fractions (25 mM Tris-HCl pH 8.2, 
10% v/v glycerol) supplemented with 0 to 500 mM NaCl. FT: flow through. (B) The size 
exclusion chromatogram of Rv3031 from Sephacryl S300 HR column. Arrow indicates 
His6 tagged Rv3031 band on the gel (∼ 60 kDa with His6 tag).  
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6.3 Expression	  and	  purification	  of	  Rv3032	  
 
 
Rv3032 was purified using immobilized metal ion affinity chromatography (IMAC) and 
anion-exchange chromatography (Figures 6-4A). Using size exclusion chromatography 
(SEC) the purity of Rv3032 was enhanced and the oligomeric state of protein was 
determined (Figure 6-4B). Rv3032 was eluted as a major peak from SEC column at 218 
mL, suggesting that this protein behaves as a monomer in the solution.   
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Figure 6-4. Purification of recombinant Rv3032. (A) SDS-PAGE analysis of the 
fractions from affinity (Ni-NTA) and anion-exchange (Q-Sepharose) chromatography.  L: 
crude lysate, CL: clear lysate, FT: flow through. (B) The size exclusion chromatogram of 
Rv3032 from Sephacryl S300 HR column. Arrows indicate 6xHis-tagged Rv3032 bands 
on the gel (∼ 47 kDa with the His6 tag).  
 
 
 
 
 
!"#$
!%#$
&'$
()$
''$
*%$
%*$
)+$
!($
,-./012$
!##$ !'#$ )##$ %##$ '##$ !###$$
,-./012$
34$5$ 65$ 34$
78$
9:;<=$
>?@>4A$ B@2CDE<F02C$
@!G##$
#G##$
!G##$
)G##$
%G##$
*G##$
'G##$
+G##$
#G##$ '#G##$ !##G##$ !'#G##$ )##G##$ )'#G##$ %##G##$ %'#G##$
!"
#$
%"
&'
()
*&
+*,
-.
*'
/
*0/
!1
2*
3$45/)*0/62*
!*
7*
!$$ !$$
)#$ +#$ !##$ !'#$ '##$
 168 
6.4 Domain	  structure	  of	  Rv3031	  and	  Rv3032	  
 
 
According to Pfam (pfam.xfam.org), Rv3031 is composed of two domains, GH57 and 
DUF1957. Glycoside hydrolase family 57, also known as GH57, is a group of enzymes 
involved in hydrolyzing glycosidic bonds between two carbohydrates. The members of 
this family have a range of different activities such as: α-galactosidase, α -amylase, α -
glucanotransferase and branching enzyme. On the other hand, DUF1957 is a domain with 
unknown activity. This domain has been identified in several branching enzymes 
including TT1467 from Thermus thermophiles (PDB entry 1UFA) and TK1436 from 
hyperthermophilic archaeon Thermococcus kodakaraensis (PDB entry 3N8T). In 
TK1436, this domain is involved in the formation of active-site cleft (Santos et al., 2011).  
 
Similarly, Rv3032 is made of two domains, glycosyl transferase 4-like domain and 
glycosyl transferases group 1. Glucosyltransferases are known to catalyze the formation 
of glycosidic bonds by using sugar phosphates as glycosyl donors 
(https://www.cazypedia.org/index.php/Glycosyltransferases).  
 
6.5 Summary	  
 
It was shown that the highest amount of recombinant Rv3031 and Rv3032 could be 
obtained only if the genes encoding these proteins are transformed in BL21 (DE3) 
competent cells and grown overnight at low temperatures (15 oC). However, it is 
advisable to use 3 - 5 liters of culture instead of one liter and the amount of inducing 
IPTG be reduced to 0.2 mM or even lower (some literatures suggest 10 µM IPTG). SEC 
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chromatogram suggest that Rv3031 and Rv3032 behave mainly as dimers and monomer 
in the solution (Figure 6-3B and Figure 6-4C).  
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7 Discussion	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It has been shown that capsule of mycobacteria, the most outer layer of cell envelope, is 
involved in modulating the host immune system (Geurtsen, et al., 2009 & Sani et al., 
2010). Thus, understanding the mechanisms of capsule biosynthesis can help us to better 
understand the biology of this pathogen, its interactions with the host cells and ultimately 
aid the development of new tuberculosis therapies. The main constituent of the capsule, 
α-glucan, is synthesized in three interlinked pathways (Chandra, Chater and Bornemann, 
2011). In the recently discovered GlgE pathway, trehalose is converted to maltose in the 
presence of TreS, Pep2 phosphorylates the latter to maltose-1-phosphate using ATP, 
GlgE transfers maltose from maltose 1-phosphate to maltooligosaccharides and GlgB 
introduces branches to the linear glucan at some position 6. In a recent study by Roy et al, 
it was shown that TreS and Pep2 form an octameric complex in Mtb and they solved the 
structure of TreS. The purpose of this study was to solve the structure of GlgE, a 
genetically validated novel anti-tuberculosis drug target, Pep2 on its own or in complex 
with TreS and determine the affinity of TreS:Pep2 association.  
 
The crystal structure of GlgE from Streptomyces coelicolor (an orthologous of M. 
tuberculosis) was described for the first time by Syson and colleagues (Syson et al., 
2011). The S. coelicolor GlgE structure (∼51% sequence similarity with MtbGlgE) 
describes the catalytic and kinetic properties of the enzyme, however, in order to be able 
to develop an inhibitor explicitly, it is essential to obtain the structure of GlgE from M. 
tuberculosis. MtbGlgE was successfully purified to ∼95% purity (single band on the 
SDS-PAGE gel) and exposed to a wide range of crystallization screens (Figure 5-1). 
Unfortunately, it did not generate any crystals. One possible solution to this problem was 
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promoting the crystallization of GlgE by improving the stability and solubility of this 
protein in the solution (Niesen, Berglund and Vedadi, 2007). Therefore, a thermal shift 
assay was performed to find the most suitable buffer and pH for enhancing the stability of 
MtbGlgE. According to thermal shift assay sodium acetate pH 5.4, MES pH 5.7 and 6.1, 
Hepes pH 7.0 and 8.0 could be the most promising buffers for MtbGlgB stabilization, 
though; these buffers also didn’t promote the crystallization of MtbGlgE.  
 
The crystal structure of GlgE from Mtb co-crystallized with maltose and acceptor 
molecule, maltohexaose, was recently described (Lindenberger et al., 2015). The 
MtbGlgE exhibits a very similar structure to Streptomyces coelicolor (Sco) GlgE with an 
R.M.S. displacement value of 2.5 Å for all Cα positions. However, SAXS data indicate a 
difference in orientation of the monomers within the homodimers of Mtb and Sco GlgE. 
This difference in homodimers can be explained as a result of forming a disulfide bridge 
between monomers in MtbGlgE.  
 
M1P binding site in MtbGlgE is highly conserved and has a similar structure and amino 
acid sequence to ScoGlgE (Lindenberger et al., 2015). It is composed of two subunits: the 
-1 subunit where the reducing end of maltose sits and the -2 subunit where the non-
reducing end of maltose binds. The main difference between M1P binding sites of two 
enzymes is observed in -2 subunit where one amino acid is changed. While MtbGlgE 
contains a serine at position 303, ScoGlgE contains a valine in this position (V279). 
MtbGlgE S303 forms a hydrogen bond with O5 atom of the substrate, while V279 in 
ScoGlgE forms a van der Waals interaction with 2 carbon atoms of the substrate.  
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Lindenberger and colleagues also found a novel maltooligosaccharide binding site in 
MtbGlgE different from previously described cyclodextrin binding site in ScoGlgE. The 
newly discovered binding site is located in Domains A and C of MtbGlgE and can harbor 
an acceptor as large as a maltohexaose through forming hydrogen bonds with its atoms. 
Cyclodextrin in ScoGlgE is identified in hydrophobic region of homodimer interface 
between Domain A of one subunit and Domain N of the second subunit. Cyclodextrin 
binding site is in close proximity of maltohexaose binding site and inhibits the activity of 
ScoGlgE by blocking the latter site and hindering the access of glucan substrate to 
enzyme active site. However, in MtbGlgE R427 and G84 residues are replaced by proline 
residues, resulting a clash between proline residues side chains with cyclodextrin. This 
prevents the bidning of inhibitor to the binding site and therefore, maintaining the activity 
of MtbGlgE. This study provided further insight into the structure and activity of 
MtbGlgE and paving the way to design more efficient inhibitors of this enzyme. 
 
The second area of interest was to explore the putative interactions of GlgE with other 
members of the pathway. Given that the accumulation of maltose-1-phosphate (produced 
by the catalytic activity of Pep2) is toxic to the mycobacterial cells, one can argue that the 
cells need to ensure that the intermediate (M1P) cannot accumulate. Using two different 
techniques, size exclusion chromatography and bacterial two hybrid systems (BACTH), I 
explored the putative interaction of Pep2:GlgE and GlgE:GlgB. Results of these studies 
suggest that the recombinant GlgE do not form a complex with either Pep2 or GlgB 
(Figure 5-5 and 5-6). However, the interaction between these pairs of proteins might be 
too weak to be detected by size exclusion chromatography and BACTH, which known to 
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produce artifacts, or additional factors such as TreS or maltose might be required to 
stimulate the complex formation, more sensitive techniques can be examined to further 
investigate these results. This is evident when probing the activity of MsmPep2 and 
MsmTreS (positive control) using bacterial two-hybrid system. Although the complex 
formation between these two proteins has been confirmed in vitro and in vivo using a 
range of biophysical techniques, the level of β-galactosidase production between cells 
carrying the complementing T18 and T25 fused to TreS and Pep2 and negative cells is 
the same, indicating there is no complex formation between MsmTreS and MsmPep2 
(Contrary to published data) (Figure 5-7). Moreover, according to the crystal structure of 
MtbPep2, Li et al. (2014) proposed that Pep2 could serve as a docking site for GlgE to 
form a super complex with TreS. However, they also failed to show this complex 
formation using pull-down and Biacore assays (Li et al., 2014). Interestingly, adding 
MsmGlgB to MsmGlgE changed the elution pattern of GlgE towards lower elusion 
volumes (Figure 5-6), which might suggest changing the oligomeric state of this protein 
in the solution.    
 
Roy and his colleagues described the structure of MtbTreS recently and confirmed the 
complex formation between MtbTreS and MtbPep2 using size exclusion chromatography, 
and analytical ultracentrifugation in sedimentation equilibrium mode. However, they did 
not solve the structure of complex nor determine the affinity of complex formation 
between TreS and Pep2. Initial attempts to crystallize Pep2 from Mtb were not 
successful. Both size exclusion chromatography and analytical ultracentrifugation (AUC) 
results showed that MtbPep2 behaves as a heterodisperse protein (forming monomers, 
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dimers and higher oligomers) in the solution (Figure 3-2), which makes the 
crystallization less likely. A small angle scattering experiment performed at ESRF’s 
bioSAXS beamline also, showed that this protein is prone to aggregation in solution (data 
not shown). Thus, I tried to crystallize its homologue from M. smegmatis. In contrast to 
MtbPep2, MsmPep2 appeared as a monomer in the solution (Figure 3-2) and formed 
sizable crystals in initial crystallization trials. However, the crystals diffracted to only 7.5 
Å and only the unit cells could be determined. My attempts to improve the diffraction 
quality of MsmPep2 crystals through systematic screening of conditions, including for 
instance the use of additives, were not successful. One reason could be the fact that this 
protein was co-purified with trace amounts of proteases, leading to degradation, with 
fragments appearing as lower bands on SDS-PAGE following ion exchange 
chromatography (Figure 3-1). These lower bands are also, seen on SDS-PAGEs of TreS. 
Western blotting of MsmPep2 and MsmTreS with an anti-His6 tag antibody showed that 
degradation happens at the C-terminal end. Degradation of TreS from M. smegmatis was 
previously reported by Pan and colleagues (2008). They monitored MsmTreS for 43 days 
and found that the molecular mass was reduced from 68 kDa to 58 kDa, loosing about 10 
kDa. I tried to examine the degradation of MsmPep2 in different periods of time and 
MsmPep2 showed to be very unstable on ice. Another possibility to improve the 
diffraction of MsmPep2 crystals was swapping the affinity tag from the N- to the C-
terminus. C-terminally tagged MsmPep2 was successfully overexpressed, purified (Figure 
3-5) and used for crystallization trials but this time it didn’t generate any crystals at all. 
Applying other techniques such as limited proteolysis or thermal shift assay to improve 
the crystallization of MsmPep2 were not successful too.  
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Using size exclusion chromatography I showed that TreS and Pep2 from M. smegmatis, 
similar to Mtb orthologues, form a complex together in the solution (Figure 4-3). 
Addition of Pep2 to TreS shifted the TreS tetramer peak (from 144 mL) towards lower 
elution volumes (Figure 4-3 and 4-4). Interestingly, it was observed that the association 
of MsmTreS and Pep2 is highly pH dependent, as the complex peak in the SEC 
chromatogram shifted towards lower elution volumes at the pH lowered. The highest 
peak was observed at pH 6.0 (134 mL) and by increasing the pH the height of peak 
reduced (142 mL at pH 9.0), suggesting a decrease in molecular mass (Figure 4-4). These 
results were confirmed by isothermal titration calorimetry (ITC) (Figure 4-6 and Table 4-
2). The strongest and lowest affinities were measured at pH 6.5 and 8.5, respectively 
(with a Kd of 3.5 µM and 34.8 µM). Probing the activity of MsmPep2 in the presence of 
MsmTreS at pH 6.0 - 7.5 indicated that the Pep2 rate-enhancement previously observed 
in Mtb (Roy et al., 2013) occurs only at pH 6.0, consistent with SEC and ITC results that 
measured the highest affinity in this pH.  Based on this fact that the stronger association 
between TreS and Pep2 occurs at mildly acidic pH, it is not very surprising to obtain the 
best diffracting crystals at reservoir pH values between 6.7 and 7.0 (see below).  
 
Given that TreS and Pep2 form a complex and that crystallization of Pep2 failed to yield 
crystals of sufficient quality, I decided to attempt crystallization of the TreS:Pep2 
complex . While co-purifying the two proteins failed to produce crystals, purifying each 
protein separately and then mixing them at molar ratios of 1:1 and 2:1 (TreS:Pep2) just 
before setting up the crystal trays was the only way to generate MsmTreS:Pep2 crystals. 
Co-purification of TreS:Pep2 together or co-eluting from size exclusion chromatography 
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hinders the crystallization. Although MsmTreS:Pep2 complex crystallized readily but 
improving the diffraction from 8.5 Å to 3.6 Å was achieved only by extensive screenings 
and systematic variation of crystallization conditions. The initial crystals appeared at 0.2 
M MgCl2, 0.1 M Tris pH 7.0 and 10% (w/v) PEG 8K. I realized that pH variation has a 
significant impact on crystal formation. Varying pH in 0.15 units was critical to obtain 
well- diffracting crystals of the TreS:Pep2 complex.   
 
The thermodynamic equilibrium favors trehalose production over maltose production 
(Zhang et al., 2011). Thus, in order to drive the pathway towards glucan biosynthesis, 
substrate channeling might be a factor that can facilitate this. Moreover, in the genome of 
a significant number of bacteria treS and pep2 are fused together (Chandra, Chater and 
Bornemann, 2011). Therefore, I was interested to test hypothesis. However, it became 
evident from crystal structure of MsmTreS:Pep2 complex that there is no substrate 
channels between the active site of TreS and Pep2 and the rate enhancement of Pep2 is 
due to the conformational changes in Pep2 induced by binding to TreS.  Superimposing 
MsmPep2 from TreS:Pep2 complex with the structures from Mtb (PDB entry 4O7P) and 
M. vanbaalenii (PDB entry 4U98) indicated that the conformational change for ATP 
binding site is limited to β8-β9 loop, which does not contact with TreS (Figure 7-1 A). 
But maltose-binding site is probably more affected by binding to TreS (Figure 7-1 B). 
Binding to TreS obstructs the bending effect of helices α11-α12, an effect, which is 
apparent in the conformation of Pep2 in the absence of TreS and upon binding of 
maltose. Secondly, contacts between the α9- α10 loop and TreS affects the conformation 
of helix α9 as a whole.  
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Figure 7-1. Comparison of MsmPep2 from TreS:Pep2 complex with Pep2 homologue 
structures and structural rational for Pep2 rate-enhancement. (A), (B) Superposition of 
chain J of Pep2 (green) in the TreS:Pep2 complex with AppCp- and maltose-bound 
structures (beige) of the Pep2 orthologues from M. vanbaalenii (PDB entry 4U98) and M. 
tuberculosis (PDB entry 4O7P), respectively.   
 
Prior to solving the crystal structure of TreS:Pep2 complex, our attempts to predict the 
tertiary structure of Pep2 using the HHpred threading server 
(toolkit.tuebingen.mpg.de/hhpred) failed to provide a structural model for the folding of 
the first 100 amino acids of the Pep2 sequence, while high-confidence models for the 
remainder of the sequence were obtained. This observation suggested that either the N-
terminal sequence encodes a unique structure or that this sequence is intrinsically 
disordered. In order to test the hypothesis of intrinsic disorder, I generated N-terminal 
truncation mutants of MsmPep2 in steps of 10 residues, removing up to 70 residues. 
Following structure determination of the TreS:Pep2 complex, it became evident that this 
region is folded but structural alignment of Pep2 with its closest structural neighbors 
(apart from the mycobacterial orthologues) demonstrated that some parts of this region, 
!" #"
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β1- β3, (Figure 4-13) are unique to mycobacterial Pep2 and are missing from the 
structural neighbors identified by distance matrix alignment (DALI (Holm and 
Rosenstrom, 2010)) (Figure 4-13). Since the function of this unique β-sheet was not 
apparent from the crystal structure, the Pep2 (Δ70) mutant was used to explore the role of 
this region of Pep2 in binding to TreS and the activity of Pep2.  Using size exclusion 
chromatography I confirmed that mutant Pep2 (Δ70) was still able to bind to TreS, 
though with lower affinity, (Figure 4-14) and the activity (Vmax) of truncation mutant 
reduced by ~10 folds compare to the wild type protein (Figure 4-15 and Table 4-5). 
These changes in affinity and activity can be described by destabilizing the N-terminal 
lobe, which contains the ATP binding site, due to truncating Pep2. Therefore, the unique 
β-sheet region is likely important for structural stability of the N-terminal lobe.    
 
The crystal structure of TreS:Pep2 indicated that four Pep2 monomers bind to a TreS 
tetramer (4 + 4 configuration) (Figure 4-12). However, exploring the stoichiometry of the 
TreS and Pep2 association in the solution using analytical ultra centrifugation (AUC) in 
sedimentation equilibrium mode and small angle X-ray scattering (SAXS) suggested that 
only 2 subunits of Pep2 bind to a TreS tetramer (4 + 2 configuration) (Figures 4-17 and 
4-18). This discrepancy in stoichiometry between the crystalized form and the behavior 
in the solution is likely due to crystal lattice contacts, in which the solvent is excluded 
and new packing interactions can affect the assembly state. In the solution state, packing 
interactions evidently play no role. Close inspection of the ITC data demonstrated that 
there is a small, but consistent deviation between the single-binding site model and the 
data points.  Fitting a two-binding site model removes this deviation, suggesting that the 
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two models have Kd values of 0.5 and 18 µM, respectively (Table 4-2). The stoichiometry 
for site one and two is 0.45 and 0.46, respectively (Table 4-2). Adding the stoichiometric 
ratios of the two sites together generate the total stoichiometry of n = 0.91, suggesting a 
TreS:Pep2 ratio of near unity. Based on this data the following model can be proposed: 
 
[TreS4 : Pep24] 
                !"!                
 [TreS4 : Pep22] + 2 Pep2 
                !"!                
 TreS4 + 4 Pep2 
 
In this model, two copies of Pep2 bind to a TreS tetramer with the higher affinity (Kd1 = 
0.5 µM), while two additional copies of Pep2 can bind with lower affinity (Kd2 = 18 µM), 
resulting the dominance of 4 + 2 configuration in the solution. The SAXS derived 
molecular envelope suggests that two Pep2 monomers bind to opposite apical positions 
on the TreS tetramer (Figure 4-17). In this case, site 1 represents the apical positions on 
both sides of TreS, while site 2 is the second open site at each apex.  
 
Solving the structure of TreS:Pep2 and determining the stoichiometry of complex 
formation in the solution can be used to explain why bacterial two hybrid system failed to 
show the interaction between these two proteins. It is well established that TreS behaves 
as a tetramer in the solution, with C-terminal β-sandwich domains participating in dimer 
interface. Fusing T18 or T25 domains of adenylate cyclase to C-terminal domain of TreS 
can hinder this dimer formation, while assembling TreS tetramer is the first step in 
complex formation with Pep2. Moreover, Pep2 monomers bind to opposite apical 
positions of the TreS tetramer with both lobes of Pep2 participating in binding interface 
(Figure 4-16). Likewise, fusing either of two domains of adenylate cyclase to Pep2 lobes 
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might affect the complex formation between TreS and Pep2. These data all together, 
suggest that BACTH may not be the best approach to probe the interaction between TreS 
and Pep2, since fusing external domains to these proteins probably influences the folding, 
subunits interface and interaction of these two proteins together.  
 
Roy and colleagues confirmed the complex formation between MtbTreS and Pep2 in vivo 
(Roy et al., 2013). They concluded that complex formation is an efficient strategy to 
direct the flow of α-glucan pathway towards glucan synthesis, despite the fact that 
thermodynamic equilibrium favors trehalose production over maltose production. This 
change in flow direction prevents the accumulation of toxic pathway intermediate 
maltose 1-phosphate. Accumulation of large amounts of maltose 1-phosphate can lead to 
inhibition of respiration, induction of the stringent response and DNA damage and 
ultimately death of Mtb (Kalscheuer et al., 2010). Using complex formation as an 
approach to regulate pathway activity has been previously reported in mycobacteria. 
Complex formation between chorismate mutase (CM) and 3-deoxy-D-arabino-
heptulosonate 7-phosphate synthase (DAH7PS) is a direct example of regulating 
metabolic pathways through complex formation between two distinct proteins in Mtb 
(Blackmore et al., 2015). They showed that both enzymes are active but complex 
formation enhances the catalytic activity of both enzymes, controls the flux of pathway 
and subsequently directs the pathway intermediate, chorismate, into phenyl alanine/ 
tyrosine or tryptophan biosynthesis.  
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Future work 
During this study we were able to determine the role of complex formation between TreS 
and Pep2 on the activity of each enzyme but the importance of this complex formation 
for GlgE pathway is not still very clear. Also, it was shown that the interaction between 
TreS and Pep2 is highly pH dependent, but what makes this interaction pH-dependent 
remains to be determined. Despite the fact that there are three pathways involved in α-
glucan production, perturbing in two pathways (either TreS and Rv3032 or Rv3032 and 
GlgA) can lead to death of Mtb (synthetic lethal interactions). Revealing the reasons 
behind synthetic lethality can shed light on understanding the mechanisms of Mtb 
survival within the host or exploiting the derived information for designing the new anti-
TB drugs. Finally, one of the key questions regarding the capsule biosynthesis is to 
understand what pathway is specifically responsible for α-glucan production and how 
these materials are transported to the outside of cell wall after being synthesized in the 
cytoplasm. These are only some of the questions still remained unexplained and future 
studies are needed to find the answer of these questions.  
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Media used in this study: 
 
 
Terrific Broth (TB) for 900 mL 
Trypton              12 g 
Yeast Extract     24 g  
Glycerol             0.4% 
 
TB salt for 100 mL 
KH2PO4           2.3 g  
K2HPO4          12.5 g   
 
Both TB and TB salt should be autoclaved separately and mixed together just before 
inoculation.  
 
MB7H9 media for 900 mL 
 
4.7 g      Difco MB7H9 
0.5%     Glycerol   
Autoclave at 121 oC for 10 min and add 100 mL of Albumin Dextrose Catalase (ADC) to 
make it to 1 L.  
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Table S9-1. All approved drugs to treat tuberculosis (Brennan, Young and Robertson, 2008).  
Drug name  Drug target/mechanism Drug resistance mechanism  In vitro activity  
Clarithromycin (CLA) Inhibits protein biosynthesis 
through binding to the 50S 
ribosomal subunit 
Methylation of the 23S rRNA Active against M. tuberculosis 
(H37Rv) and M. avium wih 
MIC 8ug/ml at pH 7.4 and 
MIC90 8 µg/ml, respectively 
Clofazimine (CLOF) Mode of action is not identified Not very well known Active against M. tuberculosis 
(H37Rv) with MIC 0.1 µg/ml  
Gatifloxacin (GATI) Fluoroquinolone, see MOXI  MIC against M. tuberculosis 
(H37Rv) 0.25 µg/ml 
Levofloxacin (LEV) Second generation quinolone, 
see MOXI 
See MOXI MIC M. tuberculosis (H37Rv) 
0.5 µg/ml 
Linezolid (LIN) Inhibits protein synthesis 
through binding to 23S rRNA, 
preventing proper binding of 
formyl-methionine tRNA 
Mutations in 23S rRNA MIC M. tuberculosis (H37Rv) 
0.25 µg/ml 
LL-3858 Not known  MIC M. tuberculosis (H37Rv) 
0.12-0.025 µg/ml 
Moxifloxacin (MOXI) As a quinolone inhibits ATP-
dependent enzymes 
topoisomerase II (DNA gyrase) 
and topoisomerase IV encoded 
by gyrA, gyrB; and parC and 
parE, respectively 
Mutations in gyrA or gyrB MIC against M. tuberculosis 
(H37Rv) 0.5 µg/ml 
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Prothionamide (PRO) See ethionamide (ETA) Cross resistance between PRO 
and ETA 
MIC against M. tuberculosis 
(H37Rv) 0.5 µg/ml 
Rifabutin (RIFAB) See Rifampin (RIF) Mutations in rpoB gene MIC against M. tuberculosis 
(H37Rv) <0.015 µg/ml 
Rifalazil (RIFAL) See Rifampin (RIF) Mutations in rpoB gene MIC against M. tuberculosis 
(H37Rv) <0.015 µg/ml 
Rifampin (RIF) Inhibits the RNA polymerase 
β-subunit encoded by rpoB 
gene 
Mutations in rpoB gene MIC against M. tuberculosis 
(H37Rv) 0.1-0.39 µg/ml 
Rifapentine (RIFAP) See Rifampin (RIF) Mutations in rpoB gene MIC against M. tuberculosis 
(H37Rv) 0.031 µg/ml 
Thioridazine  Inhibiting calmodulin or 
NADH2-menaquinone-
oxidoreductase (Ndh2) 
 MIC against M. tuberculosis 
ATCC 27294 10 µg/ml 
TMC-207 Targets c subunit of ATP 
synthase encoded by atpE gne 
Mutations in atpE gene MIC against M. tuberculosis 
(H37Rv) 0.06 µg/ml (0.03-0.12 
µg/ml) 
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Table S9-2. List of new anti-TB drugs. 
Drug name  Drug target/mechanism Drug resistance mechanism  In vitro activity  Reference 
Bedaquiline (R207910) Targets ATP synthase  Point mutations in atpE gene Inhibits both drug-
sensitive and drug-
resistant M. tuberculosis 
in vitro (MIC 0.06 
µg/mL) 
Andries et al., 2005 
OPC-67683 
(Delamanid) 
Inhibits mycolic acid 
biosynthesis 
Mutation in Rv3547, the gene 
responsible for activating the 
drug 
Inhibits both drug-
sensitive and drug-
resistant M. tuberculosis 
in vitro (MIC 0.0006-
0.024 µg/mL) 
Matsumoto et al., 
2006 
PA-824 Inhibits mycolic acid and 
protein biosynthesis 
Mutation in Rv3547, the gene 
responsible for activating the 
drug 
Point mutations in Rv0407 
encoding F420-dependent 
glucose 6-phosphate 
dehydrogenase (Fgd) 
MIC against M. 
tuberculosis (H37Rv) 
0.15-0.3 µg/ml 
Stover et al., 2000 
SQ109 Inhibits TDM synthesis by 
inhibiting MmpL3, the 
transmembrane transporter 
responsible for 
transporting precursor of 
TDM 
Mutations in mmpL3, the 
gene encoding MmpL3 
transmembrane transporter 
 Tahlan et al., 2012 
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Table S9-3. List of recently identified targets in M. tuberculosis. The targets, their roles within the cells, their inhibition impacts on 
bacilli and inhibitor (if any) are shown.   
Target  Activity Impacts on M. tuberculosis 
 
Inhibitor  Reference 
GlgE Adds maltose 1-P to the growing 
1,4 glucan chain  
Deletion of glgE gene leads to toxic 
accumulation of M1-P 
Synthetic lethality with Rv3032 
 Kalscheuer et al., 2010 
pcaA Cyclopropane synthase involved 
in the formation of mycolic acids  
Mutant bacteria fail to persist within 
mice 
Dioctylamine  Glickman, Cox and 
Jacobs, 2000 
DprE1/DprE2 Converts decaprenylphosphoryl 
ribose into decaprenylphosphoryl 
arabinose  
Inhibits the production of 
arabinogalactan  
Benzothiazinone 
Dinitrobenzamides 
Makarov et al., 2009 
MshC Encodes an ATP-dependent 
mycothiol ligase that catalyses the 
last step in the biosynthesis of 
mycothiol  
 Dequalinium 
chloride 
Sareen et al., 2002 
Peptide 
deformylase 
(Def) 
Deformylates the first methionine 
at N terminus  
 LBK611 Teo et al., 2006 
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Table S9-4. X-ray diffraction data and refinement statistics.  
 
X-ray diffraction data  
Crystal Tres:Pep2 
Beamline ID29, ESRF 
Wavelength (Å) 0.97717 
Space group P43 
Cell parameters (Å) 315.68, 315.68, 124.95 
TreS:Pep2 complexes  
per asymmetric unit 
2 
Resolution range (Å) 49.91 - 3.60 
High resolution shell (Å) 3.66 - 3.60 
Rmerge (%)1) 17.0 (154.2) 
Total observations,  
unique reflections 
1090211, 142362 
I/σ(I)1) 9.1 (1.1) 
Completeness (%)1) 99.8 (98.1) 
Multiplicity1) 7.7 (7.0) 
CC1/21), 2) 0.997 (0.343) 
Refinement  
Resolution range 49.9 - 3.6 
Unique reflections 135356 
Rcryst, Rfree (%)  26.1, 28.1 
No of non-H atoms 56072 
RMSD bonds (Å) 0.006 
RMSD angles (º) 1.0 
B-factors  
 Wilson (Å2) 126 
 Average overall (Å2) 111 
RMSD B-factors (Å2) 1.36 
Ramachandran statistics3)  
Favoured regions (%) 94.9 
Allowed regions (%) 4.5 
Disallowed (%) 0.6 
Clash score 4.6 
Rotamer outliers (%) 1.1 
 
